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Introduction: There is increasing interest in the use of ketogenic diets (KDs) as an adjuvant 
therapy for patients within glioblastoma (GBM).  In animal models KDs limit tumour growth and 
enhance survival, but there is little evidence to support the use of KDs for patients with GBM.  
The aim of this thesis was to explore the feasibility of using KDs as an adjuvant therapy for patients 
with GBM by i) reviewing the evidence for efficacy and acceptability of KDs for patients with 
gliomas; ii) exploring the level of patient interest to support any future randomised controlled 
trial (RCT); iii) exploring the deliverability of a KD intervention in an NHS setting; iv) investigating 
the feasibility of a trial protocol (KEATING) and the impact this trial would have on patients with 
GBM, such as quality of life; and v) exploring the patient perspectives on their decision-making 
when invited to participate in KEATING, to inform the design of future phase III KD trials for GBM.      
Methods: A systematic review was undertaken; the search strategy included seven electronic 
databases.  Data extraction and quality assessment were undertaken for each included study.  A 
patient survey was distributed locally and nationally to explore if there was sufficient interest in 
KD as an adjuvant treatment, that could be tested in a clinical trial.  A scoping KD service was 
established to assess if the diet could be offered to adults with gliomas within an NHS setting.  
Following this, feasibility was assessed through a single-centre, prospective, non-blinded, 
randomised, pilot trial (KEATING), with an embedded qualitative study.  Twelve newly diagnosed 
patients with GBM were randomised to the modified ketogenic diet (MKD) or medium chain 
triglyceride ketogenic diet (MCT KD). The diet was started during adjuvant chemoradiotherapy.  
The primary outcome was retention on diet; secondary outcomes included recruitment rates, 
dietary acceptability and completeness of data, assessed at 12 weeks and 12 months.  Semi-
structured interviews were conducted with a purposive sample of patients and relatives (n=15).  
Descriptive statistics were used for quantitative outcomes and qualitative data were analysed 
using thematic analysis aided by NVivo.   
Results: From the systematic review no randomised trials were identified.  Six case series or 
reports (n=39) met the eligibility criteria, all were at high risk of bias. While the review found 
minimal adverse events, suggesting KDs to be safe for patients with gliomas, the evidence for 
efficacy and acceptability of KDs was insufficient to suggest that the diet has a therapeutic 
effect in the management of gliomas.  One hundred and seventy two surveys were completed; 
66% of patients (n=114) were willing to participate in a ketogenic RCT.  During the scoping service, 
six male patients with high grade glioma tried MKD; four of whom completed the three month 
intervention.  MKD was deliverable within an NHS setting.  KEATING achieved recruitment targets, 
but the recruitment rate was low (28.6%).  Retention was poor; only four of 12 patients 
completed the three-month diet (MCT KD n=3; MKD n=1).  The median duration until 
discontinuing the MCT KD was 38 days (36-40 days; n=2) and MKD was 39.5 days (32-49 days; 
n=4).  Participants made instantaneous decisions without deliberation: relatives supported diet 
implementation.  Decliners made considered decisions factoring diet burden and quality of life. 
Patients also sought to validate their decision by seeking the opinion of relatives. A three-month 
diet was undesirable to patients who declined and those who started diet and later withdrew.   
Conclusion: Recruitment to a KD trial for patients with GBM is possible.  To assess efficacy in a 
phase III clinical trial, a six week intervention period is proposed.  Future trials should optimise 
and adequately support the decision-making of patients.  The role of relatives should not be 
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AN INTRODUCTION TO KETOGENIC DIETS AND GLIOBLASTOMA 
 
1.1 THESIS OVERVIEW 
This thesis explores the feasibility of using ketogenic diets (KDs) as an adjuvant therapy for 
patients with glioblastoma (GBM).  This research was initially motivated by patient interest 
in KDs locally and following the publication of The James Lind Alliance Neuro-Oncology 
Priority Setting Partnership  which highlighted the influence of lifestyle factors, including diet, 
on tumour growth to be one of the top 10 research priorities for patients and researchers in 
the field of neuro-oncology (1).   
 
Since the turn of the decade, KDs have been growing in popularity in the patient community, 
yet little dietetic support was offered across the United Kingdom (UK), due to limited 
evidence and a lack of funding.  Therefore, in 2015 a temporary scoping service for KDs was 
established at The Walton Centre NHS Foundation Trust (WFCT) for patients with GBM.  This 
service was funded for one year, with the aim of exploring if a KD service could be delivered 
to adult patients with gliomas in a National Health Service (NHS) setting and to assess patient 
demand for KD in glioma.  Following the success of this project, funding was sought for a KD 
trial for GBM and the Ketogenic Diet as an Adjuvant Therapy in Glioblastoma trial (KEATING) 
was established in 2017, with the aim of assessing trial feasibility with a view to informing 
the design of a future phase III trial.  KEATING was the first randomised, non-blinded, pilot, 
KD trial for patients with GBM to be undertaken in the UK and was also the first KD trial to 
utilise an embedded qualitative design to explore the decision-making of patients invited to 
participate in such trials.   
 
This thesis begins by discussing the position of this research within the current literature 
(chapter 1).  Chapter 2 presents a systematic review of evidence for the use of KDs in the 
therapeutic management of gliomas.  Chapter 3 investigates patient demand for KDs in 
glioma populations and if an adult neuro-oncology KD service could be established in an NHS 
setting, concepts which were essential to understand prior to establishing KEATING.  Chapter 
4 presents the KEATING trial, which assessed KD trial feasibility in an NHS setting (e.g. was it 
possible to recruit and retain patients) and the impact of the trial on patients (e.g. quality of 
life, changes in body mass).  Chapter 5 explores the decision-making of patients invited to 
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participate in KEATING through an embedded qualitative study and finally, the thesis 
concludes in chapter 6 by suggesting the improvements required to KEATING prior to the 






Figure 1: Diagrammatic depiction of thesis outline 
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1.1.1 CHAPTER OVERVIEW  
This chapter begins by introducing the concepts of GBM and KDs, offering an overview of 
both areas and exploring how the two relate.  A summary of the current evidence in this area 
will be provided, however this is limited to animal models and case series or reports (explored 
further in chapter 2).  Given KD is a relatively new concept, its journey from epilepsy to neuro-
oncology will be briefly discussed to provide context.   
 
After discussing GBM and KDs, an introduction to the methodological approaches adopted 
within this thesis to explore the feasibility of using KDs as an adjuvant treatment for patients 
with GBM will also be presented; including methodologies utilised for the scoping service, 
KEATING pilot trial and embedded qualitative study.  The chapter concludes by presenting 




1.2 GLIOBLASTOMA  
1.2.1 Definition and prevalence of gliomas 
 
Gliomas are malignant tumours of the glial tissue of the central nervous system (CNS) and 
are the most common form of primary intracranial tumour in adults, accounting for 81% of 
all malignant brain tumours (2).  Gliomas are graded I to IV, with grade I being the least 
aggressive and grade IV, GBM, the most aggressive.  GBMs affect 4.64 per 100,000 people 
each year in the UK (3).  
1.2.2  Presentation 
 
The clinical presentation of GBM can vary depending upon the location and size of the 
tumour (4).  Patients frequently present with symptoms of raised intracranial pressure and 
oedema, resulting in headaches or neurological deficits.  Seizures are also a common 
clinical presentation, with approximately 20% of patients at initial diagnosis and up to 50% 
of patients over the course of the disease (5).  
1.2.3 Diagnosis 
 
Gliomas are diagnosed using a combination of, magnetic resonance imaging (MRI), 
histopathology and molecular markers.  The diagnostic and management pathway includes 
discussion at an integrated specialist multi-disciplinary team (MDT) meeting.   
1.2.4 Classification 
 
Historically, CNS tumours including gliomas were classified based upon their histological 
appearance under a light microscope.  In recent years the importance of molecular profiling 
has become apparent and is now included in the latest World Health Organisation (WHO) 
classification criteria (6) and has been adopted by the National Institute for Health and Care 
Excellence (NICE) (7).  This criteria adds objectivity to the diagnostic process of gliomas, which 
in turn improves determinations of prognosis and predictions of treatment response  (6).   
 
Gliomas are now presented by histopathological name followed by genetic features to 
provide an integrated molecular-pathology diagnosis.  For GBM there are two categories; 
IDH-mutant and IDH-wildtype.  IDH-mutant accounts for the mutation of the IDH gene, whilst 
IDH-wildtype refers to the lack of mutation of the IDH gene (6).  Promoter region methylation 
of O6-methylguanine-DNA methyltransferase (MGMT) is also used to categorise GBM as the 
methylation of MGMT has been associated with a predicted benefit from temozolomide 
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chemotherapy and improved progression free and overall survival compared to 
unmethylated MGMT patients (8).  In clinical practice alpha thalassemia/mental retardation 
syndrome X linked (ATRX) gene mutations are also included in the genetic testing (7).  
Mutations in ATRX result in a loss of ATRX protein and are expressed in adult astrocytoma, 
suggesting ATRX loss in GBM to highlight an astrocytoma linage.  Within IDH-mutant 
tumours, ATRX loss has indicated a better prognosis in some studies (9).   
1.2.5 Clinical management 
 
Symptomatic management of raised intracranial pressure and seizures are usually the first 
aspects of treatment.  For patients with raised intracranial pressure,  high dose 
corticosteroids, such as dexamethasone, are often used to alleviate the surrounding oedema 
and to improve some observed symptoms (10).  Nearly all patients with GBM will receive 
corticosteroids at some point during their treatment or as the disease progresses.  However, 
steroids are also associated with side effects such as increased appetite, increased serum 
glucose, fluid retention and insomnia.   
 
For patients experiencing seizures, anti-epileptic medication is commenced.  As with steroids, 
anti-epileptic medication is not without its side effects.  These include fatigue, nausea and 
cognitive impairments (11).  There is currently a lack of evidence to support the prophylactic 
use of anti-epileptic medications in this population (12), with clinical trials ongoing in this 
area.  
 
Surgical resection is the second intervention in the clinical management of GBM, followed by 
chemo-radiotherapy.  Maximal safe resection is desired as the extent to which the tumour is 
resected has been associated with a gradual increase in progression free and overall survival 
(13–15).  Technological advances through surgical navigation systems, such as functional and 
intraoperative MRI, have improved surgical procedures by maximising resections whilst 
minimising deficits to neurological function; further enhancing survival and quality of life (16–
18).   
 
In some cases, surgical resections are not feasible, for example due to multi-focal disease and 





Following surgery, patients undergo a course of radiotherapy.  Radiotherapy has been found 
to significantly improve the survival of patients with GBM, compared to no radiotherapy 
(p<0.00001) (19).  It is offered in the form of 60Gy in 30 fractions for patients aged 
approximately 70 years or under with a Karnofsky performance status of 70 or more (7,16).  
Patients over 70 years are often treated with hypo-fractionated radiotherapy, such as 40Gy 
in 15 fractions, achieving similar survival benefits (19,20).      
 
Temozolomide chemotherapy is noted to be of greatest benefit when offered concomitantly 
to radiotherapy at a dose of 75mg/m2, followed by six cycles of adjuvant temozolomide (five 
days in every 28 days at a dose of 150-200mg/m2) for patients aged approximately 70 years 
or under with a Karnofsky performance status of 70 or more (21–23).  Temozolomide is also 
noted to be advantageous for patients with MGMT methylation (8) and could also be 
considered as concomitant to radiotherapy or alone in patients over 65 to 70 years, with 
MGMT methylation and good performance status (24,25).  As a result, radiotherapy plus 
concomitant and adjuvant temozolomide are now considered the standard of care for most 
patients with GBM.  For patients with a poor performance status (Karnofsky score less than 
50), best supportive care is considered the most appropriate option (7,16).   
 
Patients with GBM may develop seizures and oedema, requiring medical management 
through anti-epileptic drugs and steroids (dexamethasone) respectively.  Whilst the 
medications can reduce the burden on symptoms, both can result in side effects which 
negatively impact patients’ quality of life and are often tapered post-surgery if clinically 
feasible (16).  
 
The Response Assessment in Neuro-Oncology (RANO) criteria are used to assess response to 
treatment through regular monitoring of MRIs and changes in clinical features (26).  Clinical 
management in the event of recurrence is variable and can depend upon the performance 
status of the patient, their response to previous treatments and the patient’s wishes.  
Treatments can include lomustine (CCNU) chemotherapy or further surgery (7).  At present 
evidence does not support the use of bevacizumab as a monotherapy (27), but it may have 
potential survival benefits if offered in combination with lomustine (28).    
1.2.6 Prognosis  
 
Despite maximal safe resection, radiotherapy and temozolomide chemotherapy, overall 
survival for patients with GBM remains poor, with a median survival of 14 months in the UK 
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(3) and approximately 30% surviving beyond two years (3,21,29).  Table 1.1 provides a 
summary of the key characteristics of IDH-mutant and IDH-wildtype GBM in relation to 
overall survival (6). 
 
Table 1.1: Characteristics of IDH-mutant and IDH-wildtype GBM adapted from Louis et al. (2016) 
Characteristics Glioblastoma, IDH-wildtype Glioblastoma, IDH-mutant 
Precursor lesion Not identifiable Diffuse astrocytoma 
Anaplastic astrocytoma 
Proportion of GBM ~90% ~10% 
Median age at diagnosis ~62 years ~44 years 
Overall survival: 
Sx + RT 







ATRX mutations Infrequent 71% 
Abbreviations: RT= radiotherapy; Sx = surgery; TMZ = temozolomide chemotherapy. 
 
1.2.7 Treatment developments 
 
Given the poor prognosis for these patients, the past 20 years has seen an abundance of 
research into new medical technologies, particularly in the development of newer 
chemotherapy agents and targeted therapies (30). Yet, research into new chemotherapy 
agents, such as bevacizumab(27), has shown little benefit to survival.   
 
The delivery of local chemotherapy agents has also been investigated, with the development 
of biodegradable carmustine (BCNU) wafers (Gliadel wafers), which are implanted directly 
into the tumour cavity.  However, a phase III trial demonstrated only a moderate 
improvement in survival when compared to placebo wafers (median overall survival 13.9 
months BCNU; 11.6 months placebo; p=0.03) (31).  There may also be a role for catheter-
based, convection-enhanced delivery of chemotherapeutic agents, but this is currently 
undergoing phase Ib testing, with the most appropriate agent and dose yet to be established 
(32).  Yet, this direct delivery of agents via catheters has been trialled previously and did not 
demonstrate any benefits in enhancing survival (33).    
 
Targeted treatments are also growing in interest, with the role of gene therapy and molecular 
abnormalities being explored.  A notable outcome from this being the benefit of 
temozolomide chemotherapy for patients with MGMT methylation (8).  For other targeted 
treatments, such as cilengitide used in combination with radiotherapy and temozolomide for 
patients with MGMT methylation, no improvements in survival were noted (34).  Research is 
ongoing into tumour associated growth factors and anti-angiogenetic strategies (30).   
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The hallmarks of cancer describe tumours as being immunosuppressive (35), which has seen 
an increase in interest in immunotherapies, particularly in the form of vaccines.  As single 
antigens are typically only present in a sub-set of patients and so far vaccines such as 
rindopepitimut have demonstrated no difference in overall survival when combined with 
temozolomide (20.1 months)  compared to temozolomide alone (20.0 months) (36), 
combinations of tumour-associated antigens have been explored, demonstrating positive 
signs towards promoting survival (30).  However, data for combination vaccines is limited to 
phase I clinical trials, is underpowered to test effectiveness and patients still experience side 
effects and toxicities (37,38).  As with chemotherapeutic agents, there may also be a role for 
nanotechnology in aiding the delivery of immunotherapeutic agents in overcoming the 
obstacle of the blood brain barrier of CNS tumours (39).  
 
Whilst demonstrating some promise, these new and exploratory therapies target specific 
pathways or specific sub groups of patients and the reasons for the lack of progress are 
multifactorial but include the marked tumoural heterogeneity, the development of 
treatment resistance and the challenges of delivering drugs across the blood-brain barrier.  
One exception to this is the newly developed tumour treating fields (TTF) device Optune®, 
which adopts a broader approach compared to targeted therapies and has demonstrated 
clinical effectiveness in combination with temozolomide compared to temozolomide alone 
(median overall survival 20.5 months TTF and temozolomide; 15.6 months temozolomide 
alone; p=0.004)(40), whilst maintaining quality of life (TTF and temozolomide compared to 
temozolomide alone p<0.01), in patients with newly diagnosed GBM (41).  Despite illustrating 
clinical effectiveness, TTF technology is yet to demonstrated cost-effectiveness, with an 
incremental cost-effectiveness ratio of €549, 909 per life year gained (42), hence it is 
currently not recommended by NICE (43).   
 
Due to the lack of treatment options and the limited success of clinical trials, alternative 
treatment options are being explored and the James Lind Alliance Priority Setting Partnership 
reports the effect of lifestyle factors, including diet, on tumour growth to be a top 10 research 
priority for the neuro-oncology community (1).   
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1.3 DIET AND ONCOLOGY 
Diet has a dual role in oncology.  Firstly, diet can have a causative or protective effect in 
influencing cancer development.  For example, a high fibre intake is associated with reduced 
risk of bowel cancer (44).  Secondly, diet is viewed as an essential component of cancer care 
post diagnosis with the location of the cancer usually dictating the nutritional implications 
and subsequent management.  For example, cancers of the gastrointestinal tract are likely to 
lead to malnutrition and cachexia due to impaired absorption, reduced dietary intake and 
the pronounced side effects of treatment, which could result in the prophylactic placement 
of enteral feeding tubes.   
 
In gliomas, large scale prospective evidence shows little, if any, association between diet and 
glioma risk (45).  Despite treatment involving surgery, radiotherapy and chemotherapy, 
patients usually experience little, if any, nutritional consequences beyond radiotherapy 
related fatigue and steroid induced weight gain.  Consequently, the current dietary 
recommendations for patients with GBM are based upon national healthy eating guidelines 
(46,47), with referral to a dietitian for bespoke advice for patients at risk of malnutrition (48).  
 
In recent years, there has been a growing interest in the use of nutrition based 
complementary and alternative therapies (CATs), with up to 75% of patients with cancer 
using CATs during the course of their treatment, despite little evidence illustrating efficacy 
or safety (49).  In neuro-oncology, this interest has focused upon KDs for patients with GBM 
and has been driven forward by both research and patient communities.   
 
1.4 KETOGENIC DIETS 
KD is an ‘umbrella term’ used to describe high fat, low carbohydrate, adequate protein diets 
which promote the utilisation of fat for energy, in the form of ketones, thus reducing the 
requirement for glucose and mimicking fasting metabolism.   
1.4.1 History of ketogenic diets 
 
The use of KDs stems back to biblical times when fasting was noted to relieve epileptic 
seizures (Matthew 17:21) (50).  However, the first medical reference of fasting to aid seizure 
management was noted in 1911 (51).  Long term fasting had health limitations, therefore, in 
1921 KDs were developed to mimic the ketotic effect of fasting whilst maintaining a 
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nutritional intake (52).  The dietary intervention was popular for the management of epilepsy 
until antiepileptic drugs were developed in the late 1930s, when it fell out of favour.   
 
In the mid-1990s, KDs resurged in popularity due to increasing interest from parents who 
wished to reduce the epileptic drug burden for their child or to explore new avenues due to 
drug-resistance.  Since then, several randomised controlled trials (RCTs) have proved 
effectiveness of the diet in children with drug-resistant epilepsy (53) and KDs are a 
recommended treatment for drug-resistant paediatric epilepsy by NICE (54).  The KDs 
traditionally used in the management of drug-refractory paediatric epilepsy are described in 
table 1.2 (55).  
 
Table 1.2: A comparison of KDs used in the management of drug-resistant epilepsy in the UK (55–
59) 
Dietary element CKD 
(e.g. 4:1) 




4% ETER 15-30g/d or 
5% ETER 
15-18% ETER 10-20g/d 














Abbreviations: CKD = classical ketogenic diet; MAD = modified Atkins diet; MCT KD = medium chain triglyceride 
ketogenic diet; MKD = modified ketogenic diet; ETER = estimated total energy requirement; ratio 4:1 = 4g of fat 
to 1g of carbohydrate and protein combined.  
In recent years, interest in KDs has grown in clinical conditions other than epilepsy, with 
pre-clinical evidence in gastric cancer (60), colon cancer (61,62), Motor Neurone Disease 
(MND) (63) and traumatic brain injury (64,65) demonstrating positive effects.  Clinical 
evidence from pilot studies has also been generated for children with autism spectrum 
disorder (66) and adults with Alzheimer’s Disease (67), Parkinson’s disease(68), migraine 
(69) and lung and pancreatic cancer (70).  However, the area generating most interest is 
GBM. 
1.4.2 Ketogenic diets in glioblastoma therapy  
 
The interest in KDs for aiding the management of GBM stems from the alterations in the 
metabolism of cancer cells, with an up regulation of glycolysis regardless of the availability of 
oxygen; a discovery made in 1927, the so-called ‘Warburg effect’ (71).  KDs were 
hypothesised to work by exploiting the ‘Warburg effect’ through reducing the availability of 
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dietary glucose and increasing the availability of ketone bodies.  These ketone bodies can be 
readily used for energy by the body, but less readily utilised by the tumour, theoretically 
slowing growth (72–75).  A systematic review and meta-analysis of the antitumor effects of 
KD in mice demonstrated prolonged survival compared with standard diet (mean survival 
time ratio = 0.85 [95% highest density interval = 0.73, 0.97]; hazard ratio = 0.55 [95% highest 
posterior density interval = 0.26, 0.87]) (76).    
 
Recently, new theories have explored other mechanisms of action for KD in GBM, with 
ketone bodies and medium chain triglyceride (MCT) fats playing a role in tumour metabolism, 
rather than or in addition to a reduction in glucose.   Laboratory studies in GBM cell lines 
have shown ketone bodies in the absence of glucose restriction to exert growth inhibition, 
then, when combined with chemotherapy (Carmustine, BCNU) these effects are amplified 
when compared to BCNU or ketones alone (77).  This is further supported by mouse models 
of malignant glioma, whereby KD given alongside temozolomide enhanced survival 
compared to temozolomide alone (78).  The same authors also illustrate the role KDs have in 
potentiating the effects of radiotherapy, with animals living significantly longer when 
compared to radiotherapy alone (79).  Animal models also illustrate KDs to have positive 
effects on reducing peri-tumoural oedema (80) and in reducing tumour angiogenesis (73).  
Thus KDs are viewed to have a broad scope in the possible management of GBM.       
 
MCT fats can be incorporated into KDs; creating the MCT KD which is readily used in the 
management of paediatric epilepsy (see table 1.1.).  The use of MCT in oncology models is 
also growing in popularity for numerous reasons.  Firstly, MCT offers the benefit of  increased 
ketone production (per calorie of energy) compared to long chain triglyceride (LCT) fats due 
to their rapid absorption into the portal system (81) (82) .  Secondly, due to raised ketone 
levels, slightly more carbohydrate can be included in the diet, which improves palatability.  
Thirdly, MCT has an anti-inflammatory effect compared to LCT fats (83).  Finally, various 
oncology animal models have illustrated MCTs to inhibit tumour growth and increase 
survival, compared to classical KDs containing LCT (60,61,83,84).  Interestingly, the role of 
C8-MCT has been illustrated to be of greater benefit than C10-MCT at inhibiting tumour 
growth (83).  Therefore, the type of fat could also play a role in the mechanism of action of 
KDs.   
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Whilst the results appear promising, animal models have limitations.  The ‘dosing’ of the KD 
used in most models is much higher than a KD that can be tolerated in humans, such as a 8:1 
KD in mice versus 4:1 in humans (i.e. 8g fat to 1g carbohydrate and protein combined).  The 
pharmacokinetics is also likely to differ between animal models and humans.  With the 
exception of Scheck et al.,(79) the animal models do not follow the standard treatment 
pathway experienced by patients, such as radiotherapy and chemotherapy, which appears 
to influence the potential effects of KDs.  In many studies, KD is also commenced at 
tumourgenesis which is not replicable in patients.  Studies are further limited by small sample 
sizes and heterogeneity (76).  Thus, further research is required to fully understand the 
mechanism of action of KDs in GBM, including the effect of KDs and ketone bodies on the 
blood brain barrier (85).   
 
In patients with gliomas, the evidence for KD is limited to case studies and case reports.  This 
research is presented in chapter 2 and has been published elsewhere (86).  To summarise, 
the use of a KD for patients with a glioma was first reported in 1995 when two children 
commenced MCT KD as an adjuvant to standard treatment (87).  Six studies have been 
published in total; all utilising different KDs at different time points in the treatment pathway 
(KD initiated at diagnosis; KD initiated at recurrence).  No studies have investigated the 
influence of KDs on anti-epileptic medications or corticosteroids in GBM populations.  
Interestingly, one retrospective, pilot study found corticosteroids to be safe in conjunction 
with a KD for patients with epileptic encephalopathies (88).      
 
From epilepsy literature, KDs are known to have reported side effects, predominantly short 
term gastrointestinal issues at dietary initiation, such as constipation and diarrhoea (53).  
Other side effects reported in a small numbers of patients include pancreatitis, gall stones, 
weight loss and decreased bone matrix density (53).  Whilst the stricter KDs, such as classical 
KD, may attain superior results in relation to effectiveness, they are associated with a greater 
number of side effects when compared to less restrictive KDs, such as MAD (53).    
KDs can also result in altered lipid profiles; however a prospective study has illustrated the 
cardiovascular safety of MAD for 12 months in adults with epilepsy (89).  Further research is 
required to understand the cardiovascular effects of stricter KDs and the long term side 
effects of these dietary regimes (89).   
Whilst KDs appeared to be safe, the acceptability and efficacy of a KD intervention for 
patients with GBM remained to be investigated.        
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1.5 AN INTRODUCTION TO THE THESIS METHODS 
The use of KD in the therapeutic management of GBM was a relatively new concept and in 
its infancy.  Prior to designing and launching a RCT in this area, it was important to understand 
patient demand, service deliverability and trial feasibility within the NHS setting.  Patient 
demand and service deliverability were explored through a survey and scoping service, 
following which trial feasibility was explored in KEATING and an embedded qualitative study.       
1.5.1 Scoping service and survey 
 
When first embarking on using KDs in neuro-oncology attitudes of patients with gliomas 
towards KDs had yet to be explored and it was unknown if there would be sufficient interest 
within the glioma community to support a KD trial.  Therefore, a quantitative survey was 
developed by a multi-disciplinary research team, to provide insights into patient demand for 
this potential healthcare intervention (90,91).  This was distributed on a local and national 
scale.   
 
It was also important to understand if KDs could be delivered to adult patients with high 
grade gliomas in NHS hospitals.  At the time the only funded services were for paediatric 
epilepsy.  The experience of establishing a new NHS service for adult neuro-oncology would 
provide essential learning opportunities if a trial were to be used in the future as a means to 
develop new KD services in recruiting sites.  Whilst animal models have illustrated KDs to be 
most beneficial when offered alongside radiotherapy, it was unknown where in the 
treatment pathway patients would follow the diet (e.g. pre-treatment, at recurrence) and to 




1.5.2 Feasibility study 
 
A feasibility study was undertaken to explore KDs as an adjuvant therapy for patients with 
GBM.  This involved a pilot trial (KEATING; section 1.5.3) and an embedded qualitative study 
(section 1.5.4).     
 
Figure 1.2: Ketogenic diet feasibility study for patients with glioblastoma (adapted from 




1.5.3 KEATING pilot trial 
 
The use of the term ‘pilot study’ is widespread and has a multitude of meanings in clinical 
research.  For the purpose of KEATING, ‘pilot study’ refers to a preparatory study designed 
to investigate the capabilities of study design, recruitment feasibility, barriers to study 
completion, acceptability of the intervention to patients, time required for study 
participation, estimates of missing data and attrition, and protocol refinements to enable the 
development of future studies (93,94).  Given the lack of previous research, assessing such 
parameters via a pilot study was essential prior to designing a phase III KD clinical trial for 
GBM.      
 
For KEATING a prospective, non-blinded, randomised pilot study design was selected to 
mirror the study designs of future RCTs.  As it was unknown which KD, if any, would be 
effective in GBM management, two KDs previously noted within the literature were selected 
for KEATING.  A control arm was not used at this stage as the acceptability, tolerability and 
feasibility of KDs alongside standard treatment were being explored, rather than the 
feasibility of randomisation between diet and no diet.  A multi-arm multi-stage trial design 
was considered for the inclusion of a control arm (95,96), however the sample size required 
to run such a study was beyond that which could be achieved by a single site and beyond the 
scope of this thesis.      
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Over time, KEATING experienced issues with recruitment and retention of diet.  Hence, a 
qualitative study was embedded to explore patients’ decision-making when invited to 
participate in the trial.   
 
1.5.4 Embedded qualitative study  
 
Qualitative research is becoming increasingly useful within clinical trials as an embedded 
component.  It can be useful to explore uncertainties which may impact the success of clinical 
trials, such as recruitment, retention, study and intervention acceptability, implementation 
and practicality, rich data on which is difficult to obtain by quantitative means (97). 
Qualitative methods can be utilised before, during or after a clinical trial, to optimise trial 
design and practises with a view to enhancing participant experience and trial success 
through the generation of theory and models to guide intervention development (98).  When 
situated prior to a trial, qualitative methods are used to inform trial design, by addressing 
uncertainties and barriers raised by trial stakeholders, such as participants or clinicians to 
enhance the acceptability of trial procedures (97).  When embedded and used during a 
clinical trial, qualitative methods can assess the feasibility and deliverability of the 
intervention (99),  explore knowledge and understanding of trial methods (such as informed 
consent, decision-making, randomisation) and aid understanding of the participants 
perceptions of processes related to implementation and change (100).  After a clinical trial, 
qualitative research can be used to further interpret the findings of the trial, explain 
variations in results, explore the participants’ experiences of the trial and participants’ views 
regarding acceptability of the study intervention (98,100).   
Whilst there is an abundance of literature regarding the decision-making of patients involved 
in drug trials, there is little literature exploring the decision-making of incurable oncology 
populations in feasibility or early stage clinical trials, especially for dietary interventions.  
Qualitative studies have been successfully embedded into diet-oncology trials for breast and 
prostate cancers over recent years, exploring the feasibility and acceptability of dietary and 
lifestyle interventions, along with recruitment challenges and patient experiences (101–107).  
It is difficult to extrapolate these results to a KD trial for patients with GBM given the 
disparities in survival and the interventions.   
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Prior to KEATING, KDs had yet to be explored by qualitative means, either in the context of a 
trial or within clinical practice (including other conditions such as epilepsy).  Therefore this 
qualitative study was the first to explore patients’ experiences of KDs and their decisions to 
enter into and continue to participate in the trial, enabling the design of bespoke strategies 
to optimise informed consent and patient experience in future trials.   
1.6 THESIS AIMS AND OBJECTIVES 
Aim:  
 To explore the feasibility of using KDs as an adjuvant therapy for patients with GBM. 
 
Objectives: 
 To review the evidence for efficacy and acceptability of different KDs in the 
therapeutic management of patients with gliomas. 
 To explore the level of interest from patients with gliomas to support a KD RCT. 
 To explore if KDs can be delivered to adult patients with gliomas in an NHS setting. 
 To investigate if the KEATING protocol is feasible within an NHS setting and what 
impact this will have on the health of patients with GBM. 
 To explore patients’ perspectives of their decision-making when invited to 
participate in KEATING. 






A SYSTEMATIC REVIEW OF THE EVIDENCE FOR THE USE OF KETOGENIC 
DIETS IN THE THERAPEUTIC MANAGEMENT OF GLIOMAS 
 
2.1 CHAPTER OVERVIEW 
This chapter discusses the existing evidence for the use of ketogenic diets (KDs) in the 
therapeutic management of gliomas.  A systematic review and meta-analysis investigating 
the systemic anti-tumour effects of KDs in mice demonstrated a prolonged survival for the 
KD groups compared to standard diet (mean survival time ratio [MR] = 0.85 (95% highest 
posterior density interval = [0.73, 0.97]) and hazard ratio = 0.55 (95% highest posterior 
density interval [HPDR] = [0.26, 0.87])) (76).  Interestingly, KD was less effective in the brain 
tumour subgroup (MR = 0.89, 96% HPDR =0.76, 1.04), with the brain tumour model selecting 
a later starting point for KD (at least one day after tumour initiation), accounting for 26% of 
the heterogeneity, rather than initiating KD at tumourgenesis as conducted in the systemic 
cancer models (76).   
However, no such systematic review or meta-analysis existed for human studies.  For studies 
of GBM in patients, different types of KDs are utilised at different time points in the treatment 
pathway and it was not known which KD, if any, was effective and which carried the greatest 
burden for the patient.  Therefore, this systematic review not only assessed efficacy, but also 
quality of life and adverse events for the different diets.   
The chapter follows published guidance for the conduct of systematic reviews (108) and 
begins by presenting the aims of the review and methodology adopted.  The results include 
a risk of bias assessment, a summary of the effects of the intervention and of ongoing clinical 
trials in the field of KD and glioma.  Finally, the quality and acceptability of the evidence are 
discussed, concluding with implications for future practice and research.     
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2.2  INTRODUCTION 
2.2.1  Scoping search 
 
A scoping search was undertaken to aid the development of the research question.  Data 
collection categories included authors, year of publication, study location, study design, 
dietary intervention, study population and outcomes (109).     
From the results there appeared to be a small, but adequate, volume of evidence available 
from which to undertake a systematic review.  No randomised controlled trials (RCTs) were 
identified for the use of KDs in gliomas in humans; however, a range of other study designs 
were identified.   
2.2.2  Research question and aim 
 
Is there a role for KDs in the therapeutic management of adult and paediatric gliomas? 
Aim: To review the evidence for efficacy and acceptability of different KDs in the therapeutic 
management of patients with gliomas. 
2.3  METHODOLOGY 
The protocol for this systematic review was registered with PROSPERO (identification 
number: CRD42017056752).  
  
 21 
2.3.1  Inclusion criteria 
 
The inclusion criteria are illustrated in table 2.1 using the PICO method.  
Table 2.1: A PICO table illustrating review inclusion criteria.  
Population Adults and children with glioma tumours following a KD. 
Intervention Any form of KD, with KD defined as a diet that is designed to produce ketones. 
Comparator Other KDs or control diet thought to have no effect on gliomas*. 
Outcomes Objective or self-reported measures are acceptable for the following outcomes: 
Primary outcomes: 
 Overall survival 
 Progression free survival 
 
Secondary outcomes: 
 Adverse events 
 Retention rates 
 Quality of life 
 Acceptability  
 Tolerability 
 Compliance 
 Duration of KD 
 Time of dietary 
commencement (in relation 
to treatment pathway) 
 Ketone levels 
 Glucose levels 
Setting Primary, secondary or tertiary healthcare.  Inpatient, outpatient or community 
settings.  
Study design  All. 
*A comparator diet is unlikely to be identified following the results of the scoping search, therefore a comparator 
is not essential to the inclusion criteria and all study designs are permitted.  
No restriction was placed on year of study or publication status.  The search was limited to 
English language publications.   
2.3.2  Search strategy  
 
A four part search strategy was implemented to identify suitable studies for the review.  
2.3.2.1 Electronic searches 
The following electronic databases were searched:   
1. EMBASE  
2. PubMed 
3. Cochrane Library 
4. CINAHL Plus 
5. MEDLINE 
6. SCOPUS 
7. Web of Science 
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This search was undertaken on 25th January 2017, with updates identified until 18th August 
2017.  An example search strategy can be found in appendix A.   
2.3.2.2  Hand searches 
References from literature included in the review were hand searched to identify other 
possible studies.   
2.3.2.3  Study registries 
The following study registries were searched: 
1. ClinicalTrials.gov 
2. The World Health Organisation International Clinical Trials Registry Platform 
3. UK Clinical Trials Gateway 
4. International Standard Randomised Controlled Trial Number Register (ISRCTN) 
5. National Institute of Health Clinical Trials Registry  
6. National Research Register Projects Database Achieve   
7. PROSPERO 
This search was undertaken on 21st March 2017, with updates identified until 18th August 
2017. 
2.3.2.4 Other resources 
Conference abstracts and posters were included in the search to identify ongoing or recently 
completed studies.   
2.3.3  Screening and selecting 
 
2.3.3.1  Duplicate references 
Duplicate references were removed from the search results using Mendeley© reference 
manager (Elsevier, London, UK) and manual searching.   
2.3.3.2  Inclusion criteria pilot 
An inclusion criteria pilot was undertaken using the below tool (table 2.2) to screen titles and 
abstracts to identify full text papers suitable for inclusion in the review.  The tool was piloted 
on 30 articles (108), no alterations were required.    
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Table 2.2: Inclusion criteria screening tool (108) 
Review question: Is there a role for KDs in the therapeutic management of adult and paediatric 
gliomas? 
Aim: To review the evidence for efficacy and acceptability regarding the effects of different KDs in 
the therapeutic management of patients with gliomas.  
Reviewer initials: Date: 
Author: Year: 
Title: Journal: 
 Include Exclude 
Population  Adults or children with glioma  Adults and children with 
other cancers 
Intervention  Ketogenic diet  Other diets 
Comparator  None required  n/a 
Outcomes  Survival (overall or 
progression free) 
May also include: 
 Adverse events 
 Retention rates 
 Quality of life 
 Type of KD 
 Duration of KD 
 Time of dietary 
commencement 
 Compliance 
 Acceptability  
 Tolerance  
 Ketone levels 
 Glucose levels 
 No survival 
Study design  Any  n/a 
Overall decision  INCLUDED  EXCLUDED 
Notes  
 
2.3.3.3  Screening of included studies  
Inclusion criteria were applied to titles and abstracts identified in the search results.  For 
those studies identified for potential inclusion full text was obtained and inclusion criteria 
reapplied.  Screening was conducted by one author (KJM), with a second author cross 
checking 10% of the screening (NS).       
Following this, an expert in the area (Dr Adrienne C Scheck, Associate Professor, Dignity 
Health, Phoenix, USA) was contacted to ensure all relevant studies were obtained and to 
identify if any current studies were shortly due for completion or publication.  
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2.3.3.4  Reporting results of searches  
Records of search methods were maintained to allow for replication and update searches to 
be undertaken.  The following information was recorded (108): 
 Date search undertaken 
 Database version and interface used 
 Search terms for each individual search 
A PRISMA flow diagram was then be adopted to document the number of references located 
from databases searched and other sources, number of duplicates removed, records 
screened, records excluded, full text articles screened, full text articles excluded with reasons 
and the number of studies included in the final review (110).   
2.3.4  Data extraction 
 
Data extraction was undertaken by two authors independently (KJM and NS).  Discrepancies 
were discussed between the authors in the first instance.  Any disagreements were resolved 
by discussion.  A third author (MDJ) was available for consultation if required.   
A data extraction form was used to standardise the procedure.  This form was piloted on two 
of the included studies, following which the data extraction tool was adapted to specify 
duration of intervention (mean, median and range), duration of follow up periods and to 
clarify language. 
Types of data extracted included descriptive data; study characteristics (author, publication 
year, full paper/ abstract, location, funding, study design, duration of study, dietary 
intervention, dietary duration, dietary commencement, follow up period), population 
characteristics (mean age, gender, previous treatment, number of participants), and 
analytical data (overall survival, progression free survival, adverse events, retention rates, 
quality of life, compliance, tolerance, ketone level, glucose level).   
In the event of missing data, the author(s) were contacted via email.   
It was not possible to conduct a meta-analysis due to the heterogeneity of the methods and 
interventions of the included studies, therefore effect size could not be established (without 
bias).  This was assessed by two of the review authors (KJM and NS).    
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2.3.5  Quality assessment 
 
All study types were permitted for inclusion in the review, yet only case studies and case 
series were identified.  Thus, the Institute of Health Economics (Canada) Case Series Quality 
Appraisal Checklist was selected as the appropriate quality assessment tool (111)(see 
appendix B).  The tool was updated to include assessor annotations specific to this review as 
recommended by the tools authors (111).  
The quality assessment tool was piloted on two studies to ensure suitability.  Two authors 
(KJM and NS) independently quality assessed each study and then compared results to 
identify any conflicting evidence.  All disagreements were resolved by discussion.  Quality 
assessment took place after data extraction to minimise reporting bias.  Results of this 
exercise were tabulated.  It was not possible to assess the confidence of cumulative evidence 
as the evidence is based on case series, for which no scale existed to the authors’ knowledge.  
2.4  RESULTS 
2.4.1  Description of studies 
 
2.4.1.1  Results of the search 
Following the search strategy cited above 2380 records were identified, along with two 
additional records identified through other sources (hand searches of included references).  
After removing duplicates 1713 records remained.  Following the screening of records 19 
remained eligible for inclusion.  These studies underwent a full text review, following which 
a further 13 studies were excluded due to inappropriate interventions (112,113), 
inappropriate populations (114–118) and inappropriate outcome measures (119–123).  Six 
studies met the eligibility criteria for this review (87,124–128).  Figure 2.1 illustrates the 
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2.4.1.2 Included studies 
Six studies have been published since 1995, conducted in the USA and Europe. Of the six 
studies, one study was a retrospective case report (128), two retrospective case series 
(124,127), two prospective case reports (87,126) and one prospective case series (125).  One 
study was conducted in paediatrics (87) and five in adults (124–128).  Population sample size 
varied between one and 20 participants.  A variety of KD interventions were used, ranging 
from energy restricted KD (126,128), MAD (127), MCT KD (87) and 50 to 60g carbohydrate 
KDs (124,125).  Dietary duration ranged from one to 24 months.  Table 2.3 provides a 
summary of the study characteristics.  Further details can be found in appendix C.  
 
2.4.2  Risk of bias in included studies      
 
All six studies were quality appraised for internal validity.  No study met all quality assessment 
criteria set out by the Institute of Health Economics (Canada) Case Series Quality Appraisal 
Checklist (129).  A summary of quality assessment of included studies can be found in table 
2.4.  For further details refer to characteristics of included studies tables (appendix C).    
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Abbreviations: CHO= carbohydrate; ERKD= energy restricted ketogenic diet; GBM= glioblastoma; KD = ketogenic diet; MAD= modified Atkins diet; MCT = medium chain triglyceride; QoL= 
quality of life; RT= radiotherapy; S.D= standard deviation; Sx= surgery; TER= total energy requirements; TMZ = temozolomide; USA= United States of America; Yrs= years.  Definitions: Post 
treatment defined as post-surgical resection, radiotherapy and concomitant chemotherapy (full details see appendix C).
Table 2.3: Study characteristics  Survival data  
(median [range]) 




























Safety n=6 34-62 Grade III-IV 
glioma 
50g CHO KD Post Sx prior to 
RT/ TMZ 
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(3-13 weeks) 
Schwartz 




Unclear n=2 52-55 GBM ERKD  
(80% TER), 
3:1 

























Unclear n=1 65 GBM ERKD 
(600kcals), 
4:1 
Post Sx prior to 
RT/ TMZ 
1.8 25 No data 43 weeks 
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Abbreviations: OM = outcome measure(s), AE = adverse events,  = yes (item adequately addressed),  = no (item not adequately addressed),  = partial (item partially addressed), U = 
unclear, NA = not applicable.   


































































































































































































































































































































































  U        U  U U       
Nebeling 
et al., 1995 
   U       U  U U       
Rieger et 
al., 2014 
          U  U        
Schwartz 
et al., 2015 
   U       U   U       
Strowd et 
al., 2015 
          U  U        
Zuccoli et 
al., 2010 
   U   U    U  U NA       
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2.4.3  Effects of interventions  
 
A summary of the outcomes listed below can be found in table 2.5.  
2.4.3.1  Critical outcomes 
Overall survival 
Four studies (n=36) reported overall survival (87,124,125,127).  Follow-up ranged from six to 
91 weeks.  Two studies comprising of 10 patients reported no deaths (87,127).  Two studies 
comprising of 22 patients reported survival ranging from six to 88+ weeks (125,126).  Overall 
survival can be related to diagnosis and dietary intervention in table 2.3.   
Progression free survival 
Five studies reported progression free survival (PFS) (n=30).  Time to progression ranged from 
three to 45 weeks in four studies (124–126,128).  One study comprising of two patients 
reported no progression following 62 weeks on diet at the time of publication (n=1), however 
PFS for the second patient was not reported.  PFS can be related to diagnosis and dietary 
intervention in table 2.3.  
2.4.3.2  Important outcomes 
Adverse events 
All studies reported adverse events (n=39). The most frequently reported adverse events 
related to KD interventions were weight loss (124–128)), ranging from -2.2% (125) to -13% 
body weight (128) and increased cholesterol (87,126).   Other adverse effects reported in low 
numbers were deep vein thrombosis (124), grade III leukopenia (125), lymphopenia (128), 
hyperuricemia (128), hypoproteinemia (87). 
Dietary retention rates 
The retention rate could be determined for three studies (n=24), all of which were 
undertaken prospectively using a defined protocol, with retention  ranging from 50-100% 
(87,125,126)].  Retention was determined at eight weeks (n=2) (87)], 12 weeks (n=2) (126)] 
or at point of tumour progression (n=20) [22] (median PFS 5 weeks, range 3-13 weeks).  
Reasons for withdrawal from diet included tumour progression (n=1) (126)] and negative 
impact on quality of life (n=3), but no validated tool was documented (125).   
Quality of life 
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No studies reported upon quality of life using the appropriate objective or subjective 
measures.     
Acceptability  
No studies reported upon dietary acceptability using the appropriate objective or subjective 
measures. 
Tolerability 
Two studies reported dietary tolerability (n=18).  Grade I constipation was reported at dietary 
initiation (n=2), grade I fatigue (n=4) during radiotherapy and grade II fatigue (n=1) during 
30% energy restricted 30-50g carbohydrate KD (124).  Gastrointestinal assessment reported 
diarrhoea at a mean intensity of <1 (weak), constipation at a mean intensity of <1 (weak), 
hunger of mean intensity of >1 but <2 (weak to moderate) and demand for glucose mean 
intensity of >1 but <2 (weak to moderate), using a non-validated questionnaire (n=12) (125). 
Compliance 
Three studies reported upon dietary compliance (n=24).  Maintenance of ketosis was used as 
a surrogate for compliance in two studies (87,126), whilst patient self-reporting was used in 
the remaining trial and indicated compliance for 6.8 days per week (n=20) (125). 
Ketone levels 1 
Five studies reported ketosis (n=24).  Three studies reported serum ketosis (n=6), with levels 
of 0.3mmol/L* to 7mmol/L (n=4) (124,126) and maintenance of serum ketosis was reported 
by one study (n=2) (87).  Urinary ketosis was reported by two studies (n=14).  One study 
reported urinary ketones between 1.5-2.5mmol/L during first three weeks of diet (n=1) (128).  
In the other, urinary ketosis was achieved at least once in 92% participants (n=12/13) and 
when assessing all urinary measurements from 12 participants, ketonuria was present in 73% 
of cases (125).  Methodology and frequency of testing was not consistent between studies.      
Glucose levels 2 
                                                          
 
1 * indicates reported units have been converted to mmol/L from mg/dl for comparison.       
 
2 * indicates reported units have been converted to mmol/L from mg/dl for comparison.       
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Five studies reported serum glucose levels (n=18).  Three studies (n=14) reported a decrease 
in serum glucose during diet compared to pre diet levels.  Levels varied from a mean non 
fasting serum glucose of 7.9mmol/L* pre diet (no S.D.) to 4.7mmol/L* (no S.D.) (n=4) (124), 
to 7.5mmol/L pre diet decreasing to 3.5mmol/L during diet (n=1) (128), with a less extreme 
response noted in one study (5.5±1.2mmol/L* pre diet to 5.1±0.5mmol/L*during diet; n=9) 
(125).  One study reported serum glucose levels during diet only (3.5-5.5mmol/L; n=2) (87) 
and one study reported serum glucose could not be maintained below the target of 
4.4mmol/L* (n=2) (126).     
2.4.4  Ongoing trials  
 
2.4.4.1  Results of search 
Seventeen records of ongoing trials were identified within study registries.  After removing 
duplicates, 11 records relating to 11 unique trials remained (total participant n=265), all of 
which were eligible for this review (130–141) (see appendix D for details).  Of the 11 trials, 
five are being conducted in the USA.  All 11 studies are for adult GBM populations, with 
sample sizes ranging from six to 60 participants.  The studies are being conducted at different 
time points in the treatment pathway, from new diagnosis to recurrence and are utilising 
different types of KDs, including energy restricted KD, intermittent fasting KD, MCT KD, MAD.  
Table 2.6 illustrates a summary of ongoing clinical trials.   
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Abbreviations: = systematic review outcome present in study; = systematic review outcome not present in study.  
 
Table 2.5: Summary of outcomes of included studies   
Population: Adult and children with gliomas 
Setting: USA and Europe 
Intervention: Any form of KD, with KD defined as a diet that is designed to produce ketones  




































































































































Champ et al., 2014              
Nebeling et al., 1995              
Rieger et al., 2014              
Schwartz et al., 2015              
Strowd et al., 2015              
Zuccoli et al., 2010              
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Table 2.6: Summary of ongoing clinical trials 
Study Location Population condition Population 
size 
Dietary intervention(s) Primary outcomes Secondary outcomes 
Ghodsi , 2012 Iran Post Sx, CRT GBM 20 ER MCT KD (50% MCT, ER to 
25kcal/kg/day) 
Survival Quality of life 
Guimaraes Santos & 
Pereira da Fonseca, 
2016 
Brazil Recurrent GBM 30 KD v control with intranasal 
administration of perillyl 
alcohol 
Tumour size Anthropometry  
Jameson, 2014 New 
Zealand  
Newly diagnosed GBM 20 KD (<30g CHO/day) PFS Ketosis 
Treatment compliance 
Dietary compliance  
Food satisfaction 
SGA 
Adverse events  




Adverse events  
Tolerability  
Klein, 2016 USA Newly diagnosed GBM 6 ER 4:1 KD (1600kcals/day) Safety Efficacy 
Tolerability   
Rieger & Steinbach, 
2012 
Germany Recurrent GBM 50 ER KD with IF (<60g CHO/day) 











Scheck, 2014 USA Newly diagnosed GBM 14 4:1 KD reduced to MAD post 
CRT 
Adverse events Overall survival 
PFS 
Quality of life 
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Abbreviations: 4:1= 4g fat to 1g of carbohydrate and protein combined; CHO= carbohydrate; CRT= chemoradiotherapy; ER= energy restricted; GBM= glioblastoma; IF= intermittent fasting; kcals= 
kilocalories; KD= ketogenic diet; kg= kilograms; MAD= modified Atkins diet; MCT= medium chain triglyceride; MKD= modified ketogenic diet; PFS= progression free survival; SGA= subjective 
global assessment; Sx= surgery; UK= United Kingdom; USA = United Stated of America.   
 
Schwartz, 2012 USA Newly diagnosed GBM 12 ER KD 
(20-25kcals/kg/day) 
Tumour size None stated 
Song, 2016 China Recurrent GBM 60 KD v standard diet Adverse events Chemotherapy sensitivity 
Overall survival 
Ketosis 
Quality of life 





Seizure frequency  
Vaisman, 2010 Israel Recurrent GBM 40 KD v standard diet Tumour size Performance scale 
Quality of life 
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2.5  DISCUSSION  
2.5.1  Summary of main results  
 
This systematic review identified no high quality prospective studies assessing KD for glioma, 
but did identify a number of small RCTs that are currently on-going.  All six published studies 
included in this review reported overall or progression free survival, however due to the 
limited sample sizes (ranging from one to twenty participants) and the absence of a control 
group, it is not possible to make any conclusions as to the efficacy of the KD interventions.  
Adverse events were consistent across the majority of studies, predominately being weight 
loss and raised cholesterol, although two studies adopted an energy restricted KD, following 
which weight loss would be expected (126,128).  The significance and clinical impact of 
weight loss would need to be considered and could be managed through non-energy 
restricted, non-fasting regimes supported by a trained health care professional (87).  The 
impact of raised cholesterol profiles should also be considered within the context of the 
disease.  Patients have a limited expected survival; therefore raised cholesterol may not be 
a significant patient burden and requires further investigation.   
Dietary retention rates varied from 50 to 100%, but only three studies utilised a study 
protocol with predetermined intervention duration.  As sample sizes of these studies range 
from two to 20 participants the external validity of such data is questionable.  No study 
reported upon quality of life or dietary acceptability using the appropriate objective or 
subjective measures.   
Dietary compliance was inconsistently measured, with two studies citing the presence of 
serum ketones as a marker of compliance (87,126), and one study using self-reported 
measures (125).  Both methods have their limitations; including selection bias with eligibility 
criteria requiring patients to be compliant with the diet prior to recruitment (126) and 
reporter bias from self-reported measures (125).  Due to the diversity in methodologies, it is 
not possible to determine which diet was easier for participants to comply with.   
A trend for the decrease in serum glucose levels, whilst adhering to a KD, can be noted across 
the studies, with glucocorticoids having a negative impact on levels.  However, the clinical 
impact of this cannot be determined from the results of the studies so far.  Five studies 
reported upon ketones, yet due to different methodologies of urinary and serum reporting, 
no cross comparisons can be made between the diets.    
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This review also identified 11 ongoing studies, four of which were RCTs.  Three RCTs may be 
suitable for future meta-analysis (131,132,134).  These studies have comparable populations, 
outcome measures, control groups and similar dietary interventions, but further dietary and 
methodological details would be required to assess the appropriateness of such an analysis.   
The planned recruitment figures remain small and the trials are not powered to demonstrate 
efficacy.  A multi-centre RCT or the ability to undertake a meta-analysis is required.     
2.5.2  Overall completeness and applicability of evidence 
 
This review identifies only six case series, with a total population of 39 adults and children 
with gliomas.  Due to clinical and methodological heterogeneity it was not possible to 
conduct a meta-analysis.  There was no consensus for which diet is the most appropriate in 
terms of efficacy, dietary retention, tolerability, compliance or adverse events.  For outcomes 
such as tolerability and compliance, varying and in some cases inappropriate measures have 
been applied.  No studies used validated measures to assess quality of life or dietary 
acceptability and are thus subject to performance bias.  The effect of a KD on these outcomes 
is unknown.  Whilst studies note the KD to reduce serum glucose and increase ketones, 
desired targets have not been established through this review.  The evidence base has also 
yet to establish a favourable point in the treatment pathway at which the diet should 
commence and for what duration.  Thus, demonstrating the limitations of evidence for KD in 
gliomas and resulting in a lack of meaningful conclusions.  Any observations noted in 
improved survival times could be a mere coincidence, highlighting the need for further, high 
quality research to address these issues.   
2.5.3  Quality of the evidence  
 
The quality of the evidence is very low due to small sample sizes and high risk of bias, 
secondary to the methodological limitations of the case series.  Heterogeneity existed across 
the studies, due to differences in methodologies, dietary interventions and commencement 
of diet in relation to the treatment pathway.  Further research is required, providing high 
quality evidence in which clinical guidelines and services could be directed.   
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2.5.4  Potential biases in the review process  
 
Databases were thoroughly searched to identify studies suitable for this review.  Application 
of the eligibility criteria to the results identified six studies for inclusion.  Given the relative 
novelty of KD in its application to gliomas, a low number of editorials were expected.  As the 
search strategy was first piloted and the results of the search strategy supplemented by hand 
searches, it is unlikely that relevant studies were missed, further confirmed through contact 
with an expert in the field.  Therefore conclusions drawn from the review are based upon all 
available evidence.   
Language bias is present in this review.  Included studies were limited to those published in 
the English language, which may influence the positive nature of the findings.  Publication 
bias is difficult to omit, yet through searching study registries, including grey literature and 
contacting experts in the field, the review has minimised this element.       
A key strength of this review lies in the quality assessment of included studies.  The Institute 
of Health Economics (IHE) (Canada) Case Series Quality Appraisal Checklist (111) is the only 
validated quality appraisal tool for assessing the methodological quality of case series.   
A key strength of the IHE Case Series Quality Appraisal Checklist lies within its methodological 
development; a Delphi process to devise the appraisal tool criteria, a pilot exercise assessing 
inter-rater reliability, and a formal validation process using principle component analysis 
(111,142).  The tool is specifically designed for use in treatment intervention case series 
studies.  The tool was also updated to include assessor annotations specific to this review as 
recommended by the tools authors (111), to aid the quality appraisal process (see appendix 
B).  The tool does not provide a scoring system in which study quality may be distinguished 
as high or low, hence it was not possible to strictly assess the confidence of cumulative 
evidence.  As such, a narrative approach was taken in this review.  No study fulfilled the full 
study-design criteria of the quality assessment tool.  Further validation of the IHE Case Series 
Quality Appraisal Checklist is ongoing.     
Three studies utilised, and were contacted to provide, a study protocol (87,125,126).  One 
study author (126) provided the trial protocol and there appeared to be no suggestion of 
selective reporting bias.  Despite Nebeling et al. (1995) (87) utilising a study protocol, study 
eligibility criteria were not commented upon in the publication, creating low internal validity.  
Protocols were not used in the remaining studies (124,127,128), therefore there is an unclear 
risk of reporting bias for these studies as the information provided in study publications is 
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the limit to knowledge of the methodologies used and outcomes reported.  Quality 
assessment in these cases could not adequately be addressed, resulting in unclear risk of bias 
judgements.  It is also unclear if any studies blinded assessors to the intervention that 
participants were receiving; consequently it was not possible to assess performance or 
detection bias in any study.   
One study included a retrospective control group (124), but failed to statistically or 
descriptively compare the control group to the dietary intervention group.  The control group 
was also unlikely to represent the population due to convenience sampling methods and 
eligibility criteria requiring variables not held within the records, thus creating selection bias.  
Therefore this study design was also considered a case series.   
A meta-analysis was not undertaken in this review for several reasons.  Study populations 
varied from newly diagnosed grade III or IV gliomas to recurrent gliomas, thus receiving 
varying oncological treatments whilst receiving the dietary intervention.  The dietary 
interventions also varied, in terms of energy restrictions, carbohydrate restrictions and types 
of dietary fats included.  One trial also included fermented yoghurts and plant oils in addition 
to KD, presenting difficulties in evaluating clinical benefits.  Outcomes were variable between 
studies, along with the methodologies used to assess these outcomes and it was not possible 
to establish treatment effects as trials were underpowered.  Therefore a meta-analysis was 
not undertaken as the overall measure of treatment effect would be misleading.  Ongoing 
studies may provide appropriate data and synergy between protocols to allow for meta-
analysis in future reviews.         
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2.5.5  Agreements and disagreements with other studies and reviews  
 
We found no convincing evidence for the efficacy of KDs in gliomas and it is not possible to 
distinguish if one KD diet holds promise over another KD.  Dietary acceptability within this 
population also remains to be established.  The current evidence suggests that KDs do not 
appear to be harmful to this population.  Hence, this review is in agreement with the current 
standard of care for glioma patients and is in keeping with previous literature.       
2.6  IMPLICATIONS  
2.6.1  Implications for practice 
 
Due to the lack of high quality evidence it is difficult to justify the use of KDs in a clinical, non-
research setting.  Further evidence is required to explore efficacy, dietary acceptability and 
an assessment of cost effectiveness, prior to its implementation alongside the current 
standard of care in this population.  There is no evidence to justify the use of KDs as a 
replacement for the current standard of care.      
2.6.2  Implications for research 
 
Key areas for future research are: 
1. A pragmatic feasibility study to inform future RCT design; with outcomes related to 
adverse events, dietary retention rates, quality of life, dietary acceptability, 
tolerability and compliance, using validated measures. 
2. Determining if KDs are effective in the management of glioma, through high quality 
RCTs.  It will be important to consider which KD, if any, is beneficial and at what point 
in the treatment pathway.  KD concurrent to chemoradiotherapy in animal models 
has proven to potentiate the treatment effects; however, this is yet to be replicated 
within patients with GBM.   
3. A health economic assessment to establish efficiency, clinical effectiveness and value 
of the intervention, would be beneficial.  Establishing quality adjusted life years 
would be of benefit to assess disease burden, in terms of quality and quantity of life 
gained by patients, if at all any.     
2.7  CONCLUSION 
This review is based on case series evidence, the lowest position in the evidence hierarchy.  
At present this is the only published evidence available to inform decisions regarding the 
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implementation of KDs for gliomas.  While the review has found minimal adverse events, 
suggesting KDs to be safe in this population, the evidence for efficacy and acceptability of 
various KDs is insufficient to suggest they have a therapeutic effect in the management of 
gliomas.  Further high quality research would be of benefit.     
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ESTABLISHING A NHS KETOGENIC DIET SERVICE AND AN ASSESSMENT 
OF THE LEVEL OF PATIENT INTEREST FOR KETOGENIC DIETS IN GLIOMA 
 
3.1  CHAPTER OVERVIEW 
Before a ketogenic diet (KD) clinical trial could be established, it was important to assess 
patient demand for KD in glioma and if a KD service could be delivered within the National 
Health Service (NHS).  At this stage, the only funded KD services within the NHS were for 
paediatric patients with epilepsy; therefore no infrastructure was in place to support a KD 
clinical trial for adult patients with glioblastoma (GBM).   
This chapter begins by discussing the potential benefits of involving patients in research, 
before considering the challenges of establishing a trial to assess the efficacy of KD 
interventions for patients with gliomas within the NHS.  A survey and scoping service were 
utilised to explore these issues, the methodology for which is explained.  The chapter then 
presents the survey and scoping service results, before discussing the results and limitations 
to the study design, concluding with recommendations for future trials.         
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3.2  INTRODUCTION 
When establishing a trial to explore the clinical effectiveness of a novel intervention, it is 
unrealistic to envisage embarking on a randomised controlled trial (RCT) without any 
fundamental foundations.  First, it is important to understand if patients would be interested 
in participating in the trial, if they consider the intervention to be agreeable and if the 
research area is of interest to them, in order to explore the demand for services and scope 
for recruiting to clinical trials (143,144).  When relating this to a KD trial it is important to 
consider; i) if there is sufficient local and national interest in KDs within the glioma 
community; ii) if a KD service is offered to patients with glioma, which patients will follow the 
diet and at what point in the patient pathway; and iii) if KD can be delivered to adults in an 
NHS setting.   
Secondly, assessing the efficacy of interventions such as KDs within the NHS poses a number 
of challenges that need to be considered in order to inform trial design and feasibility.  One 
challenge being the lack of commissioned KD services in adult care settings, in which to 
support a multi-centre RCT.  However, without good evidence of clinical and cost 
effectiveness a KD service would not be commissioned.  Therefore, it was important to 
consider if a KD service could be established in a centre with no prior experience, for the 
purpose of supporting recruitment to a clinical trial.  This experience would provide an 
essential learning experience if a trial were to be used as a means to develop new KD services 
in recruiting sites.      
Another challenge was selecting the most appropriate KD to inform trial design.  When 
developing the initial scoping service and survey, the following KDs were considered: 
 Classical ketogenic diet (CKD) 
 Energy restricted ketogenic diet (ERKD) 
 Modified ketogenic diet (MKD) 
 Modified Atkins diet (MAD) 
The relative strengths and weaknesses of these diets are discussed in table 3.1.   
MKD was chosen above CKD, ERKD and MAD3 to assess initial interest as it is the least 
restrictive KD.  At this time, MKD was also offered to a limited number of adults with epilepsy 
                                                          
 
3 Little was known about the use of MCT KD in neuro-oncology when the initial scoping service was 
set up in 2015; therefore this KD was not considered.   
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in the UK private healthcare sector, hence a basic understanding of palatability was known 
(145).  Yet, as MKD lacked the strict implementation of other KDs, a protocol was 
implemented to ensure standardisation of procedures and comparability, whilst still allowing 
a degree of flexibility to suit individual requirements, given this is a dietary intervention.  
3.2.1  Aim and objectives 
Aim:  
 To explore KD service deliverability for patients with gliomas and assess patient 
interest. 
Objectives:  
 To assess if there is sufficient local and national interest from patients with gliomas 
to support a KD RCT. 
 To evaluate if MKD could be delivered to adult patients with gliomas in an NHS 
setting.  
 To explore the characteristics of patients who follow MKD and at which point in their 
treatment pathway.  
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Table 3.1: Summary of the strengths and weaknesses for the use of different KDs in GBM 
Diet Strengths Weaknesses 
CKD  Used in paediatric drug-resistant epilepsy since 1920s.  
 Animal models demonstrate efficacy (77). 
 Produces higher ketone levels due to fat: carbohydrate ratio with 
higher ketone: glucose ratio showing to have greater benefits in 
animal models  (146).  
 Animal models utilise unrealistic dietary ratio for people (e.g. 6:1), 
resulting in low palatability.  
 Lacks sufficient protein to meet adult nutritional requirements, in 
healthy and oncological states (147,148). 
 Requires strict implementation; dietary items to be weighed and 
calculated using computer assisted programmes.   
 Requires the use of ketogenic nutritional products resulting in 
additional costs to the NHS as only available via prescription. 
 Deficient in micronutrients (149).   
ERKD  Reduces angiogenesis, oedema and tumour growth in animal models 
(150,151).  
 Energy restriction promotes ketone production.  
 Does not meet nutritional requirements resulting in weight loss 
(126,128). 
 Low palatability. 
 Requires strict implementation; dietary items to be weighed.   
MAD  Designed for ease of use and to aid compliance, no requirement to 
weigh food items (152). 
 Notably less side effects than CKD and MCT KD (53).  
 Implementation protocol in situ from John Hopkins Institute.   
 No need for a fasted start or hospitalisation prior to dietary 
commencement (153). 
 MAD permits protein to 25% of ETER, therefore patients consume 
double their usual protein intake (on average) which in turn could 
promote the secretion of glucagon and insulin (154), thus limiting the 
ketotic state.   
 Requires the use of ketogenic nutritional products at implementation 
resulting in additional costs to the NHS as only available via 
prescription. 
MKD  Designed for ease of use and for aiding compliance. 
 Used in UK clinical practice for treatment drug-resistant epilepsy in 
adults and paediatrics (55).   
 Allows for flexibility in implementation and education compared to 
John Hopkins MAD protocol (55,145,155).  
 Can be nutritionally complete when implemented with a dietitian 
(149).   
 Fewer side effects than other, high fat, KDs (53). 
 Does not require ketogenic nutritional products.  
 Offers adequate protein for use in adult oncology (147,148).   
 Umbrella term for ‘modified’ KDs that do not exclusively follow John 
Hopkins protocol, resulting in variation in implementation strategies 
and macronutrient content.   
 Requires some skill with weighing/ quantifying portion sizes.  
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3.3  METHODOLOGY 
3.3.1  Patient survey 
Surveys are commonly used to seek explanation or understanding of a topic and to provide 
data for hypothesis testing (156); in this case to explore if patients with gliomas would be 
willing to participate in a KD RCT.  A cross-sectional patient survey was designed by a multi-
disciplinary team, including a neurosurgeon, neurologist, biostatistician and dietitian at the 
University of Liverpool and The Walton Centre NHS Foundation Trust (WCFT), with expertise 
in the area of neuro-oncology and/or clinical trial design.   
All surveys included a covering letter to assist patients with providing informed responses 
(156).  The covering letter included a brief summary of the literature regarding KDs and their 
use in glioma management, foods permitted and excluded from the MKD, anticipated dietary 
duration, potential risks associated with the diet and potential monitoring required by the 
patient and clinician.  Contact details for the study team were also provided should the 
patients have any further questions.  By completing the survey, consent to participate was 
assumed.     
The survey explored patients’ baseline demographics, attitudes towards the use of the MKD 
for glioma, their willingness to try the diet and willingness to participate in a future RCT.  
Questions were grouped by topic for ease of reading (see appendix E).   
The survey was piloted by patients at WCFT, to ensure the wording, order of questions and 
covering letters were appropriate before being distributed nationally (see appendix F).  The 
survey contained closed questions, therefore the pilot ensured sufficient and appropriate 
response categories were available.  Following the pilot, minor alterations were made to the 
wording of the covering letter and three further questions were included; tumour type, prior 
knowledge of KD and dietary changes since diagnosis.  Questions relating to veganism, ready 
meal use and supermarket preferences were removed after offering little value in the pilot.     
Non-random, convenience sampling methods were used to recruit patients (156).  All 
patients attending WCFT neuro-oncology clinics between August 2015 and January 2016 
were invited to complete the WCFT survey.  Patients were approached to participate by their 
treating neurosurgeon or oncology nurse.  The national survey was distributed online via 
brain tumour charity websites and their social media outlets between January 2016 and 
March 2016 (Matthew’s Friends, Astro Brain Tumour Fund, The Brain Tumour Charity, 
brainstrust).  Patients who completed this survey opted-in with regards to completion.   
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Descriptive analysis of the results was undertaken and no power calculation was required for 
the survey (156).  However, it is appreciated that larger samples provide a better estimate of 
the population.     
3.3.2  NHS KD scoping service  
Patients attending neuro-oncology clinics at WCFT were also offered the opportunity to try 
the MKD for a three month period, with the aim of evaluating if a KD service could be 
established within the NHS for patients with gliomas.  Patients were referred to the dietitian 
via their neurosurgeon, neuro-oncologist or oncology nurse (providing the consultant’s 
permission was sought).  Patients could commence the diet at any stage during their 
treatment pathway.  All patients considered for the service were required to meet the 
following eligibility criteria.    
Inclusion criteria:  
 Aged ≥16 years 
 Patient at WCFT  
 Performance status ≤2  (157)4 
 Confirmed histological diagnosis of high grade glioma  
 Undergone surgical resection of tumour 
Exclusion criteria5: 
 Any prior use of a KD  
 Kidney dysfunction (Chronic Kidney Disease III/IV, renal stones, cancer, low 
phosphate/potassium/salt diets) 
 Liver dysfunction  (alcoholic liver disease, non-alcoholic liver disease, cancer, 
hepatitis, haemochromatosis, primary biliary cirrhosis) 
 Gall bladder dysfunction (gallstones, cholecystectomy in past 12 months, cancer) 
                                                          
 
4 Performance status (PS) 0 is defined as normal activity; PS 1 is defined as some symptoms but 
nearly fully ambulant; PS 2 is defined as less than 50% daytime in bed; PS 3 is defined as great than 
50% daytime in bed; PS 4 is completely bed bound (157).   
5 To minimise participant bias, patients with prior use of KDs were excluded.  Diabetes, kidney, liver, 
gall bladder, metabolic and eating disorders are contraindications for the diet as recommended by 
the International Ketogenic Diet Study Group (293).  Weight loss medications such as orlistat are 
contraindicated in KDs due to the limitation in the absorption of fat, which could result in 
gastrointestinal issues.  Underweight patients, defined as BMI less than 18.5kg/m2, were excluded 
due to the risk of malnutrition and the possibility that nutrition support may be indicated (294).   
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 Metabolic disorder (carnitine deficiencies, β oxidation defects [medium chain acyl-
CoA dehydrogenase deficiency, very long chain acyl-CoA dehydrogenase deficiency, 
short chain acyl-CoA dehydrogenase deficiency, long chain 3-hydroxyacyl CoA 
deficiency, medium chain 3-hydroxyacyl CoA deficiency], pyruvate carboxylase 
deficiency, porphyria) 
 Eating disorder (anorexia nervosa, bulimia nervosa, binge eating disorder) 
 Diabetes (requiring medication)  
 Body mass index (BMI) ≤18.5kg/m2  
 Current use of weight loss medications (Orlistat, Belviq, Contrave, Saxenda, 
Phentermine, Qsymia) 
 Performance status ≥3 (157) 
3.3.2.1 Baseline assessment 
Patients were contacted by telephone to discuss their referral and the MKD.  An appointment 
was then provided with the dietitian to discuss MKD in further detail.  Literature explaining 
the diet and the scoping service was posted to the patient.  Prior to commencing the MKD, 
baseline assessments were undertaken by the dietitian; including anthropometric measures 
(weight, height, BMI, mid arm muscle circumference, fat mass), biochemistry monitoring 
(renal, bone, liver function test (LFT), fasting lipid, fasting glucose, carnitine) and review of a 
three day habitual food diary were recorded.   
3.3.2.2 Dietary commencement 
Once biochemistry was returned within range, patients were able to commence the diet.  The 
macronutrient content of MKD was 70% fat, 20g carbohydrate and protein ad lib (55).      
Patients received dietary education and literature regarding MKD, recipes, ketostix® urine 
test strips (Bayer, Leverkusen, Germany), ketone diaries and a personalised seven day MKD 
diet plan calculated by the dietitian, when commencing the diet.     
Patients were instructed to check their urinary ketones twice daily for the first month, once 
per day for the second month, then twice weekly in the third month of diet and record these 
figures in the ketone diary provided.  Adequate urinary ketosis was defined as values 
≥4mmol/L (152).    
3.3.2.3 Dietetic follow up 
After commencing the diet, patients were assessed by the dietitian in clinic at six weeks and 
three months, and by telephone review at weeks one, three and nine.  During clinic 
assessments anthropometry, biochemistry and food and ketone diaries were collected and 
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reviewed.  Telephone reviews were utilised for trouble-shooting and on-going dietary 
support.   Dietary advice was tailored to the patient’s individual requirements.  Figure 3.1 
provides a schematic of the service design and the timing and type of assessments 
undertaken. 




















A Anthropometry (weight, height, BMI, MAC, TSF, MAMC, FM) 
B Biochemistry (renal, bone, LFT, fasting lipid, fasting glucose, carnitine [only on initial screen]) 
C Collect food and ketone diaries 
D Exit survey  
Abbreviations: BMI = Body Mass Index; FM = Fat Mass; LFT = Liver Function Test; MAC = Mid Arm Circumference; 
MAMC = Mid Arm Muscle Circumference; TSF = Triceps Skin Fold.  
  
Appointment booked by telephone and KD information sheet posted 
Clinic appointment 1 (45min) 
Baseline assessment (A B C) 
 
Clinic appointment 2 (1hr) 
Education and commence MKD 
 
Telephone review 1 (week 1) 
 
Telephone review 2 (week 3) 
 
Clinic appointment 3 (45min)  
A B C (week 6) 
 
Telephone review 3 (week 9) 
) 
 
Clinic appointment 4 (45min)  




Nutritional analysis of food diaries was undertaken using DietPlan 7© (Forestfield Software 
LTD, Horsham, UK).  Dietary compliance and tolerance were monitored, along with changes 
to medications; however, medications were permitted to be altered in-line with the 
clinician’s recommendations.  Radiotherapy and chemotherapy were provided in-line with 
the current standard of care.    
For those patients who wished to continue with the MKD after the initial three month period, 
follow up with the dietitian was offered quarterly in clinic, with anthropometric measures, 
biochemistry and food and ketone diaries being collected. 
One full time equivalent dietitian employed by the WCFT was supplied through an NIHR 
research capacity grant.  The dietitian was collaborating on both this study and one other 
study.  The service was dietetic led, with the dietitian reporting any medical concerns directly 
to the consultant neurosurgeon.  Time logs were held by the dietitian to help inform future 
service provision and research capacity.   
3.3.2.4 Exit survey 
Patients completed an exit survey to assess dietary tolerance, willingness to participate in 
future trials and to evaluate the dietetic service after following MKD for three months or at 
the point of diet discontinuation if prior to this (see appendix G).  Patients received the survey 
by post or in person in the clinic. 
3.3.2.5 Analysis 
Descriptive statistics were used to summarise the results of the patient survey data and the 
NHS KD scoping service.  The study was not powered to measure efficacy. 
A 12 week cost analysis was calculated from the time logs completed by the dietitian, in 
addition to biochemistry monitoring (standard laboratory pricing) and ketostix use (ketostix 
costs calculated based on cost per unit).  Clinical time was associated with patient facing 
activities in clinics.  Non-clinical time was associated with non-patient facing activities (e.g. 
analysing food diaries, calculating meal plans).  Administrative tasks (e.g. letter drafting) was 
completed by an administrator.  Costs were then calculated based on the median number of 
dietetic and admin hours per patient, based upon the midpoint of NHS staff Agenda for 
Change banding.  This was supplied by the WCFT finance team.    
3.3.2.6 Ethical approval 
The scoping service was approved by WCFT Research, Development and Innovation 
committee.  All patient literature, including surveys, were approved by WCFT Patient 




3.4  RESULTS 
3.4.1  Patient survey 
 
172 surveys were completed; 50 at WCFT and 122 nationally.  The responses from the pilot 
survey at WCFT and the national survey are presented separately.   
3.4.1.1 Baseline demographics  
WCFT pilot survey:  
Sixty eight percent (n=26) of participants were male, 32% (n=12) female, 24% (n=12) not 
recorded, all aged between 30 and 69 years.   
National online survey:  
Thirty six percent (n=43) of participants were male, 64% (n=76) female, 3% (n=3) not 
recorded.  All were aged between 16-69 years.  Diagnoses were self-reported by the online 
population group; 30% (n=35) GBM (grade IV), 25% (n=30) anaplastic astrocytoma or 
oligodendroglioma (grade III), 43% (n=50) low grade glioma (grade II astrocytoma or 
oligodendroglioma and 2% (n=2) other.  Fifty eight percent (n=70) of the online population 
reported prior knowledge of KD, with charity websites (n=38, 39%) and online forums (n=22, 
22%) being key information sources.  Since receiving their diagnosis 55% (n=65) had made 
changes to their diet.      
3.4.1.2 Willingness to participate in a clinical trial 
WCFT pilot survey: 
Fifty six percent of patients (n=29) would be willing to participate in a clinical trial to 
investigate deliverability and tolerability of the diet.  Of these, 46% (n=17) would still be 
willing to participate in the trial if it were randomised between MKD with standard care and 
standard care alone.  Sixty five percent (n=31) of patients would be willing to try MKD for 
three months.  Forty eight percent (n=15) would prefer to commence the diet before surgery, 
23% (n=7) immediately after surgery, 13% (n=4) after surgery during chemo-radiotherapy 
and 16% (n=5) after radiotherapy during chemotherapy.   
National online survey: 
Seventy one percent of patients (n=85) would be willing to participate in a clinical trial to 
investigate effectiveness and tolerability of the diet.  Of these, 61% (n=45) would still be 
willing to participate in the trial if it were randomised between MKD with standard care and 
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standard care alone.  Seventy eight percent (n=94) of patients would be willing to try MKD 
for three months.  There was no clear preference in timing of when to start the diet: 20% 
(n=33) preferred to start the diet before surgery, 22% (n=35) immediately after surgery, 15% 
(n=24) after surgery during chemo-radiotherapy, 11% (n=17) after radiotherapy during 
chemotherapy and 32%, (n=52) after treatment during the monitoring phase.  Patients were 
also questioned about their motivators and barriers to participating in a clinical trial (table 
3.2 and 3.3). 
Table 3.2: Motivating factors to trial participation  








To help other adults with glioma 30 (31) 90 (37) 
To access the diet myself 23 (23) 66 (27) 
To get expert advice about the diet 20 (20) 65 (27) 
To improve quality of life 25 (26) 0 (0) 
Other 0 (0) 18 (7) 
 
Table 3.3: Barriers to trial participation 








Extra expense of travelling  6 (14) 46 (24) 
Extra burden on visiting a dietitian  12 (28) 27 (14) 
Extra expense of the diet  8 (18) 31 (16) 
Fear of side effects  0 (0) 25 (13) 
Not applicable (no perceived burden) 0 (0) 24 (13) 
Not enough time to devote to the study  6 (14) 10 (5) 
Carer or family burden  0 (0) 11 (6) 
Do not wish to participate in a study  2 (5) 2 (1) 
Other 9 (21) 16 (8) 
 
3.4.1.3 Ketogenic service demand 
WCFT pilot survey: 
Fifty seven percent (n=28) of the WCFT population reported patients with gliomas should 
have access to the MKD.   
National online survey: 
Seventy six percent (n=91) of the online population reported patients with gliomas should 
have access to the MKD.   
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3.4.2  NHS KD scoping service 
 
Eight adults with high grade glioma (n=7 glioblastoma [WHO grade IV]; n=1 anaplastic 
astrocytoma [WHO grade III]) were referred for consideration of MKD.  Six patients 
commenced diet (n=5 GBM; n=1 anaplastic astrocytoma), whilst two patients declined the 
dietary intervention due to their deteriorating performance status.  There were no 
contraindications to MKD in any patient.  Table 3.4 illustrates baseline patient demographics 
of the six patients who commenced MKD.  
Abbreviations: Bx= biopsy; CCNU =Lomustine; IDH = Isocitrate dehydrogenase; KD = Ketogenic diet; RT = 
Radiotherapy; TMZ = Temozolomide; Sx = Surgical resection.  Legend: Ɨ Histology classified by WHO 2007 criteria 
in use at time of diagnosis (158). *Dexamethasone dose decreased whilst on diet. Ɨ Dexamethasone dose 
increased whilst on diet.  
3.4.2.1 Attrition 
Of the six patients who commenced MKD, four completed the three month intervention 
period.  Two patients discontinued the diet before three months, one (anaplastic 
astrocytoma) due to clinical deterioration leading to hospital admission, where the MKD was 
unsustainable, and one patient (GBM) due to dietary preferences.  Median dietary duration 
for those discontinuing diet was 34 days (range: 22-45 days).  One patient temporarily 
discontinued the MKD for three weeks during the intervention period due to an unrelated 
chest infection, following which the diet was reinstated.  Of the four patients who completed 
the three month intervention period, three stayed on the diet for the longer term (≥360 
days), whilst one discontinued the diet after 167 days due to tumour progression and clinical 
deterioration.    
Table 3.4: Baseline demographics 









1 Male 34 Glioblastoma; 
IDH-wildtype 
CCNU Sx, RT, TMZ 0-1* 
2 Male 47 Glioblastoma; 
IDH-wildtype 
RT, TMZ Sx 2-6* 
3 Male 66 Anaplastic 
astrocytoma; 
IDH-wildtype 
RT, TMZ Sx 0 
4 Male 44 Glioblastoma; 
IDH-mutant 
TMZ Sx, RT, Sx, 
Glial wafers 
0-12Ɨ 
5 Male 45 Glioblastoma; 
IDH-wildtype 
TMZ Sx, RT 0.5-1* 
6 Male 49 Glioblastoma; 
IDH-wildtype 
RT, TMZ Sx 2 
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3.4.2.2 Dietary tolerance 
Two patients reported constipation whilst following MKD.  Constipation was reported in the 
first two weeks after commencing the diet and resolved with dietary modification in all 
patients.  No other dietary intolerances were reported by patients, such as diarrhoea, nausea, 
vomiting or acid reflux.   
3.4.2.3 Ketosis  
Adequate urinary ketosis of ≥4mmol/L was achieved in all patients within one week of 
commencing the diet.  Of those who completed three months of diet (n=4), three maintained 
ketosis during this time.  The patient who temporarily discontinued the MKD for three weeks 
due to a chest infection did not maintain ketosis during this time.  
3.4.2.4 Anthropometry  
Table 3.5 illustrates anthropometry (body composition) at baseline and at follow up, after 
completing 12 weeks of MKD (n=4).  No clinically significant changes were noted between 
measures pre and post diet.  
Table 3.5 Anthropometric changes over 12 weeks 
Measure Baseline 3 month review 


















Paired values were available for n=4 for all measurements.  Values are median (range) except weight illustrated 
as mean (standard deviation). 
3.4.2.5 Laboratory values 
Changes in laboratory values are illustrated in table 3.6 for patients with baseline and 12 
week follow up data (n=4). No derangements were noted in renal, bone or liver function 





Table 3.6: Laboratory values 
Measure Baseline 3 month review 




















Paired values were available for n=4 for all measurements.  Values are median (range). Abbreviations: LDL = Low 
Density Lipoprotein; HDL = High Density Lipoprotein; TG = Triglycerides.  
3.4.2.6 Exit survey 
Six patients completed an exit survey to assess their experience of the diet and service 
provided.  Five patients reported their weekly grocery shop had increased in cost since 
commencing MKD, mainly due to the added expense of high protein foods, such as meat and 
fish, fats such as olive oil and specialist carbohydrate free food products.  However, the 
financial costs to patients were not specified.   
All patients would recommend the MKD and all patients would recommend the WCFT 
ketogenic service to other patients.  The majority of patients (n=4) would recommend 
commencing the diet after surgery, before radiotherapy, from their experiences.  Four 
patients expressed an interest in participating in a clinic trial to assess effectiveness and 
tolerability, of which one patient would still be interested if the trial were randomised into 
MKD with standard care and standard care alone (i.e. no dietary change).  All patients would 
consider following the diet for longer than three months as part of a clinical trial.     
3.4.2.7 Cost analysis 
Costs of the initial 12 week intervention can be found in table 3.7.  These costs were based 
on the dietetic intervention equating to 8.8 hours per patient (4 non clinical, 4.8 clinical) over 
a 12 week period.  Biochemistry and ketone monitoring were calculated based on timings 




Table 3.7: Cost analysis 
Item Cost per patient for 12 weeks 
(£) 
Dietitian (mid-point band 6 salary)  148.50* 
Biochemistry monitoring  108.69× 
Urinary ketone monitoring 11.20 
Administration support 17.61# 
Total 286.00 
*Dietetic intervention equated to 8.8 hours per patient (4 non clinical, 4.8 clinical) over a 12-week period.  × 
Carnitine accounts for £52.26 of total biochemistry costs.  All costings are based on patients who completed the 
full 12 weeks (n=4).  #Administration support equated to 2 hours per patient over a 12 week period.      
 
3.5  DISCUSSION 
The results of this study show MKD to be deliverable within a NHS setting in a centre with no 
prior experience of KDs; essential information when considering the infrastructure required 
to support a multi-centre RCT.  Survey data indicates that there would also be sufficient 
patient interest to support a national multi-centre trial.  Patient participation in a clinical trial 
would be affected by randomisation if the control arm was standard treatment with no KD.  
The findings related to patient interest in KD aligns with the James Lind Alliance Neuro-
Oncology Priority Setting Partnership report that identified the influence of lifestyle factors 
(including diet) on tumour growth to be one of the top 10 clinical uncertainties (1).   Since 
the most effective way to assess dietary influence and therefore effectiveness would be to 
undertake a RCT, careful consideration of the trial design would be needed to ensure 
maximum recruitment, whilst achieving maximum methodological integrity.  Nevertheless, 
the patient survey results should be interpreted with caution due to reporting bias, especially 
results generated from the online population, since those interested in KDs may be more 
likely to seek out information online and via charities, which has led to a positive bias in the 
survey data when comparing online and WCFT populations.     
The key motivators for participation in KD clinical trials were distributed between altruism 
(helping others), improving quality of life, having personal access to the diet and gaining 
expert advice, which should be considered in future trial designs or service models.  The main 
barriers to participating in a KD trial include burden of dietetic visits and extra expense of 
travel.  Burden of dietetic consultations can be addressed using the proposed service design 
since telephone consultations negate the expense of travel, the inconvenience of clinic 
attendance and require less dietetic time.  Dietitians should consider cost implications when 
devising diets, since the patients reported an increase in the weekly grocery shop whilst on 
diet.  This could be addressed by the prescription of ketogenic dietary supplements, although 
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this would increase the cost burden to the NHS; an aspect worthy of further investigation 
using health economic frameworks (159).    
Of the eight patients referred into the service, six were started on diet.  Two patients, one a 
newly diagnosed GBM post resection, the other a recurrent GBM receiving second line 
chemotherapy, were not able to attend the first clinic appointment due to rapid disease 
progression and clinical deterioration resulting in a poor performance status.  This highlights 
the challenges of starting the diet in a timely manner and it would be beneficial for future 
service designs and clinical trials to consider performance status as part of the eligibility 
criteria.  The WCFT has a catchment population of approximately 3.5 million and treats 
around 100 to 120 patients with newly diagnosed glioblastoma each year.  After setting up 
the KD service it received one referral per month which represents only 10% of all new GBM 
patients.  The low referral rate is likely to be due to a combination of factors, including a lack 
of awareness by referring clinicians, as well as a lack of suitable patients.  The expected 
referral rates and patient demand should be considered when designing trials and 
determining the number of trial sites.   
In the clinic, four patients completed the initial three months of diet and the attrition rates 
are comparable to those seen in previous studies (125,127).  However, it is important to note 
the higher carbohydrate intake of 60g/day in the ERGO study (125), which is likely to improve 
dietary tolerance and compliance.  Of those who completed the initial three months (n=4), 
three stayed on the diet for the longer term, which highlights the tolerability of the diet and 
the motivation of the patients in the scoping service who self-selected to try MKD whilst 
undergoing treatment for a terminal tumour.   
Side effects were limited, with only two patients reporting constipation which was resolved 
through dietary changes (the inclusion of daily linseeds/flaxseeds and increased oral fluids).  
No other side effects were reported by patients, including diarrhoea, nausea, vomiting or 
acid reflux, comparing favourably to a previous study of KD in cancer patients (125) and was 
below that reported in MKD epilepsy populations (152,160–162).  Whether this is as a result 
of reporter bias or perhaps due to patient perception of acceptable gastrointestinal side 
effects requires further investigation.  There were no clinically relevant changes in 
cholesterol profiles (cholesterol ratio maintained below 4) over the course of the diet, 
contradicting previous literature (152,163).  Longitudinal data, of larger populations, may 
provide a more informative result.  The lack of reported side effects in this limited number 
of patients, provides some reassurance that the diet is safe in the glioma population.  In 
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addition, there was a median increase of 5.4cm in mid arm muscle circumference over three 
months, which suggests that the MKD may not be detrimental to the nutritional status of 
glioma patients.  This is further supported by the minimal change to weight, BMI and fat 
mass, over the three month period.  The increase in muscle could be as a result of the athletic 
and gender bias of our population, rather than simply diet, with six participating in weight 
bearing exercise, five of who maintained a daily aerobic exercise regime.  Future studies are 
required to investigate this effect in a larger population. 
Adequate urinary ketosis is deemed to be ≥4mmol/L (152), and was achieved in all patients.  
Stable ketosis was achieved in three patients who completed the three month dietary period.  
Urinary ketones were the measurement of choice, due to cost implications associated with 
blood ketone monitoring (£0.09 per urinary ketone strip versus £2.50 per blood ketone strip).  
This is acknowledged as a potential methodological limitation due to effects of hydration and 
time lag on readings, however laboratory or home testing would have been prohibited due 
to cost for implementation in this service.  Urinary ketones are also limited to measuring 
acetoacetate and changes in the ratio of acetoacetate to beta-hydroxybutyrate, may result 
in low readings, as the patient becomes keto-adapted.  In future trials, blood ketones may be 
considered, but the implications of monitoring should be considered within NHS economic 
models and frameworks.   
Dietetic involvement per patient over three months was 8.5 hours (4 hours non clinical, 4.8 
hours clinical), costing £286 per patient for 12 weeks.  In previous KD trials in paediatric 
epilepsy [15, 17] and for commissioned paediatric epilepsy KD services patients are screened 
for carnitine deficiencies and fatty acid oxidation defects.  We also undertook carnitine 
testing in our pilot, but all tests were negative.  Given that fatty acid disorders are rare in 
adults [26] and the MKD allowing free protein (source of carnitine) carnitine testing would 
arguable not be necessary in future adult glioma trials or KD services.  Health economics, 
perhaps utilising quality adjusted life years (QALYS), would be beneficial if a large scale RCT 
were undertaken (159).  These patients were following the diet at various stages of treatment 
(table 3.4) which provides information on how the diet is tolerated during all parts of the 
patient pathway.  The two patients who discontinued diet before three months were 
following a MKD whilst receiving adjuvant chemo radiotherapy.  Whilst the literature from 
animal models cites this to be the most opportune time in relation to efficacy (164,165), 
patients are more likely to suffer from side effects of the treatments at this point, including 
fatigue and nausea.  Despite this, four of the patients who completed an exit survey would 
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recommend consuming a MKD whilst receiving adjuvant chemo radiotherapy.  Future trials 
should assess the tolerability of MKD at this time-point. 
The study had several limitations.  In relation to the survey, non-random, convenience 
sampling was used at WCFT and patients self-selected to complete the online national 
survey, both of which could create a positive bias in the results.  Following the WCFT pilot, 
tumour demographic information was incorporated into the national survey, consequently 
this information is lacking in the 50 WCFT responses.    
In relation to the scoping service, the small numbers of patients included were self-selecting, 
self-referring patients, who all started MKD at different time-points in their treatment 
pathway.  This limits the generalisability of our results in the context of the high grade glioma 
population as a whole.  The number of patients with whom KD was discussed remains 
unknown; therefore it is difficult to determine if adequate recruitment could be achieved in 
a clinical trial setting.  Despite the high levels of patient interest illustrated in the previous 
surveys, this interest may not directly translate into adequate recruitment and patients’ 
willingness to take part.  Importantly, this study shows that the MKD can be delivered within 
the NHS setting.  Since the study was not designed to assess efficacy, the impact of MKD on 
tumour control could not be assessed, and whilst all patients self-reported good quality of 
life, this was similarly not objectively assessed.   
3.6  IMPLICATIONS  
3.6.1  Implications for practice 
 
 Ketogenic services for patients with gliomas can be established within a dietetic-led 
NHS setting, should new services be required to support a multi-centre RCT. 
 From the small patient sample, MKD appears to be safe for use within this 
population, as an adjuvant to standard treatment at various points in the treatment 
pathway.    
 Further research to establish the efficacy of KDs in gliomas is required before KDs can 
be offered in mainstream healthcare; KDs are currently not supported by NICE 




3.6.2  Implications for research 
 
 There is interest from the glioma patient community to support clinical trials with KD 
interventions.  Randomisation to a control arm of ‘no diet’ could affect recruitment.  
Further patient and public involvement (PPI) would be critical to ensure study 
methods are acceptable to patients. 
 A large scale multi-centre RCT is required to establish clinical and cost-effectiveness 
for KDs in glioma populations.  The feasibility of running such a trial requires further 
exploration, given the apparent bias of self-selected, self-referring populations, 
utilised in the NHS scoping service  and previous research (124,128,167).   
 Motivations and barriers to participating in dietary trials and factors affecting dietary 
retention could be explored by qualitative means.   
 Impact of KDs on quality of life should be explored through objective, validated 
measures.   
3.7 CONCLUSION 
KDs appear to be gathering momentum as an adjuvant therapy within the glioma patient 
population.  The scoping study illustrates MKD for adults with gliomas to be deliverable 
within a dietetic-led, NHS service with no prior experience of KDs.  The diet itself was 
tolerable, with limited side effects and there appears to be high levels of interest within the 
glioma patient community to ensure adequate recruitment would be possible within the 
context of a clinical trial.  Whether MKD is an effective adjuvant therapy for glioma tumours 
remains to be proven.  Further studies are required to establish clinical trial feasibility, 
following which an RCT could be established to investigate patient benefit.  This will be 
required before the KDs are offered as a clinical service within the NHS.  
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KETOGENIC DIETS AS AN ADJUVANT THERAPY IN GLIOBLASTOMA 
(KEATING): A PROSPECTIVE, NON-BLINDED, RANDOMISED, PILOT 
TRIAL 
 
4.1  CHAPTER OVERVIEW  
Prior to undertaking a definitive randomised controlled trial (RCT) to determine the efficacy 
of ketogenic diets (KDs) as an adjuvant therapy for patients with glioblastoma (GBM), a 
feasibility study is required.  This consisted of two parts; i) a pragmatic pilot trial to test 
protocol methodology in an NHS setting, to explore the potential impact of KDs on patient’s 
quality of life and health; and ii) a qualitative study embedded into the pilot trial to explore 
patients’ decision-making when invited to participate in the pilot (see chapter 5).  The results 
of this feasibility study will inform the design of future KD trials for GBM.  
This chapter focuses on the pilot trial KEATING and starts by introducing the role of feasibility 
and pilot studies in healthcare research, prior to exploring and justifying the methodology 
adopted for KEATING.  Descriptive statistics are used to present the results at various time 
points in the trial.  The chapter concludes by offering a discussion of the findings and 
recommendations for further research.  The Consolidated Standards for Reporting Trials 
(CONSORT) extension for the reporting of pilot trials was utilised throughout this chapter 
(168).    
The KEATING protocol (version 4, 20/DEC/2017) can be found in appendix H, along with 




4.2  INTRODUCTION 
Animal models have demonstrated KDs to be most effective when utilised alongside 
radiotherapy (79), but current evidence for patients is limited to case studies and one 
prospective pilot study (86,87,124–128), with no studies having utilised KDs prospectively, 
whilst the patient is receiving radiotherapy.   
We have previously shown that KDs can be delivered within a dietetic-led NHS service (169) 
and that a proportion of patients with gliomas are interested in participating in a KD RCT (see 
chapter 3).  However, prior to the design of a phase III RCT it is important to consider 
feasibility.   
4.2.1  Feasibility and pilot designs 
 
A feasibility study is defined by the National Institute for Health Research (NIHR) as a piece 
of research conducted before the main trial to understand if a trial can be undertaken.  This 
feasibility phase allows researchers to identify and address problems that could undermine 
the acceptability and delivery of the intervention or conduct of the RCT (170).  Parameters of 
interest that can be estimated by a feasibility study include eligibility rates, retention rates, 
compliance, response to questionnaires and completeness of data.  Feasibility studies for 
RCTs do not necessarily follow the methods of the RCT, such as randomisation, and are not 
powered to assess efficacy.  A feasibility study can include a pilot of the main trial and have 
a qualitative element (92).    
A pilot trial is a version of the main trial, but on a smaller scale.  As with feasibility studies, it 
is not powered to test efficacy, but instead is beneficial to explore recruitment rates, 
retention rates and if the trial protocol is sufficient and can be adhered to, by both the 
research team and participants (170).  A pilot trial can be internal or external to the main 
trial.        
This form of prior investigation, whether via a pilot or a feasibility study is recommended by 
the Medical Research Council (MRC) and NIHR Health Technology Assessment (HTA) 
programme, prior to full evaluation (171).  A set of predefined success criteria for the 
preliminary study are recommended; if no problems exist or exist but are addressable by 
protocol modifications, the study can progress to a full RCT, or if fundamental problems exist 
the study would return to a development phase (172).  For clinical trials, the two main 
concerns often relate to recruitment and retention of participants.   
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Recruitment to trials can be difficult due to a variety of reasons.  For physicians, barriers such 
as a dislike of trial protocol, concerns with physician-patient relationship, time limitations, 
gaining informed consent,  poor impression of the scientific merit, demographic and 
socioeconomic disparities affect their willingness to recruit (173–176).  For prospective 
participants, the decision to participate can be influenced by personal values, family values, 
concerns with trial protocol, physician bias or lack of equipoise, health literacy, personal 
benefits, acceptability of the intervention, quality of life and side effects related to the 
intervention (106,174,175).   
Despite improvements to recruitment practices for HTA and MRC  funded trials since the 
1990s (177), recruitment success continues to hinder clinical trials with only 56% meeting 
pre-defined targets between 2004 and 2016 (178) and fewer than one in twenty adult 
patients with cancer enrolling in a clinical trial (173).  To compensate poor recruitment rates, 
the recruitment period is often extended, requiring additional time extensions and grant 
support, alternatively the recruitment target is reduced affecting the validity of the results 
and implementation into routine clinical practice (177,178).   
Retention within trials is also important, with high levels of attrition reducing power and 
potentially introducing bias to trials (179).  The median retention rate of patients for HTA 
funded trials between 2004 and 2016 was 89%, with retention defined at the point whereby 
the primary outcome was assessed (178).  Factors influencing retention vary by trial, but can 
be related to patient expectations, motivation, demographics, time commitments, 
engagement and ongoing communication by the trial team (180,181).    
4.2.2.1 Feasibility studies in dietary trials 
Feasibility designs are currently being used to investigate dietary interventions in other fields, 
such as malnutrition in care homes (182) and the Mediterranean diet in human 
immunodeficiency viruses (HIV) dyslipidaemia (183), with pilot studies recently published for 
KD in Alzheimer’s disease and migraine (67–69).  There is no prior evidence of feasibility of 
KDs for patients with newly diagnosed GBM.   
4.2.2 Selecting KD interventions for KEATING 
 
In chapter three, we showed that the delivery of KDs within an NHS setting was possible using 
the modified ketogenic diet (MKD).  Since that temporary service was initiated, 
developments in the area have led to the exploration of using medium chain triglyceride 
ketogenic diets (MCT KD) in oncology, with MCT KD being as effective as a 6:1 CKD in animal 
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models with human glioblastoma tumour line (83,84).  MCT KD also offers the potential 
benefits of palatability, reduced blood glucose levels (87,119) and being nutritionally 
complete (see table 4.1) (84).  Therefore, when designing KEATING, the opportunity was 
sought to include both MCT KD and MKD given there is little prior evidence of dietary 
acceptability, recruitment rates or dietary retention rates in ketogenic-oncology trials using 
either diet.  Equipoise existed between the diets; it was not known which, if any, would be 
of benefit to patients with GBM or which would be better tolerated.   
The relative strengths and weaknesses of MCT KD as presented in table 4.1. 
Table 4.1: Summary of the strengths and weaknesses for using MCT KD in GBM 
Diet Strengths Weaknesses 
MCT KD  Used in paediatric drug-resistant 
epilepsy since 1970s.  
 Animal models demonstrate 
efficacy of MCT KD to the same 
extent as 6:1 CKD and in 
comparison to controls (83,84).     
 Can reduce blood glucose levels 
(87,119).   
 Can be nutritionally complete 
when implemented with a 
dietitian. 
 Offers adequate protein for use in 
adult oncology patients in a 
hypermetabolic state (0.17-0.25g 
nitrogen/kg/day (147)) and meet 
the WHO safe protein intake 
(0.83g protein/kg/day (148).   
 MCT allows for an increased 
amount of dietary carbohydrate, 
which aids palatability.  
 Most beneficial ‘dose’ of MCT 
unknown.  
 Limited evidence for use of MCT 
KD in adults; compliance and 
tolerability unknown. 
 Ketogenic (MCT) nutritional 
products create an additional 
cost to the NHS as only available 
via prescription.  
 MCT products can result in 
gastrointestinal discomfort e.g. 
constipation; diarrhoea. 
 Requires some skill with 
weighing/ quantifying portion 
sizes.      
Abbreviations: CKD = classical ketogenic diet; MCT KD = medium chain triglyceride ketogenic diet; WHO = World 
Health Organisation.  
A diet protocol was designed to standardise procedures, enabling comparability of the diets.  
In MCT KD, the amount of MCT incorporated into the diet varies (21-80% of estimated total 
energy requirements) and a pre-defined protocol did not exist.  Table 4.2 provides a summary 
of the macronutrient content of MCT KD used in oncology; eight published studies were 
identified (six animal models (60–62,83,84,184), two human studies (119,185)) and one 
ongoing trial (139)).   
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Table 4.2: Comparison of the macronutrient content of MCT KD in oncology.   
Classification Study Population LCT fat 
(% total energy) 
MCT fat 
(% total energy) 
Carbohydrate 
(% total energy) 
Protein 
















Tisdale et al. (1988)(62) Mice: murine colon 
adenocarcinoma MAC16 
U 68 U U 
Beck et al. (1989) (184) Mice: murine colon 
adenocarcinoma MAC16 
U 80 U U 
Otto et al. (2008)Ɨ(60) Mice: human gastric cancer cell 
line 23132/87 
35.5 21.45 0.2 13 
Hao et al. (2015)*(61) Mice: human colon cancer cell 
line HCT116 
32.8 36.2 3 20 
Martuscello et al. 
(2015)(84) 
Mice: human glioblastoma cells 
 
30 30 10 30 
Aminzadeh-Gohari et al. 
(2017) (83) 
Mice: human neuroblastoma cell 
lines SH-SY5Y, SK-N-BE(2) 


















Fearon et al. (1988)(186) Adult cachexia (lung, gastric, 
ovarian); n=5 
0 70 16 14 
Nebeling et al. 
(1995)(87,119) 
Paediatric gliomas; n=2 
 
















Ghodsi et al. (2012)(139) Adult GBM; target n=20 U 50 U U 
 ƗData as presented by authors. *7.5% accounted for as fibre and micronutrient supplements. Abbreviations: GBM = Glioblastoma; LCT = long chain triglyceride; MCT = medium chain triglyceride; 
U = unknown.      
68 
 
The MCT KD regimes noted in table 4.2 were diverse and so the evidence of MCT KD from 
paediatric literature was consulted for further comparison.  Here, the MCT content varied 
between 30 to 60% (187–189).  Table 4.3 presents the macronutrient content of the three 
most widely used MCT KD dietary regimes in the UK (190).   
Table 4.3: Comparison of the macronutrient content of MCT diets in epilepsy.   

























11 60 10 19 
Adult 
epilepsy; n=4 
41 30 10 19 





30 45 15 10 
  Abbreviations LCT = long chain triglyceride fat; MCT = medium chain triglyceride fat.      
After reviewing the literature, MCT KD for KEATING followed a ‘supplemented’ approach of 
30% of total energy derived from MCT (84,189), with the aim of ensuring gastrointestinal 
tolerance.   
A summary of the macronutrient content of MCT KD and MKD used within KEATING are 
highlighted in table 4.4.  This was the starting point for the diets, from which ‘fine tuning’ 
took place to optimise ketosis for each individual patient.   
Table 4.4: Comparison of the macronutrient content of the dietary interventions used in 
KEATING  
Ketogenic diet LCT fat 
(% total energy) 
MCT fat 
(% total energy) 
Carbohydrate 
(% total energy) 
Protein 
(% total energy) 
MKD6 80 0 5 15 
MCT KD7 45 30 10 15 
Abbreviations LCT = long chain triglyceride; MCT = medium chain triglyceride; MCT KD = medium chain triglyceride 
ketogenic diet; MKD = modified ketogenic diet.       
  
                                                          
 
6 The macronutrient content of MKD was altered slightly from the scoping service (previously 70% fat 
and 20g carbohydrate) to aid standardisation across the two KD interventions for KEATING.   
7 As MCT offers the benefit of  increased ketone production (per calorie of energy) compared to long 
chain triglyceride (LCT) fats due to their rapid absorption into the portal system (81,82), 
carbohydrate requirements are increased and fat reduced slightly. 
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A control arm was not used at this stage, although a multi-arm multi-stage trial design was 
considered for the inclusion of a control arm (95,96).  However, the sample size required to 
run such a study was beyond that of which could be achieved by a single site within a limited 
time frame and was considered beyond the scope of this thesis.  The scoping survey also 
illustrated that a trial including a control arm (no diet) may be difficult to recruit to at this 
early stage and as the acceptability and feasibility of KDs were being explored alongside 
standard treatment, rather than the feasibility of randomisation between diet and no diet, a 
control arm was not included.   
4.2.3  Summary 
 
KEATING consisted of two parts; a pilot trial and a qualitative study.  To investigate the 
feasibility of KDs as an adjuvant therapy for patients with newly diagnosed GBM undergoing 
chemoradiotherapy a prospective, non-blinded, single-centre, randomised pilot trial was 
undertaken (93,94).  To further inform issues with recruitment and dietary retention, a 
qualitative study was embedded into the pilot trial to explore patients’ decision-making 
when invited to participate in KEATING (see chapter 5).  Overall, KEATING would inform the 
feasibility and design of future KD trials for patients with GBM.  
4.2.4  Aims and objectives  
 
4.2.4.1 Aim 
 To investigate protocol feasibility and impact on patients by comparing two KDs in 
an NHS setting, with a view to informing the design of future phase III clinical trials. 
 
4.2.4.2 Primary objective 
 To estimate dietary retention rate to assess if a phase III trial is feasible. 
 
4.2.4.3 Secondary objectives 
Protocol feasibility objectives to inform future study design and sample size calculations:  
 Estimation of recruitment rates. 
 Enrolment of patients (consent, randomisation, baseline screening) pre oncological 
treatments. 




 Enrolment of patients (consent, randomisation, baseline, screening) post oncological 
treatments (within four months of surgical intervention).  
 Long term dietary retention.  
 Dietary adjustments required to achieve ketosis. 
 Dietary compliance. 
 MCT supplement compliance.  
 Ketosis levels.   
 Dietetic time required for each intervention.  
 Protocol refinements required. 
 Completeness of data for all trial outcomes. 
 
Patient impact objectives to inform future study design:  
 Quality of life. 
 Food acceptability.  
 Gastrointestinal side effects. 
 Changes in biochemical markers. 
 Anthropometric changes. 
  
4.3  METHODOLOGY 
  
4.3.1  Trial design 
 
A prospective, non-blinded, single-centre, randomised pilot trial with patients allocated at a 
ratio of 1:1 to MCT KD or MKD.   
4.3.1.1  Ethical approval 
Ethical approval was granted by the North West - Greater Manchester West Research Ethics 
Committee (17/NW/0013).  The trial was granted permission to proceed by the Sponsor 
University of Liverpool on 29th March 2017 and opened to recruitment 1st April 2017.    
The trial was registered with the International Standard Randomised Controlled Trial Number 
registry (ISRCTN71665562) and ClinicalTrials.Gov (NCT03075514).   
The National Cancer Research Institute (NCRI) Brain Tumour Clinical Studies Group (CSG) 
provided portfolio support following peer review.     
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4.3.1.2  Amendment 1 
Due to initial slow recruitment rates, an amendment was implemented in July 2017 (protocol 
version 2, 28/JUN/2017) to expand the inclusion criteria for the trial, with a view to 
broadening the trial population, by including biopsy patients and those patients receiving 
radiotherapy or chemotherapy, rather than combined chemoradiotherapy only treatments.  
Initial figures relating to the number of people with GBM that were surgically resected 
annually at The Walton Centre NHS Foundation Trust (WCFT) and going on to receive 
chemoradiotherapy were found that have been overestimated, possibly affecting projected 
recruitment targets.  Hence, by including biopsy patients and those receiving radiotherapy 
and/or chemotherapy the eligible population from which to recruit increased in size.    
In addition, following initial feedback from patients approached about KEATING, the option 
to commence KD post radiotherapy was implemented with a view to promoting uptake.  To 
minimise the effect of this change on data heterogeneity, patients were permitted to 
commence the diet post radiotherapy, but within four months of surgery, to ensure most 
patients would likely be receiving adjuvant chemotherapy when starting their KD.  Given the 
evidence from animal models previously discussed, it was considered desirable to commence 
patients on KD concurrently with an oncological treatment.  Details of the amendments to 
inclusion criteria are detailed in table 4.5.  
Table 4.5: Amendments to inclusion criteria 
Protocol version 1 inclusion criteria Protocol version 2 inclusion criteria  
Age ≥16 years  Age ≥16 years  
Patient at WCFT  Patient at WCFT  
Performance status ≤2 (157)  Performance status ≤2 (157) 
Confirmed histological diagnosis of GB (WHO 
grade IV (6)) 
Confirmed histological diagnosis of GB within 
last four months (WHO grade IV, (6)) 
Undergone surgical resection of GB Undergone surgical resection or biopsy of GB 
Will go onto receive chemoradiotherapy  Will go onto receive or is currently receiving or 
completed adjuvant oncological treatments 
(radiotherapy, chemotherapy or combination 
chemoradiotherapy) 
NB: Amendments highlighted in bold. 
4.3.1.3 Amendment 2 
The initial trial recruitment period was 12 months.  However, as recruitment rates remained 
low six months into the trial, this amendment extended the recruitment period of the study 
by a further 12 months (24 month recruitment period in total), following recommendations 
from the Trial Steering Committee (TSC; see section 4.7) in December 2017 (protocol version 
4, 20/DEC/2017).      
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In conjunction with this, a qualitative study was embedded to explore patients’ decision-
making when invited to participate in KEATING, by undertaking semi-structured interviews 
with a sub-sample of patients and their relatives/ carers.  This would enable the design of 
bespoke strategies to optimise the decision-making of future patients invited to participate 
in ketogenic-glioblastoma trials (see chapter 5).    
4.3.2  Participants 
 
Patients were recruited from a single adult neuroscience site (WCFT), which receives 
approximately 100 new cases of GBM each year.  The target population were adults with 
newly, diagnosed GBM.  All patients considered for the trial were required to meet the 
following eligibility criteria:  
4.3.2.1  Inclusion criteria  
 Age ≥16 years.  
 Patient at WCFT.  
 Performance status ≤28 (157).  
 Confirmed histological diagnosis of glioblastoma within last four months via surgical 
resection or biopsy9 (WHO grade IV, (6)).  
 Planned to receive or currently receiving or completed adjuvant oncological 
treatments (radiotherapy, chemotherapy or combination chemoradiotherapy)10. 
 A performance status of 2 or less was selected; ensuring patients were likely to 
receive adjuvant oncological treatments and were fit enough to attend clinic 
appointments11.   
  
                                                          
 
8 Performance status (PS) 0 is defined as normal activity; PS 1 is defined as some symptoms but 
nearly fully ambulant; PS 2 is defined as less than 50% daytime in bed; PS 3 is defined as greater than 
50% daytime in bed; PS 4 is completely bed bound (157).   
9 A confirmed histological diagnosis of glioblastoma graded using the WHO criteria (6) was required 
to ensure a consistent sample.   
10 Patients were to be receiving or have received oncological treatments as animal models 
demonstrate the diet to be most effective at enhancing survival if commenced concurrently with 
oncological treatments, adjuvant to surgery (79,80).   
11 A time span of four months post-surgery was determined appropriate as this is the approximate 
time required to complete chemoradiotherapy (STUPP protocol (21)).  However, courses of 
radiotherapy or chemotherapy alone were shorter in length.        
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4.3.2.2  Exclusion criteria 
 Any prior use of a KD12*.  
 Kidney dysfunction (CKD III/IV, renal stones, cancer, low phosphate/potassium/salt 
diets)13#. 
 Liver dysfunction (alcoholic liver disease, non-alcoholic liver disease, cancer, 
hepatitis, haemochromatosis, primary biliary cirrhosis)*. 
 Gall bladder dysfunction (gallstones, cholecystectomy in past 12 months, cancer)*. 
 Metabolic disorder (carnitine deficiencies, β oxidation defects [medium chain acyl-
CoA dehydrogenase deficiency, very long chain acyl-CoA dehydrogenase deficiency, 
short chain acyl-CoA dehydrogenase deficiency, long chain 3-hydroxyacyl CoA 
deficiency, medium chain 3-hydroxyacyl CoA deficiency], pyruvate carboxylase 
deficiency, porphyria)*. 
 Eating disorder (anorexia nervosa, bulimia nervosa, binge eating disorder)*. 
 Diabetes (requiring medication)*.  
 Body mass index (BMI) ≤18.5kg/m2. 14* 
 Current use of weight loss medications (Orlistat, Belviq, Contrave, Saxenda, 
Phentermine, Qsymia)15*. 
 Currently pregnant or breastfeeding16*.  
 Performance status ≥3 (157)*. 
 Medical conditions that may increase risks associated with KD*. 
 
  
                                                          
 
12 To minimise participant bias, patients with prior use of KDs were excluded.   
13 Diabetes, kidney, liver, gall bladder, metabolic and eating disorders are contraindications for the 
diet as recommended by the International Ketogenic Diet Study Group (293).   
* Assessed through clinical history. 
# Assessed via biochemistry.  
14 Underweight patients, defined as BMI less than 18.5kg/m2, were excluded due to the risk of 
malnutrition and the possibility that nutrition support may be indicated (294).   
15 Weight loss medications such as orlistat are contraindicated in KDs due to the limitation in the 
absorption of fat, which could result in gastrointestinal issues.   
16 The effect of KD in pregnancy and breastfeeding women is uncertain (295), therefore these 
patients were excluded from the study. 
* Assessed through clinical history. 
# Assessed via biochemistry. 
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4.3.2.3  Screening and consent   
Following a histological diagnosis of GBM, patients were referred to the trial by their 
neurosurgical team at the WCFT and the neuro oncology multi-disciplinary team (MDT) 
meeting, following initial discussions with a member of their clinical team.  Patients were 
then telephoned by the trial dietitian who briefly discussed KEATING and provided a patient 
information sheet by post (see appendix J).  Patients were re-contacted one week later and 
offered an information/ screening appointment, ensuring patients had adequate time to 
consider trial involvement.   
At the information/ screening appointment, the trial dietitian discussed KEATING trial 
procedures and dietary interventions with the patient and their relative/carer (if present).  
Patients were provided with the opportunity to ask questions, following which written, 
informed consent was obtained.  Baseline biochemistry tests were then undertaken to 
ensure eligibility for the trial.     
4.3.3  Interventions  
 
Two KDs were included in KEATING; MCT KD and MKD.  A summary of the macronutrient 
content of each diet can be found in table 4.4  Patients and their relative/carer (if present) 
received dietary education from the dietitian and were provided with a bespoke seven day 
meal plan, recipes, dietary information sheets and food diaries (see appendices K, L, M).  
Patients could input into their diet by calculating their own MKD or MCT KD recipes and meal 
plans through the use of carbohydrate and fat ‘choice lists’.  A three-month dietary 
intervention was planned (primary end point), following which patients could choose to 
continue with the diet for a total of 12 months (secondary end point).  
Both diets were commenced promptly, without fasting (191), at the patients’ home (rather 
than hospital) to minimise costs and aid practicality.  Those patients consuming MCT 
supplements were encouraged to titrate these to target dose over a one-week period, to aid 
dietary tolerance.       
All KDs were calculated to the patients nutritional requirements using the British Dietetic 
Association (BDA) Parenteral and Enteral Nutrition Specialist Group (PENG) methods (192–
198), with requirements being tailored for patient activity levels (194).  Energy requirements 
were tailored for weight loss or maintenance dependent upon the patient’s needs and wishes 
and were recalculated each time a new weight was obtained.   
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After calculating nutritional requirements, the KD was calculated based on the macronutrient 
content of the randomised diet (MKD or MCT KD, see table 4.6).  This was known as the KD 
‘prescription’.  MCT was delivered using Betaquik® (Vitaflo International Ltd, Liverpool, UK), 
a ‘ready to drink’ food for special medical purposes, the volume of which was calculated by 
the dietitian to provide a target of 30% of total estimated energy requirements.   
Table 4.6: Example calculation for macronutrient content of KDs based on 48yr old male, weighing 
78kg, requiring 2100kcals/day. 
Macronutrient MCT KD MKD 
LCT Fat (2100kcals*45%)/9 = 105g/dƗ (2100kcals*80%)/9 = 187g/dƗ 
MCT Fat (2100kcals*30%)/9 = 70g/d 0 
Carbohydrate  (2100kcals*10%)/4 = 52g/d (2100kcals*5%)/4 = 26g/d 
Protein  (2100kcals*15%)/4 = 79g/d (2100kcals*15%)/4 = 79g/d 
NB: The energy yield of each macronutrient is as follows; fat 9.4kcals/g, protein 4.7kcals/g, 
carbohydrate 4.1kcals/g and MCT 9kcals/g (199).   
Patients (and relatives/ carers when appropriate) were also educated in blood glucose, blood 
ketone and urinary ketone monitoring and target levels. 
4.3.3.1 Timing of intervention 
Patients commenced the diet within four months of surgical intervention (resection or 
biopsy), prior to, during or post the concurrent oncological intervention.  All surgical and 
oncological interventions were undertaken as per current standard of care (200).   
4.3.3.2 Dietetic monitoring and follow up 
After starting the diet all patients were reviewed by telephone at weeks one, three and nine, 
and in an outpatients clinic at weeks six and twelve (primary completion of trial).  Patients 
who wished to continue with the diet were then reviewed at six, nine and twelve months 
(secondary completion of trial); providing long term data.  Table 4.7 provides further 
information of assessments and figure 4.1 presents a schematic of the trial design.        
Patients were requested to monitor urinary ketones twice daily for the first six weeks, then 
weekly thereafter using Ketostix® (Bayer, Germany).  Blood ketones and glucose levels were 
monitored once weekly using GlucoMen Aero 2K® home monitoring kit (Abbott Laboratories, 
UK).  
At each time point the dietitian would compare ketone levels to dietary intake and 
recommend adjustments to the diet (when required) to improve ketone levels, 
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gastrointestinal tolerance, compliance and dietary acceptability; alongside modifications 
required due to alterations in anthropometry (such as weight).          
The dietary trial period was completed at twelve months and those patients wishing to 




Abbreviations: QoL= Quality of life.  NB: *Including tumour location, surgical procedure, histopathology and 
molecular pathology subtypes for glioblastoma (MGMT, IDH-1, ATRX, 1p/19q status).  Ɨ Including nutritional 
supplementation, food allergies, level of physical activity, nutritional requirements, gastrointestinal complaints, 
food/fluid modification, use of clinically assisted nutrition.  
 































































































































































































































































































































































































































Informed consent  X          
Eligibility screen  X          
Randomisation  X          
Medical history 
review* 
 X          
Medications 
review 
 X          
Anthropometry  X    X  X X X X 
Biochemistry   X      X X X X 
Food diary  X    X  X X X X 
Ketone diary      X  X X X X 
QoL 
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EORCT QLQ C30 








 X    X  X X X X 
Dietary review Ɨ  X X X X X X X X X X 
Ketone review    X X X X X X X X 
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Patients with GB undergo surgery (resection or biopsy) 
 
Histology confirms GB 
 
Patient referred by consultant into trial 
 
 Patient telephoned to book appointment 
 
 Clinic appointment 1 
Consent obtained and registered 
Baseline assessment (A B C D) 
 




Clinic appointment 2 
Commence MCT KD 
 
 
Telephone review 1 (week 1) 
 
 Telephone review 2 (week 3) 
 
 Clinic appointment 3 (week 6)  
A C D 
 
 Telephone review 3 (week 9) 
 
 
Clinic appointment 7 (12 months)  
A B C D   
 
 
Clinic appointment 6 (9 months)  
A B C D  
 
 
Clinic appointment 5 (6 months)  
A B C D  
 
 
Clinic appointment 4 (week 12)  
A B C D  
 
 







Table 4.8: Schematic of trial design key 
A Anthropometry (weight, height, waist circumference, fat mass, body mass index [BMI], hand 
grip strength [HGS], mid arm muscle circumference [MAMC]) 
B Biochemistry (renal, bone, liver function test (LFT), fasting lipid, fasting glucose) 
C Collect food and ketone diaries 
D Quality of life and food acceptability questionnaires 
*Patients are able to telephone between appointments should further dietary support be required.  
 
4.3.4  Outcomes 
 
4.3.4.1  Primary outcomes 
Assessment of dietary retention and drop-out rates, defined as:  
I. The number of patients who start randomised treatment as a proportion of the 
number randomised, with reasons for non-compliance.  
II. The number of patients who complete three months of diet as a proportion of the 
number randomised, with reasons for non-compliance.  
III. The time to dietary discontinuation.  
 
4.3.4.2 Secondary outcomes: protocol feasibility  
I. Estimation of recruitment rates 
Actual recruitment rates (over 24 months) were compared to proposed recruitment figures 
(12 patients over 12 months) with purpose of demonstrating trial feasibility for future, 
potential phase III clinical trials.    
II. Enrolment of patients  
Ability to comply with protocol enrolment time lines assessed by the number of patients 
initiated on diet prior to, whilst receiving, and post oncological treatment.  This will inform 
the feasible time lines in future clinical trials.  
 
III. Long term dietary retention  
Duration to dietary discontinuation after three months. 
IV. Dietary adjustments required to achieve ketosis 
Dietary adjustments required from baseline to achieve ketosis to inform future protocols.    
V. Dietary compliance 
Percentage compliance with fat and carbohydrate targets, calculated through patient food 
diaries and compared to predefined fat and carbohydrate requirements.   
VI. MCT compliance  
80 
 
VII. Percentage compliance with MCT targets, calculated through 
patient food diaries and compared to predefined MCT supplement 
volume.  Ketosis levels 
Adequate urinary ketosis defined as ≥4mmol/L.   
There are no robust guidelines for adequate levels of blood ketosis in adults with GBM.  
Preliminary work suggests levels of 2-4mmol/L to be beneficial (146).  Patients were asked to 
record levels to aid future research.   
VIII. Dietetic time required for the interventions 
Dietetic time spent on both clinical and non-clinical activities related to the trial was recorded 
at each contact to aid future protocol design.   
IX. Protocol refinements required 
Deviations from the protocol were documented on the deviation log.  This will be used to 
refine future protocols and inform future clinical trials.  
4.3.4.3 Secondary outcomes: impact on patients 
I. Quality of life 
Quality of life was evaluated though the European Organisation for Research and Treatment 
of  Cancer (EORTC) Quality of Life Questionnaire (QLQ) QLQ-C30 and QLQ-BN20 prior to 
commencing the diet, at week six, month three and every three months thereafter.  
II. Food acceptability 
Food acceptability was assessed through the Food Acceptability Questionnaire (201) 
completed prior to commencing the diet, at week six, month three and every three months 
thereafter.   
III. Gastrointestinal side effects 
The Common Terminology Criteria for Adverse Events ([CTCAE], version 4.0) was used to 
grade gastrointestinal side effects documented on the CRF at each dietetic contact, following 
a baseline evaluation.   
IV. Changes to biochemical markers 
Biochemical markers (fasting lipid, fasting glucose, liver, renal and bone profiles) were 
undertaken at baseline and repeated three monthly until discontinuation of diet.   
V. Anthropometric changes  
Anthropometry (height, weight, body mass index (BMI), waist circumference, mid upper arm 
circumference (MUAC), mid arm muscle circumference (MAMC), tricep skin fold (TSF)[Body 
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Care, UK], hand grip strength (HGS) [Takei, Japan] and fat mass [Omron, Japan]) were 
measured at baseline, week six, month three and every three months thereafter.  All 
measurements were undertaken as per measurement methodology cited in BDA PENG, 
pocket guide to clinical nutrition (198).  
VI. Completeness of data for all trial outcomes 
Completeness of documented data was assessed to inform feasibility of future clinical trials.  
4.3.4.4 Defining success 
Little guidance is available from which to define the success of an external pilot or feasibility 
study like KEATING.  Therefore, pilot success for KEATING was graded using a predetermined 
traffic light system designed for use in internal pilots, which considered recruitment success, 
dietary retention rates, extent of missing data, dietary acceptability and the commencement 
of diet pre chemoradiotherapy (172).  
Targets for determining success were discussed with the Trial Monitoring Committee (TMC) 
and funder.  Targets were considered aspirant for the trial team to achieve, yet flexible in 
allowing for amendments during the study and were reviewed monthly by the TMC and 
quarterly by the TSC.   
 
Success criteria were as follows17:  
Green (go): 
 Recruitment rate of ≥75% of target (n=9) achieved within the 12 month recruitment 
period. 
 ≥75% of patients commenced KD prior to chemoradiotherapy. 
 Dietary retention rate of ≥75% at three months. 
 Diet acceptable to ≥75% of patients at three months.  
 ≥75% of the proposed data collection completed for each end point.  
Amber (review): 
 Recruitment rate of ≥50% of target (n=6) achieved within the 12 month recruitment 
period. 
                                                          
 
17 Retention rate, dietary acceptance and data collection were assessed for each diet independently.  




 ≥50% of patients commenced KD prior to chemoradiotherapy. 
 Dietary retention rate of ≥50% at three months.  
 Diet acceptable to ≥50% of patients at three months.  
 ≥50% of the proposed data collection completed for each end point. 
 
Red (stop): 
 Recruitment rate <50% of target (n=5) achieved within the 12 month recruitment 
period. 
 <50% of patients commenced KD prior to chemoradiotherapy. 
 Dietary retention rate of <50% at three months. 
 Diet acceptable to <50% of patients at three months. 
 <50% of the proposed data collection completed for each end point. 
 
Components of the pilot considered not feasible or unacceptable to patients were evaluated 
(amber and red criteria above) (202) and the ADePT method was used to evidence the 
decision making process (see section 4.5.2) (203).  Recommendations were devised for 
consideration by phase III KD trials for patients with GBM in keeping with the CONSORT 
guidelines (see section 4.5.2) (168).       
 
4.3.5  Sample size  
 
UK pilot studies have been found to have a median sample size of 30 participants (range 8-
114 participants) (204), with sample sizes of 10-40 participants considered to be statistically 
adequate (205).  Previous feasibility work estimated recruitment targets of one patient per 
month (169), in keeping with NIHR/HTA funded trials (178).  As this study was being 
conducted as part of a PhD thesis the recruitment period was limited to 12 months, therefore 
the recruitment target was set at 12 patients over this time frame.   
Results of the scoping service (chapter 3) demonstrated a likely dietary retention rate of 70% 
at three months (169).  With a sample size of 12, it was possible to estimate retention rates 
of 70% to within a 95% confidence interval of ±25.93% (206).  Whilst the confidence interval 
may be broad at present, data synthesised from this pilot will inform sample size estimates 
for future, phase III clinical trials.  
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 4.3.6  Randomisation 
 
Once biochemistry was returned and if within range, the patient was randomised to either 
MCT KD or MKD using the 'sealedenvelope'™ randomisation system and a permuted block 
randomisation method, to ensure similar numbers in each group, at a ratio of 1:1.  This was 
set up and administered by the trial statistician, who was not involved with recruiting 
patients.  Patients were then informed of their dietary intervention group by telephone and 
initiated diet within five working days of consent.     
4.3.7  Procedures for assessing efficacy   
 
Efficacy was not determined from this trial due to the limited sample size (168).  However, 
Magnetic Resonance Imaging (MRI) was used to interpret tumour progression and 
progression free survival for those patients enrolled on the study.   
Progression free survival was defined as the time from date of randomisation to date of 
recurrence on MRI.  Recurrence was defined by a Neuroradiologist using the Response 
Assessment in Neuro-Oncology (RANO) criteria (207).  Progression free survival data was 
assessed by Kaplan-Meier survival analysis.  
Overall survival was defined as the time from date of randomisation to date of death from 




4.3.8.1 Terms and definitions 
Adverse event (AE): is any unexpected situation that takes place during the course of the 
trial.  An AE may be related to the dietary intervention or an unrelated cause. 
Serious adverse event (SAE): an event which results in death, is life threatening, requires 
hospital admission or prolongs hospital stay, results in significant or persistent disability or 
incapacity or results in a birth defect. 
Life threatening: potentially fatal illness or injury at time of occurrence. 
Related: resulted from the administration of the dietary intervention. 
Unexpected: type of AE or SAE not listed on the protocol and is not a likely occurrence.  
84 
 
4.3.8.2 Adverse event inclusions and exclusions 
Inclusion: 
 Injury or accident 
 Abnormalities in biochemistry that require further investigation or treatment 
 Exacerbation of a pre-existing illness 
 Development of an illness during the trial 
 Worsening of baseline symptoms  
 
Exclusion: 
 Previously planned hospital admission 
 Past medical conditions that do not worsen with intervention 
 Medical or surgical procedures undertaken due to the adverse event 
 Elective cosmetic surgery 
 Gastrointestinal side effects unless resulting in hospital admission 
 Altered lipid profiles unless resulting in the commencement of lipid lowering 
medication or further investigations  
 
The Common Terminology Criteria for Adverse Events ([CTCAE], version 4.0) was used to 
grade AEs.  All SAEs were reported to the Heath Research Authority (HRA) Research Ethics 
Committee (REC).   
4.3.9  Statistical analysis 
 
Descriptive statistical methods have been used and a Kaplan-Meier survival curve was 
estimated for overall survival and progression free survival and displayed graphically with 
95% confidence intervals.  Quality of life was assessed according to the EORTC QLQC30 and 
BN20 scoring manual (208). 
Adverse events (AE) and serious adverse events (SAE) were reported as per CONSORT for 
pilot and feasibility studies (168). 
4.3.9.1  Post-hoc analysis 
Over the course of the trial, dietary retention became an issue.  Therefore, a sub analyses 
was introduced at week six for primary and secondary outcomes, with a view to providing 
further information which would inform the design of later trials.  In addition, the global 
health status of patients (EORTC QLQC30) was analysed comparing those who withdrew and 
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those who retained within each diet (MCT KD and MKD).  This was not included in the 
protocol.  This study was funded via a PhD studentship from Vitaflo (International) Ltd.  The 
funder had no input into the analysis or interpretation of the study findings.  
4.3.10  Patient and public involvement 
 
Patients and their relatives/ carers from the scoping service were invited to attend a patient 
and public involvement (PPI) focus group during the design phase of KEATING, led by the trial 
dietitian.  Their active involvement was sought in identifying research priorities and outcome 
measures for the use of KDs for patients with GBM.  Their opinion was also sought for 
improvements required to patient information leaflets, recruitment processes, clinic 
appointments and reducing patient costs to enhance trial participation.  The ideas and 
opinions from the PPI group were developed and incorporated into the protocol and 





4.4  RESULTS  
4.4.1  Participant characteristics 
 
Fifty seven patients were screened for eligibility between April 2016 and March 2017.  Of 
these, 15 were ineligible (26.3%), 30 declined (52.6%) and 12 (21.1%) were recruited to 
participate in KEATING.  Of those recruited eight were male and four female, with a median 
age of 57 years (44 – 66 years).  Three patients had undergone a gross total resection, six a 
near total resection, one a sub-total resection and two a biopsy, prior to commencing 
chemoradiotherapy.  Four patients had O6-methylguanine-DNA methyltransferase (MGMT) 
promoter methylation status.  Follow up was at 12 months from the date of commencing the 
diet.  Figure 4.2 depicts patient flow through the trial and table 4.9 presents the demographic 














Assessed for eligibility (n=57) 
Randomised (n=12) 
Excluded (n=15) 
 PS>2 (n=4) 
 BMI<18.5 (n=2) 
 Liver dysfunction (n=1) 
 No STUPP (n=2) 
 Gallbladder dysfunction 
(n=2) 
 T2DM requiring medications 
(n=1) 
 Kidney dysfunction (n=1) 
 Other (n=2) 
 
Declined participation (n=30) 
 Declined research 
involvement (n=12) 
 No contact (n=7) 
 Burden of visits (n=6) 
 Dietary burden (n=3) 
 Study funder (n=1) 
 Protocol (n=1) 
MKD (n=6) MCT KD (n=6) 
Withdrew (n=4) 
 Dietary burden 
(n=2) 
 Tumour progression 
(n=1) 
 Nausea (n=1) 
Withdrew (n=2) 
 Dietary burden (n=1) 
 Recruited to another 
trial (n=1) 
Complete 12 weeks (n=3) Completed 12 weeks (n=1) 
Withdrew (n=1) 
 GI intolerance (n=1) 
Completed 12 months (n=2) Completed 12 months (n=1) 
Withdrew prior to 
commencing diet (n=1) 
 Non related SAE 
(n=1) 
Withdrew prior to 
commencing diet (n=1) 
 Changed mind (n=1) 
 
Commenced MCT KD (n=5) Commenced MKD (n=5) 
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MGMT IDH-1 ATRX 
T01 Male 53 Right temporal GTR, RT, TMZ Unmethylated Wildtype Retained 5 
(2-4) 
MCT KD 22.4 32.4 35.4 
T13 Male 49 Left parietal NTR, RTX, TMZ Unmethylated Wildtype Retained 4 
(0) 
MCT KD 5.1 14.4 60.6 
T23 Female 54 Left frontal NTR, RTX, TMZ Unmethylated Wildtype Retained 4 
(0) 
MCT KD 5.7 44.4 83.6 
T27 Female 62 Right occipital GTR, RTX, TMZb Methylated Wildtype Retained 2 
(0) 
MKD 0 5.1 NAe 
T28 Male 64 Left temporal Bx, RTX, TMZa Unmethylated Wildtype Retained 4 
(3-4) 
MKD 7 13.1 67.3 
 
T39 Female 66 Right parietal NTR, RTX, TMZ Methylated Wildtype Retained 4 
(0) 
MKD 5.3 64.3 NAe 
T44 Male 44 Right temporal GTR, RTX, TMZ Methylated Mutated Mutated NA 
 
MKD 52 NAd NAe 
T45 Male 46 Left frontal NTR, RTX, TMZ, 
Lomustine 
Unmethylated Wildtype Retained 3 
(2-3) 
MCT KD 52 14.0 NAe 
T47 Female 58 Right frontal NTR, RTX, TMZa Inconclusivec Wildtype Retained 2 
(0) 
MKD 4.6 14.0 31.6 
 
T51 Male 57 Left frontal STR, RTX, TMZ Methylated Mutated Mutated 1 
(1-1.5) 
MCT KD 52 NAd NAe 
T52 Male 60 Left frontal NTR, RTX, TMZa Unmethylated Wildtype Retained 2 
(0) 
MCT KD 0 23.9 NAe 
T57 Male 57 Right multifocal Bx, RTX, TMZa Unmethylated Wildtype Retained 2 
(0) 
MKD 6 14.0 57.1 
Abbreviations: ATRX = alpha thalassemia/mental retardation syndrome X linked; Bx = biopsy; DEX = dexamethasone; GTR = gross total resection; MCT KD = medium chain triglyceride ketogenic diet; MGMT = O6-methylguanine-DNA 
methyltransferase; MKD = modified ketogenic diet; NA = not applicable; ND = no data recorded by patient; NAe = not applicable (alive at time of reporting); NTR = near total resection; OS = overall survival; PFS = progression free survival; RTX = 
radiotherapy; SD = standard deviation; STR = subtotal resection; TMZ = temozolomide; Treatment = treatment received whilst following a ketogenic diet; a = unknown if completed full course of radiotherapy and chemotherapy as withdrew from 
trial; b = 6 days of temozolomide not given; c= insufficient tissue to perform MGMT analysis; d= no progression at time of reporting (08/MAR/2019); e= alive at time of reporting (08/MAR/2019). 
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4.4.2  Primary outcome 
 
4.4.2.1  Dietary retention at three months  
Of the 12 patients recruited to KEATING (n=6 MCT KD; n=6 MKD), two withdrew following 
randomisation but prior to commencing the diet (n=1 MCT KD; n=1 MKD).  Reasons for 
withdrawal were a non-dietary related SAE (n=1) and a patient changing their mind about 
participating (n=1).   
Of the 10 patients who commenced diet, six withdrew prior to reaching the three month 
primary end point (n=2 MCT KD; n=4 MKD).  Reasons for withdrawal from the MCT KD group 
were dietary burden due to diet and supplement intolerance (n=1) and having been recruited 
to another trial (n=1; Novo Tumour Treating Fields trial).  Patients’ reasons for withdrawal 
from the MKD group were dietary burden due to high fat nature of diet (n=2), nausea (n=1) 
and early tumour progression (n=1).  The median duration until discontinuing the diet was 
38 days (36-40 days; n=2) for the MCT KD group and 39.5 days (32-49 days; n=4) for the MKD 
group. 
Six patients stayed on diet until week six, after which four continued for a total of three 
months (n=3 MCT KD; n=1 MKD).  All four of these patients then continued with their 
allocated KD beyond three months.  A summary of patient flow is presented in figure 4.2 and 
figure 4.3 illustrates dietary retention throughout the course of the trial.        
The predefined, lower limit criteria for successful retention was 50%.  The overall dietary 
retention rate at three months for KEATING was 33.3%.  
Figure 4.3: Dietary retention during KEATING 
 
NB: T27 and T52 withdrew prior to commencing the diet.  

































4.4.3  Secondary outcomes: Protocol feasibility  
 
4.4.3.1  Recruitment 
Twelve patients were recruited from a sample of 42 eligible patients, achieving a recruitment 
rate of 28.6% (or 21% of the overall screened population).  Reasons for declining participation 
included the patient declining research involvement (n=12), the research team being unable 
to contact patient (n=7), the burden of visits (n=6), the burden of diet due to restriction of 
carbohydrate foods (n=3), the study funder (due to Nestle [the parent company of the trial 
sponsor Vitaflo] previously funding powdered baby milk research; n=1) and the trial protocol 
was unagreeable (n=1), see figure 4.1.   
During the first six months, recruitment was in keeping with the predefined mid-limit of 50%, 
recruiting three patients (see section 4.3.1.2 for amendments).  During the final six months 
recruitment improved, exceeding the predefined, higher recruitment target of 75%; 
recruiting 12 patients over 12 months.  Figure 4.4 shows recruitment over the 12 month 
period, in comparison to predefined recruitment targets and recruitment success criteria.    
Figure 4.4: Recruitment tracker 
Abbreviations: Target = target number of patients to recruit each month as a total aggregate total; Actual = actual 
recruitment each month as a total aggregate; <50% = lower limit predefined recruitment target; ≥50% = mid-limit 
































4.4.3.2  Enrolment of participants prior to, during and post chemoradiotherapy 
commencement 
All patients (n=12) were enrolled and consented prior to starting chemoradiotherapy.   
Three patients commenced KD before starting chemoradiotherapy (n=3 MKD), seven during 
chemoradiotherapy (n=5 MCT KD, n=2 MKD; median delay 5 days [3-16 days]; delay at 
patients request due to oncology appointments) and no patients commenced diet after 
completing chemoradiotherapy.   
The predefined lower limit criteria for enrolment and dietary commencement were 50%.  
During KEATING, 30% of patients (n=3) commenced KD prior to chemoradiotherapy.  
4.4.3.3  Long term dietary retention 
Of the 12 patients recruited to KEATING, four continued with their KD after month three (n=3 
MCT KD; n=1 MKD).  One patient (MCT KD group) then stopped at month six due to 
gastrointestinal side effects.  In total, three patients completed the 12 month intervention 
period (n=2 MCT KD; n=1 MKD).  These patients all chose to continue with their KD after 
completing the trial.   
4.4.3.4.  Dietary adjustments required to achieve ketosis 
Four patients required dietary adjustments from baseline calculations to improve ketosis.  
These changes took place during the first six weeks following dietary initiation.  All four 
patients were in the MCT KD group.  For two patients, carbohydrate intake was reduced 
(mean -10.5g/d; standard deviation [S.D] ±7.4g/d) and long chain triglyceride (LCT) fat 
increased (mean 6g/d; S.D. ±2.8g/d); for one patient carbohydrate intake reduced (-10g/d) 
and medium chain triglyceride (MCT) fat increased (15g/d); and for one patient LCT was 
exchanged for MCT (15g/d).     
 
4.4.3.5 Dietary compliance 
Dietary compliance was assessed at week six (n=4 MCT KD and n=4 MKD), week 12 (n=3 MCT 
KD and n=1 MKD) and at month 12 (n=1 MCT KD) on the basis of returned food diaries.  At 
week six, patients following MCT KD achieved their fat (LCT) target (mean -0.6%; S.D. ±4.6%) 
and those following MKD over consumed fat (LCT) (mean 12.4%; S.D. ±3.2%).  The MCT KD 
group over consumed carbohydrates (mean 45.4%; S.D. ±1.3%) and MKD group under 
consumed carbohydrate (mean -9.6%; S.D. ±0.4%) compared to their calculated 




At month three, patients following MCT KD (n=3) over consumed fat (LCT) (mean 69.9%; S.D. 
±3.1%); but these patients had reduced their intake of MCT (see section 4.4.3.4).  The patient 
(n=1) following MKD under consumed fat (14%).  At this stage, both groups under consumed 
carbohydrate (MCT KD mean -45.8% S.D. ±10.5%; MKD -71.5%).   
 
At month 12, one patient over consumed fat (LCT) by 21.2% and under consumed 
carbohydrate by 32.7% compared to their calculated macronutrient requirements (n=1); 
whilst three patients completed the 12 month trial period only one patient completed a food 
diary.    
 
The extent to which this over and under consumption of macronutrients affected the balance 
of the diets is presented in table 4.10.  In the MCT KD group the consumption of LCT fat 
increased over the course of the trial and whilst MCT fat reduced (see section 4.4.3.6).  For 
MKD, the consumption of fat (LCT) remained static throughout.  Carbohydrate consumption 
reduced over time in both groups, with an increase at month 12 in MCT KD (n=1).   
 
Table 4.10: Average macronutrient consumption over duration of trial  
 Macronutrient 
Diet Time point Fat (LCT) 
(%TEI) 












Initiation target 45 30 10 15 
Week 6 (n=3) 50 26 8 16 
Month 3 (n=3) 59 25 5 11 





Initiation target 80 NA 5 15 
Week 6 (n=3) 81 NA 3 16 
Month 3 (n=1) 80 NA 3 17 
Abbreviations: LCT = long chain triglyceride; MCT KD = medium chain triglyceride ketogenic diet; MKD = modified 
ketogenic diet; TEI = percentage of total energy intake.  NB: Macronutrients based upon completed and returned 
food diaries.  One patient following MKD completed 12 month follow up but did not complete food diary, 





4.4.3.6 MCT compliance  
MCT compliance was assessed at week six (n=4), month three (n=3) and month 12 (n=2).  At 
week six, three patients were 100% compliant with the volume of MCT and one patient was 
under consuming the supplement by 28.6%.  At month three, one patient was 100% 
compliant and two patients were under consuming the MCT supplement by 21.1% (S.D. 
±12.1%).  At month 12, the both patients were under consumed the supplement by an 
average of 26% (S.D. ±13%; n=2).  Reasons for non-compliance were reported as excessive 
volume by all patients affected at each time point (n=3).    
 
On average, the total energy intake provided by MCT supplements reduced over the duration 
of the trial (see table 4.10).     
 




The average level of urinary ketosis for each patient for their duration on diet is presented in 
figure 4.5.  Those who withdrew from the trial reported lower urinary ketone levels than 
those who retained to month 12. 
 
For those patients who completed six weeks on diet (n=6), the median urinary ketone level 
was 4mmol/L (0-16mmol/L) for MCT KD group (n=3) and 4mmol/L (0-8mmol/L) for MKD 
group (n=3).  During this time, 79.7% of MCT KD and 79.3% of MKD recordings were within 
the desired level of ≥4mmol/L.   
 
For those patients who completed three months on diet (n=4), the median urinary ketone 
level was 4mmol/L (0-16mmol/L) for MCT KD group (n=3) and 8mmol/L (4-8mmol/L) for the 
MKD patient (n=1).  Over the course of three months, 77.4% of MCT KD and 100% of MKD 
reported recordings were within the desired level of ≥4mmol/L.   
 
For those patients who completed 12 months on diet (n=3), the median urinary ketone level 
was 4mmol/L (0-16mmol/L) for MCT KD group (n=2) and 8mmol/L (4-8mmol/L) for the MKD 
patient (n=1).  Over the course of 12 months, 96.7% of MCT KD and 100% of MKD reported 


























































The average level of serum ketosis for each patient for their duration on diet is presented in 
figure 4.6.  Those who withdrew from the trial early generally reported lower serum ketone 
levels than those who retained within the trial.     
 
Figure 4.6: Median serum ketone level for each patient for their duration on diet 
 
 
NB: T51 stopped assessing serum ketones at week six due to tryanophobia, yet continued with diet for 12 months, 
therefore median data for T51 is based on first six weeks.  Remaining patients’ data is reflective of their duration 
on diet.   
 
For those patients who completed six weeks on diet (n=6), the median serum ketone level 
was 1mmol/L (0.3-4.5mmol/L) for MCT KD group (n=3) and 1.5mmol/L (0.7-3.4mmol/L) for 
MKD group (n=3).  During this time, 29.4% of MCT KD and 35.7% of MKD recordings were 
within the desired level of ≥2mmol/L.   
 
For those patients who completed three months on diet and monitored serum ketones 
(n=3)18, the median serum ketone level was 1mmol/L (0.3-4.5mmol/L) for MCT KD group 
                                                          
 
18 Four patients completed three months of KD, however one patient declined to use the serum 













































(n=2) and 2.6mmol/L (1.9-3.4mmol/L) for the MKD patient (n=1).  Over the course of three 
months, 18.1% of MCT KD and 90% of MKD reported recordings were within the desired level 
of ≥2mmol/L.   
 
For those patients who completed 12 months on diet and monitored serum ketones (n=2), 
the median serum ketone level was 1.1mmol/L (0.1-4.5mmol/L) for MCT KD patients (n=1) 
and 2.4mmol/L (1.9-3.4mmol/L) for the MKD patient (n=1).  Over the course of 12 months, 
36.8% of MCT KD and 97.4% of MKD reported recordings were within the desired level of 
≥4mmol/L.   
 
An example of how urinary and serum ketones compared for patients following MCT KD and 
MKD is illustrated in table 4.11.   
 
Table 4.11: A comparison of urinary and serum ketones at week 6 for patients following MCT KD 
and MKD  





























 T01 46.3 19.8 12.2 19.8 0.5 
 
0.9 22.4 




 T23 80 NA 3 16.3 1.5 1.5 5.7 
T39 84.9 NA 3.7 10.4 4 1.2 5.3 
T44 75.8 NA 2 21 8 3.4 52 
Abbreviations: CHO = carbohydrate; NA= not applicable; %TEI = percentage of total energy intake. NB: Five 
patients returned completed food diaries and ketone diaries at week six, therefore could be included in analysis.  
Remaining percentage contribution to total energy intake is derived from fibre and water.  
 
4.4.3.8  Dietetic time required for the dietary interventions 
 
The duration of time associated with clinic visits and non-clinical activities during the first 
three months and full 12 months are presented in table 4.12 (details of activities undertaken 




Table 4.12: Summary of average dietetic time per participant associated with trial 






















































NB: Time presented as mean ± standard deviation.  
 
4.4.3.9  Protocol refinements   
There were 24 deviations from protocol during the trial, from seven patients.  Deviations 
occurred due to unreturned food diaries (n=7), unreturned serum ketone diaries (n=7), 
unreturned urinary ketone diaries (n=3), consultations exceeding schedule or undertaken 
ahead of schedule (n=1 due to patient commencing diet two weeks after education; n=1 due 
to patient unable to attend nine month review until month 11; n=1 due to patient attending 
for review one month ahead of schedule due to clinic facilities), biochemistry derangements 
(n=1 raised ALT; n=1 raised sodium, both of which were within range on repeat sample), 
intermittent fasting regimes (n=1) and inclusion of nutritional supplements  (n=1).     
   
4.4.3.10 Completeness of data 
Seven food diaries (21.1%; n=33), seven urinary ketone diaries (21.1%; n=33) and seven blood 
ketone diaries (21.1%; n=33) were not returned over the course of the trial.  At 12 months, 
two of the three patients who completed the trial did not return their final food or ketone 
diaries (n=1 MCT KD, n=1 MKD), which resulted in less than 50% completion rate at 12 
months for ‘ketosis levels’ and ‘dietary compliance’ outcomes (predefined lower limit criteria 
for completeness of data was 50%).  All remaining outcomes were greater than 75% 
completed for all time points, meeting the predefined higher limit success criteria, after 




4.4.4 Secondary outcomes: Impact on patients  
 
4.4.4.1 Quality of life 
The global health status of between both dietary groups for those who withdrew and those 
who retained in the trial was compared. 
 
At baseline, there was little difference between the global health status of those patients 
who would go on to withdraw and those who retained within the trial, in either dietary group 
(withdrew MCT KD 72.2±20.7 [n=3]; retained MCT KD 75±6.8 [n=3]; withdrew MKD 70±13.8 
[n=5]; retained MKD 80±0 [n=1]).   
 
At week six, the global health status of those who withdrew reduced, falling below the brain 
cancer reference value in both MCT KD and MKD (withdrew MCT KD 41.7±0 [n=1]; withdrew 
MKD 50±0 [n=2]).  For those who retained in the trial, global health status improved for the 
patient following MKD (retained MCT KD week six 66.7±0 [n=3]; retained MCT KD month 
three 66.7±13.6 [n=3]; retained MCT KD month 12 66.7±8.4 [n=2]; retained MKD 100±0 [n=1] 
from week six onwards) and reduced for those patients following MCT KD, in both cases 
global health status remained above the brain cancer reference value (see figure 4.7).   
Figure 4.7: Global health status of patients who withdrew and retained in the trial 
 
 
NB: At baseline withdrew MCT KD n=3, retained MCT KD n=3, withdrew MKD n=5, retained MKD KD n=3; at week 
six withdrew MCT KD n=1, retained MCT KD n=3, withdrew MKD n=2, retained MKD n=1; at month 3 retained 










































Based on patient averages, symptoms (QLQ-C30 and QLQ-BN20 questionnaires) were 
below the brain cancer reference value with the exception of appetite (QLQ-C30), motor 
dysfunction (QLQ-BN20), communication deficit (QLQ-BN20) and drowsiness (QLQ-BN20).  
Of interest for this dietary intervention are appetite and drowsiness.  At baseline, appetite 
was scored zero by all patients (n=12).  Appetite worsened during the course of the trial, 
with appetite loss peaking at week six in both groups (41.7±31.9 MCT KD, n=4; 33.3±33.3 
MKD, n=3).  At month 12 appetite had resumed baseline levels in the MKD (n=1), with 
appetite loss worsening in the MCT KD group by month 12 (n=2) (see figure 4.8).    
Figure 4.8: Appetite loss reported by patients during trial 
 
 
NB: At baseline MCT KD n=6, MKD n=6; week six MCT KD n=4, MKD n=3; month three MCT KD n=3, MKD n=1; 
month 12 MCT KD n=2, MKD n=1.  
 
At baseline, drowsiness was scored above the reference value for both groups (27.8±22.1 
MCT KD [n=6]; 27.8±22.1 MKD [n=6]; reference value 17.8).  Drowsiness then resolved in the 
MKD group at week six (score 0 [n=3]) and henceforth for the remainder of the trial (month 
three and month 12 [n=1]).  In the MCT KD group, drowsiness worsened during the course of 




































Figure 4.9: Drowsiness reported by patients during the trial        
 
 
NB: At baseline MCT KD n=6, MKD n=6; week six MCT KD n=4, MKD n=3; month three MCT KD n=3, MKD n=1; 
month 12 MCT KD n=2, MKD n=1.  
 
4.4.4.2 Food acceptability 
Food acceptability reduced from baseline in both groups, with week six receiving the lowest 
score (baseline MCT KD 60.7±10.5 [n=6]; baseline MKD 54.3±6.2 [n=6]; week six MCT KD 
42±8.9 [n=4]; week six MKD 43.5±12.8 [n=4]).  Food acceptability then improved between 
week six and three months (MCT KD 49±2.9 [n=3]; MKD 58 [n=1]), but reduced slightly before 
the end of the trial (MCT KD 47.5±6.5 [n=2]; MKD 53 [n=1]).  Figure 4.10 illustrates food 
acceptability during the course of the trial.    
 
As more than 50% of patients withdrew before three months, the predefined lower limit 
































Figure 4.10: Food acceptability over the course of the trial 
 
 
NB: At baseline MCT KD n=6, MKD n=6; week six MCT KD n=4, MKD n=4; month three MCT KD n=3, MKD n=1; 
month 12 MCT KD n=2, MKD n=1.  
 
4.4.4.3 Gastrointestinal side effects 
During the first six weeks, the MCT KD group reported four incidences of gastrointestinal side 
effects and the MKD group two incidences.  For the MCT KD group these were diarrhoea 
(n=1, CTCAE grade 1), nausea (n=1, CTCAE grade 1), vomiting (n=1, CTCAE grade 2), dyspepsia 
(n=1, CTCAE grade 1) and for the MKD group these were vomiting (n=1, CTCAE grade 1) and 
a dry mouth (n=1 MKD, CTCAE grade 1).   
 
At month six, one patient (MCT KD) experienced dyspepsia (CTCAE grade 1), constipation 
(CTCAE grade 1) and diarrhoea (CTCAE grade 1) which led to their withdrawal from the trial.  
Another patient (MKD) also reported constipation (CTCAE grade 1). 
 































4.4.4.4 Changes to biochemical markers 
Four adverse events were noted due to deranged biochemical markers; hypokalaemia (n=2, 
CTCAE grade 1), hypernatremia (n=1, CTCAE grade 1) and hypocalcaemia (n=1, not classified 
as adjusted calcium >2mmol/L).   
 
Repeat cholesterol data was available for three patients in MCT KD group and one patient in 
MKD group.  Total cholesterol reduced over time in MCT KD group (baseline 6.3mmol/L [4-
6.9mmol/L]; month 12 5.6mmol/L [5.3-5.9mmol/L]; n=2) but slightly increased in MKD 
patient, with this patient experiencing a reduction in LDL and an increase in HDL (baseline 
total 4.9mmol/L; month 12 total 5.1mmol/L).  Total cholesterol to HDL ratio reduced over 
time in both groups (MCT KD baseline ratio 4 [2-5], month 12 ratio 3.5 [3-4], n=2; MKD 
baseline 4, month 12 ratio 2, n=1).  Changes to cholesterol for both dietary interventions are 
presented in table 4.13.       
 
Table 4.13: Changes to cholesterol over the duration of the trial 
























































































Total: HDL 4 
 
3 2 
Abbreviations: HDL = high density lipoprotein; LDL = low density lipoprotein; MCT KD = medium chain triglyceride 
ketogenic diet; MKD = modified ketogenic diet; TG = triglycerides. NB: Baseline data MCT KD n=3, MKD n=1; three 





4.4.4.5 Anthropometric changes 
Repeat anthropometric measures were available for three patients in the MCT KD group and 
one patient in MKD group.  For the MCT group (n=3), weight, body mass index (BMI), mid 
arm muscle circumference (MAMC), right hand grip strength (HGS) and waist circumference 
reduced over time, whilst on average, fat mass was maintained, along with left HGS.  Changes 
were clinically insignificant, with centile ranges being maintained for all measures.   
 
For the one patient following MKD, weight, BMI, MAMC, waist and fat mass reduced over 
time, whilst HGS was maintained on average.  Changes were clinically significant, with BMI 
reducing from obese to overweight, MAMC reducing from greater than 95th centile to 15th to 
25th centile range, waist circumference reducing from high risk to healthy and fat mass 
reducing from greater than 95th centile to 50th to 75th centile range.  Table 4.14 presents 
changes in anthropometric measures over the duration of the trial.  
 
Table 4.14: Changes in anthropometric measures over the duration of the trial 























































Weight (kg) 130.5 
 
97.6 96.6 
BMI (kg/m2) 35.8 
 
31.9 28.9 
MAMC (cm) 33.7 
 
29 28.9 
Left HGS (kg) 43.6 
 
30.9 48.1 








Fat mass (%) 35.2 
 
35.3 23 
Abbreviations: BMI = body mass index; HGS = hand grip strength; MAMC = mid arm muscle circumference; MCT 
KD = medium chain triglyceride diet; MKD = modified ketogenic diet. NB: Baseline data MCT KD n=3, MKD n=1; 




 4.4.4.6 Adverse and serious adverse events  
Five adverse events and three serious adverse events occurred over the course of the trial.  
Adverse events were due to hypokalaemia (n=2, CTCAE grade 1), hypernatremia (n=1, CTCAE 
grade 1), hypocalcaemia (n=1, not classified as adjusted calcium >2mmol/L) and a partial 
seizure (n=1, CTCAE 1).  Serious adverse events were due to post-operative wound infection 
(n=1, CTCAE grade 3, resulting with withdrawal from trial), seizure (n=1, CTCAE grade 2) and 
back pain (n=1, CTCAE grade 2), none of which were related to the dietary intervention.       
 
4.4.4.7 Survival analysis  
The median time to progression was 14.4 weeks (SE 14.6; 95% CI 0-42.9 weeks). Figure 4.11 
illustrates the progression free survival (PFS) of patients who commenced diet (MCT KD n=5; 
MKD n=5).  
Figure 4.11: Progression free survival 
 




Median overall survival was 67.3 weeks (SE 6.2; 95% CI 55-79.6 weeks).   Figure 4.12 
illustrates the overall survival of patients who commenced diet (MCT KD n=5; MKD n=5).   
Figure 4.12: Overall survival 
 












4.5  DISCUSSION 
 
KEATING was designed to investigate if the trial protocol was feasible and explore what 
impact KD trials would have on patients with GBM, in relation to health and quality of life, 
comparing two different KDs, in a pragmatic NHS setting.  The findings from KEATING will be 
used to inform the design of future phase III KD trials for GBM.  
 
KEATING experienced problems with dietary retention; of the 12 patients recruited, 10 
commenced KD and only four completed the three-month dietary intervention, three of 
which followed a MCT KD.  These retention rates were lower than anticipated, with previous 
oncology trials reporting trial retention rates of 89% (178), dietary interventions for weight 
loss reporting dietary retention rates of 50 to 66% at 12 months (209) and previous KD studies 
for patients with GBM reporting dietary retention rates of 50 to 100% (87,125,126).  Yet, 
patients in these previous KD studies commenced the diet at recurrence or post treatment, 
rather than at diagnosis, therefore patients’ motivations for remaining on diet may differ 
from those of KEATING and this is explored further in the qualitative study (see chapter 5).  
The intervention periods of these previous KD studies also differed to KEATING; such as eight 
weeks (n=2)(126) or to the point of progression (n=20; median five weeks; range three to 13 
weeks)(125).  Two of the studies also had a limited population (n=2)(87,126).  The dietary 
retention rates for KEATING were lower than our previous NHS scoping service (67% at three 
months; chapter 3) (169), but both in previous KD studies and the NHS scoping service, 
patients self-selected to try the diet.  These patients may be more motivated than those 
approached for KEATING, especially if commencing KD following progression.  Interestingly, 
a pilot trial for KD in patients with advanced cancers (breast, ovarian, lung, gastrointestinal), 
experienced similar dietary retention rates to KEATING (retention rate 31%, n=5 of 16), in a 
trial which permitted a more liberal KD (70g of carbohydrates per day) and where all food 
provision was provided (210).  Thus, a more flexible dietary approach may not be the simple 
solution.     
 
Those who withdrew from KEATING did so either after randomisation but prior to 
commencing the diet (n=2) or after having followed a KD for approximately six weeks (MCT 
KD median 38 days [36 to 40 days], n=2); MKD 39.5 days [32 to 49 days], n=4), during which 
time chemoradiotherapy was given to all patients.  These results highlight that KDs can be 
offered alongside chemoradiotherapy for patients with GBM and this is important since data 
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from animal models suggest that KD is most effective in combination with radiotherapy (79).  
Nevertheless, future trials may benefit from a shorter intervention period for example, KD 
delivered for six weeks during chemoradiotherapy only.   
 
Patients who completed the initial three-month intervention stayed on diet for the longer 
term, with three of the four patients completing the full 12-months.  These patients had 
higher urinary ketone levels compared to those who withdrew, indicating greater dietary 
compliance amongst those who stayed on diet.  Of those who completed the initial three 
months, three followed MCT KD and one MKD.  Our data illustrates patients have a tendency 
to under consume the supplement, in comparison to paediatric dietary regimes, with MCT 
accounted for 25% of total energy at three months; a factor to be considered by future clinical 
and pre-clinical trials as adherence would be required to explore efficacy.     
 
Patients reported reasons for withdrawal to be related to dietary burden and side effects, 
such as nausea.  A recent KD trial for patients with Alzheimer’s disease, also highlighted 
dietary and carer burden to be influential over patient withdrawal (67).  As with other 
oncology trials, withdrawal could also be related to the patients’ poor understating of the 
trial, their motivations and expectations (181,211); factors which are explored further in the 
qualitative study (see chapter 5).     
 
Initially, recruitment to KEATING was slow, resulting in amendments to the protocol.  This 
included expanding the inclusion criteria to broaden the potential trial population, to offer 
the possibility of commencing KD during or post treatment rather than prior to treatment 
commencing, extending the recruitment period by 12 months and embedding a qualitative 
study.  Expanding the inclusion criteria allowed the recruitment of two patients who had 
undergone biopsy rather than a resection and embedding a qualitative study allowed for the 
decision-making of patients to be explored, which will be pivotal to the design of future trials 
(see chapter 5).  Patients also benefited from commencing the diet before or during 
chemoradiotherapy, although no patients commenced the diet post treatment.  The 
extended recruitment period was redundant following an improvement in recruitment rates 
over the final six months.   
 
The time required for KEATING to embed into clinical services, whereby clinicians acted as 
gatekeepers for participant involvement (212), was underestimated and may explain the 
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initial delay to recruitment.  Staged recruitment targets, as adopted in other oncology trials 
(213), would help to alleviate this issue, as would an ‘upstream’ approach to trial design to 
alleviate barriers and promote engagement of the clinical team at sites (214).  How the trial 
is initially articulated to patients can also impact recruitment, along with clinician preferences 
over interventions (215,216).  A qualitative study embedded at the point of recruitment 
would help to explore recruitment practices and patient understanding of the trial and the 
demands of continued participation.  Further research into clinician’s opinions of KD trials for 
patients with GBM would also be beneficial.   
 
Other diet trials have found that shorter dietary/patient information leaflets were beneficial 
in improving recruitment (102).  Whilst we used public and patient involvement (PPI) to 
design KEATING, we failed to consider how the information sheets and protocol would work 
in a real-life trial setting (217).  The PPI group also involved patients and their relatives who 
had self-selected to try MKD in the previous scoping service.  On reflection, this was perhaps 
unrepresentative of the overall GBM population from which KEATING would recruit.   
 
KEATING met the recruitment target within the desired timeframe.  Despite this, the overall 
recruitment rate was 28.6%; lower than seen in NIHR HTA funded oncology clinical trials of 
50 to 89% (178), with patients declining to participate predominantly due to research 
involvement, burden of the diet and burden of visits.  These barriers are reflective of those 
usually experienced by cancer trials (174) and trials of complementary therapies (218).  The 
burden of visits could be addressed through utilising linked scheduled clinician appointments 
between the trial dietitian and oncologist.  This would also alleviate the short delay 
experienced by some patients when commencing the diet due to conflicting appointments.  
This service was not feasible for KEATING due to dietetic and oncology divisions operating 
across two separate hospital trusts.  
 
Prior to KEATING little was known about the implementation of KDs for adult patients with 
GBM.  Over the course of the trial, patients who remained on KD, under consumed 
carbohydrate and over consumed fat.  Both MCT KD and MKD groups achieved adequate 
urinary ketosis (4mmol/L or more)(152), which was maintained over the 12 month trial 
period.  Interestingly, the median serum ketone levels for all but one patient was below the 
desired level of 2mmol/L over the course of 12 months (219).  However, the evidence from 
which the desired levels are obtained is predominantly based upon animal models, and these 
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targets may not be achievable in patients, despite good levels of dietary compliance.  There 
is very little evidence in oncology to suggest if these desired levels of ketosis, both urinary 
and serum, are sufficient to inhibit tumour growth and promote survival, therefore further 
research is essential.  Our findings also highlight that urinary and serum ketones are not 
comparable, supporting previous literature (220,221).  Whilst urinary ketones are cheaper 
and easier to use, blood ketones offer accuracy; the cost and benefits of which would need 
to be considered by future trials.    
 
Both diets required a comparable amount of dietetic time over the course of the 12 month 
trial, approximately 10 hours per patient of face-to-face contact time and 10 hours of non-
clinical time, in-keeping with the previous scoping service (chapter 3)(169).  Non-clinical tasks 
included planning of patient menus and recipes (individualised for each patient) cannot be 
avoided.  Some tasks could be delegated to research nurses (anthropometry collection) or 
administration support (completion of CRFs) which could offer potential cost saving 
measures for future trial designs.      
 
KEATING is the first KD trial for patients with GBM to assess quality of life by validated means.  
Those patients who withdrew from the trial at week six, reported quality of life to decrease, 
with global health status reducing from baseline and falling below the brain cancer reference 
value in both KD groups.  For those patients who retained within KEATING, global health 
status of those following MCT KD reduced, but not to the extremes of those who withdrew.  
The global health status of the one patient following the MKD diet improved.  The sample of 
patients who stayed on diet within the trial from which to assess quality of life was small 
though (n=3), which limits the conclusions that can be drawn.  Our findings contradict those 
of a previous pilot of KD for patients with advanced cancers (breast, ovarian, 
gastroenterological and lung) in which global health status remained stable, but this 
advanced cancer pilot did not account for the experiences of those patients who withdrew 
(dietary retention rate 31%; n=5 of 16)(210).  Previous trials with dietary interventions have 
related withdrawal to a reduction in quality of life (222), yet this was not stated as a reason 
for withdrawal by patients of KEATING.  It could be assumed that dietary burden resulted in 
a reduction in patients’ quality of life, given theoretically this was the primary reason stated 
for withdrawal and with dietary acceptability reducing over the course of the trial, but this 
could also be as a result of tumour progression or disease burden (223) and consequently 
requires further investigation via qualitative means (see chapter 5).  Further to global health 
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status, appetite, motor dysfunction, communication deficit and drowsiness also reduced to 
below the brain cancer reference value.  It is unlikely that changes in communication or 
motor dysfunction would be related to KD, a reduction in appetite would hinder adherence 
with the diet.  Although paediatric literature finds drowsiness to improve with KD, it is likely 
that this is due to a reduction in anti-epileptic medication rather than KD itself and also due 
to a lack of validated measures (53).  When considering the patients enrolled in KEATING had 
neurological tumours, fatigue may occur as a consequence of radiotherapy and neurological 
injury, as such, drowsiness was to be expected.  EORTC QLQC30 and BN20 questionnaires 
whilst validated, are time consuming to complete and some questions were irrelevant for 
patients following KDs.  It may be beneficial for future KD trials to reduce the length of the 
questionnaire and therefore patient burden, focusing particularly on global health status; 
these questions were insightful during KEATING.  
 
Both KDs were found to be safe for use within a GBM population.  The MCT KD group 
experienced more gastrointestinal side effects at initiation than the MKD group, but this was 
anticipated when using a MCT supplement (56).  Gastrointestinal side effects led to the 
withdrawal of two patients, one within the first six weeks (MKD) and one at six months (MCT 
KD).  Four patients experienced CTCAE grade one electrolyte derangements, all of which 
resolved by repeat testing.  Whilst research into the effect fat has on cholesterol and cardiac 
health offers contradictory reports, supporting both low fat and high fat diets (224,225), our 
data offers some preliminary insight into the effect of KDs on cholesterol, with the ratio of 
total cholesterol to HDL reducing over 12 months and supports previous KD research in adults 
with epilepsy (89).  The results from KEATING contraindicate those of the initial scoping 
service in which cholesterol increased (169), but this can be explained as patients enrolled in 
KEATING experienced planned weight loss is due to being overweight or obese at baseline 
and weight loss known to have a positive impact on cholesterol (226).  A larger trial would 
provide further data on cholesterol and weight loss.  Three serious adverse events were 
noted, none of which were related to KD or the trial.  All side effects of KD were less severe 
than previously noted in paediatric patients (53).   
 
This trial was not powered to assess efficacy or clinical effectiveness on overall or progression 
free survival.  The KEATING population was representative of the usual GBM population in 
terms of survival (21) and was not biased with respect to known prognostic factors of age, 
performance status, extent of resection and MGMT methylation status.  As anticipated, four 
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patients held MGMT methylated genes, two of which also held IDH-1 and ATRX mutations.  
Both of these patients completed the 12 month intervention and were progression free.   
 
4.5.1  Limitations  
 
This trial has several limitations.  As time progressed within the trial, the number of returned 
patient diaries reduced.  This is most noticeable at 12 months, when only one of the three 
patients returned their diaries, subsequently affecting the 12 month analysis.  This is a 
common problem, given the time commitment required to return diaries.  Technology may 
help to alleviate this issue, through the use of mobile apps, but this could also result in a 
health inequality.  Further PPI work may be beneficial to explore the use of mobile apps and 
if this would create or alleviate the burden of completing diaries for patients and their 
relatives.  All accounts of dietary intake were also self-reported and at risk of reporter bias 
(227).  However, a review of dietary intake was required to improve ketosis levels and 
inaccuracies in reporting would be at a personal detriment to the patient.  The food 
acceptability questionnaire, whilst validated for use in vegan diets, was not validated for usw 
in KDs.   
 
Due to the high withdrawal rates around week six, a post-hoc analysis was introduced to 
extrapolate further information which may help to explain the withdrawal rates and improve 
future trial design.  Due to poor retention rates only limited analysis could be undertaken at 





4.5.2  Pilot success 
 
There were five pre-defined criteria for pilot success.  Table 4.15 describes the success 
criteria along with proposed amendments.  A phase III KD trial for patients with GBM may be 
feasible if proposed amendments are implemented, but an internal pilot phase would be 
recommended.  The wider ‘keto-oncology’ community may also benefit from the proposed 
amendments given issues with retention in previous trials (210).   
 
Table 4.15: Pilot success and proposed amendments  





Dietary retention rate 
of ≥75% (n=9) at 
three months 
33% (n=4) dietary 
retention at three 
months 
Shorter intervention period of 




Use of an embedded 
qualitative study to explore 
patient experience and 
decision-making (92). 
Recruitment Recruitment rate of 
≥75% of target (n=9) 
achieved within the 
12 month 
recruitment period 
100% of recruitment 
target (n=12) within 




≥75% of patients 
commenced KD prior 
to 
chemoradiotherapy 
30% enrolled prior to 
chemoradiotherapy  
KEATING protocol amended 
to allow patients to 
commence KD during or post 
treatment (see section 
4.3.1.2).  Following which all 
patients enrolled prior to or 
within 16 days of treatment 
commencing. 
 





Diet acceptable to 
≥75% of patients at 
three months 
<50% due to 
withdrawals 
Six week KD intervention. 
 
Employ a validated 
questionnaire, if available.   
Completeness 
of data 
≥75% of the proposed 
data collection 
completed for each 
end point 
>75% completion rate 
for all outcomes, with 
the exception of 
ketone levels and 
dietary compliance at 
month 12  
Further PPI to investigate if 
digital solutions for the 
completion and return of food 
and ketone diaries would be 
acceptable to patients.  




4.5.3  Implications 
 
The findings of this pilot have several implications for subsequent KD trial designs for patients 
with GBM.  In order to optimise protocol feasibility and patient experience future trials 
should consider the following suggestions: 
4.5.3.1 Suggestions to optimise trial design  
 A shorter intervention period of six weeks may be favourable, given the average time 
to withdrawal during KEATING being 38 days for MCT KD arm and 39.5 days MKD 
arm.  As animal models demonstrate that KD enhances the effects of radiotherapy, 
it would be advantageous to offer KD during this time within the confines of a trial.  
During KEATING conflicting clinic appointments between the dietitian and oncologist 
resulted in a delay in the patient commencing diet of up to 16 days post radiotherapy 
initiation.  Linked appointments, held at one centre, would help to alleviate this issue.     
 The trial took time to embed within clinical practice; therefore recruitment figures 
were initially slow.  Future trials should consider a staged, incremental recruitment 
rate to compensate for this problem.  An ‘upstream’ approach to trial design may 
improve recruitment practices and clinical team engagement.   
 Qualitative studies would be beneficial to gauge clinicians’ interest in KD trials for 
patients with GBM, as this is currently unknown.  Furthermore, qualitative studies 
embedded during the design phase would help to identify challenges unique to the 
phase III trial, such as randomisation to a control ‘no diet’ arm, from which strategies 
to improve the protocol and patient experience could be timely implemented.      
 Further PPI would be beneficial to explore if digital media would aid the completion 
of food and ketone diaries.  This PPI should involve patients who have tried KDs 
before and their relatives/ carers, but also patients to whom KD would be new, a 
view point which could be essential if dietary retention and trial completion rates are 





4.5.3.2 Clinical implications  
 MCT KD appears to be safe to use in adults with GBM, but leads to more 
gastrointestinal side effects at initiation than MKD.  There may be a role for MCT 
supplements in adult KDs, but the volume of supplements should be considered.  
Paediatric levels cannot be tolerated by adults, but volumes equating to 25% of total 
energy requirements appear acceptable.   
 The desired level of ketosis, both urinary and serum, remain unknown for oncology 
patients following a KD.  Future research in this area is essential if efficacy is to be 
established.     
 Further research is required before KDs can be implemented in neuro-oncology.  KDs 
are currently not recommended by NICE (166).  
 
4.6  CONCLUSION 
 
Recruitment of patients with GBM to a KD trial is possible.  To assess efficacy in a clinical trial, 
a six week intervention period is proposed.  Further qualitative studies embedded within 
these clinical trials are essential to optimise trial design and patient experience.  A phase III 
trial would benefit from an internal pilot to further test the recommendations derived from 
KEATING.    
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DECISION-MAKING OF PATIENTS WITH GLIOBLASTOMA INVITED TO 
JOIN A PILOT TRIAL OF KETOGENIC DIETS (KEATING): QUALITATIVE 
STUDY 
 
5.1  CHAPTER OVERVIEW 
Following on from the quantitative findings of KEATING reported in chapter 4, this chapter 
presents a qualitative exploration of patients’ perspectives of their decision-making when 
invited to participate in KEATING.  This study was conceived following recognition that 
KEATING faced challenges with recruitment.  Eight months in to the twelve month 
recruitment period, with an uptake of less than 30%, KEATING was falling behind on 
recruitment targets.  It was therefore deemed crucial to understand why some patients were 
deciding to participate, whereas others were deciding to decline involvement.  Whilst there 
is an abundance of literature regarding the decision-making of patients involved in drug trials, 
there is little evidence on the decision-making of terminal oncology populations in feasibility 
or early stage clinical trials, as noted in the narrative review to follow, especially for dietary 
interventions.  To our knowledge, patients’ views on ketogenic diets (KDs) generally have also 
not been explored by qualitative means, either within the context of a trial or within clinical 
practice.  Following discussions with the Trial Management Group (TMG) and Trial Steering 
Committee (TSC) of KEATING, a pragmatic, solution-based decision was made to embed a 
qualitative study within KEATING.  
This chapter begins by introducing decision-making in healthcare settings, followed by a 
narrative review of the qualitative literature relating to the decision-making of patients with 
advanced cancer, when faced with early phase clinical trial participation.  The chapter then 
progresses to present the methodology adopted by this embedded qualitative study and the 
analysis of data and defined themes, prior to discussing the results in the context of the wider 
literature.  The chapter concludes with recommendations for future KD trials for patients 
with GBM.   The Standards for Reporting Qualitative Research (SRQR) was utilised throughout 
this chapter (228).  
The study protocol (version 4, 20/DEC/2017) can be found in appendix H, along with 




5.2  INTRODUCTION  
5.2.1  Decision-making in healthcare 
 
Shared decision-making, between a patient and healthcare professional, is the pinnacle of 
patient centred care (229,230).  This approach is tailored to individual patients’ needs, and 
allows patients to weigh up the risks and benefits of a treatment or intervention whilst taking 
account of their personal values, thus enabling them to make an informed decision about the 
care they are receiving in relation to their health (230,231).   
Shared decision-making is widely accepted throughout healthcare and is recommended by 
the National Health Service (NHS; (232)).  However, whilst this practice is considered the  
‘gold standard’ in relation to healthcare decisions, the process of decision-making in health 
is complex  and can vary according to the nature and type of decision being made (233).  For 
most patients, the decision goes beyond cognitive processes, such as weighing up the risks 
and benefits, to include factors such as emotion, feelings of fear or hope (234).  These 
emotions can have a greater influence on decision-making depending upon the severity of 
the disease.  Some patients may prefer others (healthcare professional or relative) to assist 
with the decision-making, taking a relational approach to autonomy (235).  Thus, the extent 
of the role the patient wishes to have and the role of the healthcare professional can vary on 
an individual basis.  
The extent to which the patient wishes to be involved in the decision may also change over 
time and can be dependent upon their condition  (231).  For patients with advanced cancers, 
initially prolonging life can be the patient’s main focus when deciding about treatment 
options; with quality of life becoming more important than prolonging life, as the disease 
progresses (231).  This occurs at a time when patients seek increased control over the 
decisions regarding their care, becoming more active in the decision-making process (231).    
5.2.2  Decision-making in clinical trials 
 
One area of particular importance in which patients are required to make decisions relates 
to participation in clinical trials.  Clinicians seek informed consent from patients when they 
are enrolling into a clinical trial.  When considering trial involvement, it is presumed patients 
will enter into a deliberation phase of decision-making, whereby they seek and process 
information relevant to their decision, assess the sufficiency of their knowledge, consider 
counterarguments to their decision, account for how emotions will influence their decision, 
consider their personal preferences in the construction of their arguments to support their 
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decision and consider their own readiness to make a choice (236).  In practice, decision-
making for clinical trial involvement is often more complex, in part due to the lack of optimal 
consent procedures and insufficient decision-making support, which may result in patients 
having a poor understanding of the clinical trial (229).   
Recent research attention has been paid to the importance of understanding patients’ 
decision-making with regards to clinical trial participation, particularly in oncology, so as to 
optimise both informed consent to trials and the patient experience.  Several qualitative 
studies have been successfully embedded into diet-oncology trials for breast and prostate 
cancers with varying aims such as investigating barriers to recruitment and exploring 
patients’ views on prostate cancer and diet  (101–107).  Whilst these studies are of interest 
methodologically, the findings are unlikely to be transferable to patients with advanced 
cancers, such as glioblastoma (GBM).  Whilst 78% of patients with breast cancers (237) and 
84% of patients with prostate cancers survive beyond 10 years (238), only 5% of patients with 
GBM survive beyond 5 years (239).  Moreover, trials of interventions aimed at providing 
remission are readily available for patients with breast and prostate cancers, but for patients 
with advanced cancers such as GBM, early phase clinical trials investigating safety and toxicity 
of treatments are often the only clinical trials available.  Therefore, the offer to join a trial is 
may have a different meaning for patients with GBM, compared to those with breast or 
prostate cancers.  In order to adequately support patients with advanced cancer in making 
decisions about participation in early phase clinical trials, a better understanding of their 
decision-making processes is vital.  
5.2.3  Decision-making of patients with advanced cancers regarding participation in 
early phase clinical trials: a narrative review  
 
The following narrative literature review explores the qualitative literature relating to the 
decision-making of patients with advanced cancers regarding participation in early phase 
clinical trials (see appendix P for narrative review methodology and appendix Q for search 
strategy (240)).  Five publications, from four studies, were identified for inclusion in this 
narrative review (241–245).  Each is briefly discussed below, followed by a summary of their 
strengths and limitations, and collective findings.  
The first embedded qualitative study exploring decision-making processes of patients with 
advanced and metastatic cancers was undertaken in the late 1990s (241).  This study found 
patients did not follow theoretical decision-making pathways, such as those outlined 
previously (236), but instead made an instantaneous decision about participation which was 
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based upon intuition.  Patients did not report considering the advantages and disadvantages 
of participating, or deliberating their decision.  Whilst participants described seeking further 
information about the trial, and valued being given time to consolidate their decision, these 
factors did not affect the participants’ initial decision.  Later emotional factors, such as hope 
for a cure, prolongation of life, reducing fear of death were considered, reducing anticipated 
decisional regret.  Having small children or a partner also provided motivation to participate.  
Despite the instantaneous initial decision and contrast with theoretical models of decision-
making (236), most participants described being happy with their decision on reflection.  
Those who did experienced greater side effects from the chemotherapy intervention were 
unhappy within the trial (241).  
Whilst this study was the first of its kind and provided insight into the decision-making 
processes of patients with advanced cancer regarding trial participation, there are several 
limitations which may restrict the generalisability of its findings.  First, despite data being 
collected on contextual factors such as education, employment and religion, the influence of 
this on the decisions and opinions of participants was not taken into account.  Second, 
patients who declined to participate in the clinical trial were under-represented in the 
qualitative sample (n=13 consented; n=1 declined).  This is an important omission because, 
in some cases, the perspectives of those who declined can be invaluable to understand how 
the rationale for their decision and the processes behind their decision may differ from those 
of consenting participants (173).  In relation to recruitment, understanding the thoughts and 
decisions of those who decline and those who withdraw are essential to improve trial design 
and minimise health inequalities relating to health literacy barriers (246–249).  Finally, the 
interviews were conducted at the trial hospital sites by a research nurse, which may have 
caused response bias.  Strengths to the study included interviews being undertaken 
longitudinally, to gain depth about the participants’ decision and how this may change over 
time, and were analysed by four healthcare professionals, one of whom was a psychologist, 
aiding triangulation and reducing reporter bias.                
Madsen et al., (2007) were the next research group to explore the attitudes of advanced 
breast and ovarian cancer patients regarding participation in early phase clinical trials 
(242,243).  The semi structured interview study used grounded theory, and included patients 
who did and did not take part in clinical trials.  In contrast to Huizinga et al., (1999) (241), all 
patients, both those who consented and those who declined, reported giving full 
consideration to participation, yet many reported lacking sufficient knowledge to make 
educated choices (243).  Their decision processes were consistent with Gillies et al. (2014) 
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decision-making theory in that participants weighed personal advantages against the risks 
and disadvantages of participation.  In keeping with the findings of Huizinga et al. (1999), 
patients made their decision based on their personal interests, primarily in a non-altruistic 
manner.  Yet, on later reflection, those who participated partially considered their decision 
to be due to a moral obligation.  A perceived lack of clinical equipoise between the 
intervention and control arms and a lack of understanding about randomisation also 
influenced the patients’ decisions.  Those who participated perceived the intervention arm 
to be of superior benefit, whilst those who declined considered the intervention arm to be 
of greater risk, resulting in fear due to the ‘chance’ of being allocated to the intervention.  
The random allocation of trial groups potentially removed the aspect of ‘hope’ which the 
intervention provided to those who wished to participate.  Whilst all participants were 
positive in attitude towards clinical trials, those who declined, when faced with the personal 
decision to participate, were more cautious in their approach than those who consented, 
which influenced their decision to refuse.  Most patients were confident with the clinician 
making the decision for them, further indicating the importance of relational autonomy in 
this patient group (235).   
Whilst this study included both participants who consented and those who declined, the 
sample was female dominant due to the nature of the diseases in question, advanced breast 
and ovarian cancers.  Unlike Huizinga et al., (1999), interviews were conducted at one time 
point, rather than longitudinally, six months after the patients’ initial decisions.  Therefore, it 
is unknown if the views expressed by patients were a true reflection of their decision-making 
at the time of the event or if they could have been influenced by participating in the study or 
the passing of time.  Due to the decision of the ethics panel, moral obligation could not be 
explored and those without a treatment response could not be interviewed, consequently 
their experiences and opinions remain unknown. However, interviews were carried out at 
the patients’ own homes, which reduced interviewer bias.  The sample was also fairly 
balanced between those who consented and those who declined. 
A subsequent qualitative, cross sectional, interview study exploring the decision-making 
processes of advanced haematological and melanoma cancers patients participating in phase 
I clinical trials was undertaken by Godskesen et al. (2013) (244).  Participants reported the 
main reason for participating in a phase I trial as being ‘renewed hope’.  Despite receiving 
written and oral information about the study, no participant could recall the purpose of the 
study.  As this study included phase I clinical trials only, no control arms were present.  
Patients, therefore, perceived the introduction of trial participation by the clinician as a 
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positive experience, as they believed the clinician would not present an ineffective treatment 
option.  Like Huizinga et al. (1999), patients recalled making an instant decision to participate, 
with many not reading the consent form before signing it.  This contrasts with the decision-
making processes reported by Madsen et al. (2007), and points to difficulties in obtaining 
informed consent in this study.  Patients’ instantaneous decision to participate was 
influenced by their failed treatment history and the advanced nature of their cancer, 
indicating an emotional aspect to their decision-making.  Some participants shared their 
decision with a family member, seeking validation and support, whilst others independently 
decided whether or not to participate.  For some, trial participation provided an aspect of 
hope and optimism for a cure, with many participants disproportionately over anticipating 
the likely outcome of survival or likely success of a phase I trial, and most considering hospice 
care to be their next option if the trial failed.  Some also believed this optimism would provide 
therapeutic benefits.  As with previous studies (241,242), most participated for personal 
benefit, rather than for altruistic reasons.                
This study had several limitations.  The sample demographics for this study are unknown, 
hence it is difficult to interpreted if the study is influenced by gender bias as with those 
previously discussed (241–243).  However the oncological conditions applicable to this study 
do affect both male and female populations.  An element of recall bias may be present - two 
of the fourteen participants completed the phase I trial four months prior to being 
interviewed, whilst the remainder completed the interview whilst still enrolled on a trial.  The 
duration between consenting to the trial and being interviewed was not reported.  The 
interviews took place at patients’ referring hospitals, which could result in reporting bias, and 
interview duration was short in some cases (mean 30 minutes, range 15-55 minutes), which 
may affect the quality, depth and richness of the data.  The study did not include any patients 
who declined to participate in phase I trials, therefore their views and decision-making 
processes remain unknown.  Furthermore, only participants of the trial were interviewed, 
thus the views of their family members, and the potential influence of these on patients’ 
decision-making, were not fully explored.  Nevertheless, all interview material was discussed 
between five authors, which provided a means of triangulation and increased credibility.     
More recently, an embedded, qualitative, semi-structured, interview study using a grounded 
theory approach was undertaken to identify the motivations and barriers of patients with 
advanced stage IV breast cancer and their decision-making processes for participating in 
phase I clinical trials (245).  As with previous studies, the purpose of the phase I studies (i.e. 
investigating toxicity and safety rather than efficacy) was not well-understood by the 
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majority.  Many participants over-exaggerated the possible health benefits afforded by 
participation, with many reporting the study to be investigating efficacy.  Yet, some 
participants did note that efficacy was related to their own personal agenda and optimism, 
and not the true purpose of the study, illustrating issues with understanding and their 
appreciation of that knowledge (250).  The clinician’s recommendation and participants’ trust 
in the clinician were the main influence over their decision to participate, as previously 
reflected in other studies (242,243).  Some participants were influenced by relatives with pre-
existing healthcare knowledge.  Face-to-face consultations and trial information sheets were 
the only resources participants used to make their decision, which contrasts with models of 
decision-making, and with the findings of other studies (236,241,242).  Some participants 
described dependants, such as young children, as a motivation for their decision to 
participate, which is consistent with Huizinga et al. (241).  Several participants considered 
receiving cancer treatments as a ‘fight’ for their life, and saw the addition of a phase I 
treatment alongside their standard care as an additional benefit.  They thus described 
viewing the trial as providing access to better treatment.  The option of receiving hospice 
care instead of a phase I trial was not considered by this population.  Most were able to recall 
some risks associated with the trial, but for most these risks did not appear to influence their 
decision.  In agreement with a previous study (244), hope appeared to be a key influence 
over their decision to participate; participants spoke about the trial offering hope for a cure 
or preventing progression, and many viewed hope alone as having a positive influence over 
their health and coping with cancer, despite their understanding of their prognosis.      
As with other studies, only those who participated in the trials were interviewed, and 
therefore the views of those who declined to participate remain unknown.  Participants were 
interviewed after their decision to participate, but the time between the consent procedure 
and the interview was not specified by the authors, raising the possibility of recall bias.  
However, all interviews were conducted by a researcher independent to the trial team and 
participants’ care, which may potentially have reduced reporter bias and researcher 
influence over the data.  Two coders also independently coded the data (245), offering the 
benefits of data triangulation and improving the validity of their results.      
Summary of findings  
Despite a comprehensive literature search, few studies were identified which explored the 
decision-making processes of patients with advanced cancers regarding participation in early 
phase clinical trials.  Narrative synthesis of these studies provides some clues as to factors 
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which may play an important role in decision-making in this context.  All studies present 
optimism through hope as influencing participants’ decisions.  Some theorists consider this 
optimism bias, a desire for an extraordinary outcome compared to the average patient, to 
compromise informed consent (251).  Despite this, in later studies, the authors present 
optimism as a coping strategy for dealing with a cancer diagnosis, thus not invalidating 
informed consent (252), which supports the theories of others (253).  Most studies also 
present emotionally-laden situations as leading to an instantaneous decision about 
participation (241,244), rather than a decision which is necessarily constructive and 
considered (242).  Despite this, findings from the above mentioned studies suggest that 
participants do not generally regret their decision to participate, and increased time to reflect 
upon their decision does not appear to alter their initial decision.  Data also suggest that 
patients’ decisions are often personal and made in a non-altruistic nature, although point to 
the importance of family influences on decision-making, thus suggesting the role of 
conditional altruism in influencing participants’ decisions (254).  The role of relational 
autonomy through trust in the clinician was also apparent and, in certain instances, may 
influence participants’ understanding of equipoise.  
Although informative, the literature exploring decision-making processes for early phase 
clinical trials in oncological conditions has several limitations which make generalisability to 
GBM populations difficult.  First, it is based predominantly on the accounts of females with 
non-neurological tumours, hence may not directly relatable to the decision-making of 
patients with GBM, particularly given that patients with GBM may also experience cognitive 
decline which could influence their decision-making processes.  However, all patients’ 
conditions were advanced in nature with treatment offered for palliative purposes, which is 
a similar treatment and prognostic position to GBM care. Second, although all included 
studies explored patients’ initial decisions to participate, there is no literature exploring how 
or if this decision changes over time for patients with advanced cancer, despite knowing 
patients’ decision-making in relation to their healthcare changes as the disease progresses 
(231).  There is also very little evidence exploring the decisions of patients who declined to 
participate in early phase advanced cancer trials or exploring the roles of relatives in the 
decision-making of patients, therefore their views remain unknown.  In order to optimise 
informed consent and patient experience in subsequent KD trials, we need to know more 




5.2.4 Aims and objectives  
 
This study aimed to explore patients’ and their significant others’ perspectives of their 
decision-making when invited to participate in KEATING.   
Specific objectives were to:  
 Understand patients’ perspectives of their decision-making participation in KEATING.   
 Explore the views of relatives and their influence on patients’ decision-making.   
 Explore patients’ ongoing decision to participate in the intervention once recruited.     
 Design bespoke strategies to optimise the decision-making of future patients with 
GBM invited to participate in KD trials.  
5.3  METHODOLOGY 
 
5.3.1  Study design  
 
A qualitative study embedded into KEATING eight months into the initial recruitment period 
due to difficulties with recruitment and dietary retention of patients.  The study involved 
semi-structured interviews with patients and their relatives.   
5.3.2  Ethical and study approvals 
 
Ethical approval was granted by the North West - Greater Manchester West Research Ethics 
on 20th December 2017 (protocol amendment 2), along with Sponsor and WCFT approvals.   
5.3.3  Presentation of KEATING to patients  
 
To provide context to the embedded qualitative study, a recap of the approach taken to 
recruit potential patients will be briefly described (for full details see chapter 4).   
Following a histological diagnosis of GBM, a member of the neurosurgical/ oncology team at 
the hospital Trust briefly discussed KEATING with the patient.  If s/he was interested, the trial 
dietitian provided further details of the KD and the trial, supported by written information. 
After providing consent, patients were randomised to follow either a medium chain 
triglyceride ketogenic diet (MCT KD) or a modified ketogenic diet (MKD) for three months 
(primary end point) (for details of the interventions see table 5.1).  All patients received 
dietary education.  This consisted of recipes, meal plans, KD information sheets on foods to 
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consume or avoid and the home monitoring required, such as urinary and blood ketones 
(high ketones being associated with compliance and efficacy in animal models).  Patients also 
had regular dietetic contact throughout the trial.  Outcomes included protocol feasibility 
(estimation of retention and recruitment rates for a phase III clinical trial, dietary adjustments 
required to achieve ketosis, dietary compliance, ketosis levels) and the impact on patients 
(quality of life, dietary acceptability, gastrointestinal side effects, anthropometric and 
biochemistry changes). 
For KEATING, 57 patients were approached to take part between March 2017 and February 
2018.  Of these, 15 were excluded, 30 declined and 12 consented.  Six were randomised to 
MCT KD and six to MKD.  Of these, three completed the three month dietary intervention 
MCT KD arm and one in the MKD arm.       
Table 5.1: Comparison of MCT KD and MKD dietary interventions 
Intervention MCT KD MKD 
Macronutrients 10% carbohydrate 





15% protein  
Example meal  Bacon x 2, eggs x2 scrambled with 
2 dsp double cream, ½  avocado, 1 
½ tomatoes, ½ slice low carb 
bread, handful spinach and 100ml 
Betaquik MCT nutritional product 
Bacon x 2, eggs x2 scrambled with 4 dsp 
double cream, ½ avocado, handful 




Urinary ketones twice daily 
Blood glucose and ketones weekly 
Intermittent food diaries 
Dietitian appointments 
Urinary ketones twice daily 
Blood glucose and ketones weekly 
Intermittent food diaries 
Dietitian appointments 
NB: Bold text highlights differences between the dietary interventions. MCT nutritional products 
provided in the form of Betaquik (Vitaflo International Ltd). Ketones are monitored Further details of 
the interventions and monitoring can be found in a previous publication (255). Abbreviations: dsp = 




5.3.4  Participants 
 
Eligibility criteria for qualitative study: 
1. Patient interviews 
a) Patient approached to participate in KEATING (see chapter 4 for KEATING 
eligibility criteria). 
b) Capacity to give informed consent.  
2. Relative interviews 
a) A relative of a patient approached to participate in KEATING. 
b) Capacity to give informed consent.  
As the qualitative study was introduced eight months after KEATING had commenced, 
patients approached for KEATING from this point onwards were eligible for the qualitative 
study or if they had been approached to participate in KEATING three months prior to the 
qualitative study commencing.  
Patients could be interviewed for their sole experience, whilst relatives were only invited to 
participate as a dyad with the patient.    
5.3.5  Sampling 
 
Participants for the qualitative study were a purposively sampled sub-set of patients who had 
been approached to participate in KEATING, and their relatives (256,257).  Sampling was 
informed by review of screening logs maintained as part of KEATING and aimed to include 
those who consented to KEATING, those who declined KEATING, those randomised to MCT 
KD and those randomised to MKD.  The principles of informed consent mean that when 
patients withdraw or decline from trials they are not obliged to give a reason for their 
decision if they do not wish to.  However, this qualitative study invited patients to participate 
even if they declined or withdrew from KEATING as they may have wished to convey their 
perspectives and it is important to understand the experience of both those who consent 
and those who decline. 
Adequate sample size was determined using the ‘information power’ concept (258,259).  
5.3.6  Semi structured interviews  
 
Primary data was generated by the researcher through semi-structured interviews which 
explored the patients’ perceptions of their decision-making after being invited to participate 
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in KEATING.  Interviews were selected over focus groups to provide a depth of information 
about participant’s and their relative’s decision making, rather than the breadth offered by a 
group dynamic (92).  Furthermore, interviews allowed for discussion of sensitive topics given 
the patient’s prognosis.  Participants were also dispersed geographically and interviews were 
to be completed within set timescales (260).  Interviews were conversational and patient-
centred, using open-ended questions.  Questions were adapted depending upon if the 
patient consented or declined to participate.  As the researcher had a dual role (dietitian and 
qualitative researcher), the interviews were conducted in a gentle, sensitive and non-judging 
manner, to make the experience as comfortable as possible for patients.   
The interviews were topic guided (for patient, relative and dyad topic guides see appendix R) 
and iterative, allowing for the development of interviews over time.  The topic guide was 
informed by published literature and incorporated the study objectives.  It was devised by 
two members of the research team, one of who had extensive qualitative experience.  Any 
questions in which the patient or relative felt obliged to justify their decision were avoided.  
Patients and relatives were free to decline to answer any questions or terminate the 
interview at any point.  An overview of the topic guide can be found in table 5.2. 
Interviews took place in the patients’ own home, workplace, by telephone or at WCFT 
depending on the patient or relatives preference. Patient and relative interviews were 




Table 5.2: Overview of the topic guide 







Who initially told you about the study? Can you tell me about the run up to the study?  Can you remember when you were first 
diagnosed?  Is there anything would you change about how you were approached?  When 
would you prefer to be approached?  Who would you prefer to approach you about the study? 
What is your understanding of the reason why the study is being done? What is your understanding of what the study aimed to investigate? Are you able to tell me a 
bit about what this involves for patients? 
We posted an information sheet to you about the study (demonstration 
sheet provided).  What are your views on it? 
Did you find the wording and layout suitable? Is there anything that you would change? Were 
any parts helpful? Did you have any questions after reading the leaflet? 
Decision-
making 
Before making your decision about taking part did you seek information 
from anywhere else?  
Did you discuss your involvement in the study with your family or friends? Did you discuss the 
study with a doctor or nurse? 
Can you tell me about how you came to your decision to take part/not 
take part in the study? 
When did the decision start to form in your mind?  How do you usually make decisions (gut 
reaction or evidence based/ informed decision)?  How certain were you with your decision?  
How confident were you with your decision? 
Are there any potential changes that could be made to alter your opinion? Any changes to the study design?  Changes to how you are told about the study and what it 
involves?  
When thinking about the treatment you have received, is there any time 
when you think starting the diet would be most appropriate? 
This could be not at all, before/after surgery, before/ during/ after radiotherapy or before/ 
during or after chemotherapy or after all treatment has finished. Can you tell me a bit more 
about that? 
Did you consider any other studies or treatments? Other studies that may be open to you locally or nationally?  Have you taken part in research 
previously? Would you take part in potential future studies? Have you looked into any other 
diets or nutritional supplements? 
If you had the chance to be involved in the study again would you make 
the same decision?  






What did you think when you were told about your allocated diet?  Did you have any worries or expectations?  Do you have any particular views on being 
randomised to one diet or the other? 
What has your experience of the KEATING study been so far? Has your experience influenced your views on research?  Do you have any tips for a similar 
study in the future? Has any part been particularly burdensome? Have there been times when 
the diet has been more difficult to follow?  Have there been times when the diet has been 
easier to follow?   
Conclusion  Is there anything else you would like to talk about that we haven’t 
covered? Do you have any questions for me?  Thank you for taking the 
time to talk to me.  




5.3.7  Data management and transcription 
 
All interviews were audio recorded and transferred onto a password protected file held on 
University of Liverpool Active DataStore for analysis.  All audio recordings were transcribed 
verbatim, checked and anonymised for analysis.      
5.3.8  Data analysis 
 
Analysis drew on the Braun and Clarke  thematic approach to identify patterns of meaning 
within the data (261), with KM initially familiarising herself with the data, then generating 
initial codes, searching for themes, reviewing themes, defining and naming themes and the 
careful placement of theory prior to producing a report.  KM lead a process of iterating 
between the developing analysis and new data (familiarisation,).  Other members of the 
qualitative study team (BY and GC) read a sub-set of transcripts and developed the analysis 
by periodic discussion.  Qualitative researcher BY is an academic psychologist with extensive 
experience of embedded qualitative studies within trials, and GC is a clinical psychologist 
specialising in oncology and has experience in nested qualitative studies and research 
exploring patient perspective.  An adequate sample was obtained drawing on the concept of 
‘information power’ (258).   
Analysis did not take accounts only at face value; rather the approach was interpretive and 
considered both latent and manifested aspects of the data (e.g. what we could learn from 
the way that patients and relatives talked as well as the explicit content).  Context to the 
interviews was provided through the use of field notes taken by the researcher at the time 
of interview.  The design, conduct and analysis of the qualitative study was informed by 
procedures that support quality in qualitative research including systematic data coding, 
triangulation and exceptional case analysis (262,263).  The Index of Multiple Deprivation 
(IMD) for England and for Wales, qualitative studies of deprived areas, were also consulted 
to provide context to the results (264,265).   Analysis was assisted by qualitative analysis 
software (NVivo 11).  Results were fed back to the KEATING TSC. 
5.3.9  Philosophical underpinnings  
 
The orientation of this qualitative study was both inductive and deductive, with the study 
being designed pragmatically to explore the decision-making processes of patients invited to 
participate in KEATING.  To understand patients’ decision-making (the phenomenon in 
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question), a subjectivism/ constructivism ontological approach was taken,19 understanding 
patients’ decisions through their perceptions and interpretations of events.  Their interviews 
were then analysed interpretatively, constructing meaning and interpretations, from both 
latent and manifested aspects of the verbal accounts (266,267).   
5.3.10  Reflexivity   
 
Reflectivity is important in qualitative research as it allows the researcher to contemplate 
how their beliefs, background, attitude and values affect the research (268).  A personal 
reflection attempts to limit researcher subjectivity to reduce potential bias in the collection, 
analysis and interpretation of data, thus improving trustworthiness and validity of the study 
(269–271).   
Personal reflection  
I am a white-British, married female, residing in the north west of England.  I am a registered 
dietitian and have worked within the NHS for the past ten years, the last five of which I have 
specialised in neurological conditions, with expertise in KDs.  I obtained qualitative research 
skills through University of Liverpool modules and two Social Research Association (SRA) 
courses.            
For KEATING I held a dual role; i) trial dietitian and ii) qualitative researcher.  I immediately 
appreciated the bias this may present, given I would be recruiting patients, providing dietary 
education and support, and managing the day to day running of the trial, whilst interviewing 
patients and relatives about their experiences of recruitment and their decision to 
participate.  Ideally, a researcher independent of the trial team would conduct and analyse 
an embedded qualitative study.  However, given the trial was being undertaken as part of my 
PhD studies and the lack of alternative resources available, this was the only viable approach.  
Therefore, I considered any obvious and conscious bias I might present before conducting 
the research. 
I appreciated that I was in a potential role of power due to my clinical relationship with 
patients, which may affect their responses during interview.  Thus, I tried to maintain 
neutrality in the context of data collection, interpretation and presentation (269).  I assured 
                                                          
 
19 Constructivism is the perception that participants construct their knowledge from experiences and 
are in a constant state of revision (266).  
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all interviewees that I was conducting the interviews in my capacity as a researcher, rather 
than a dietitian, with a view to improving patient experience in future trials.  I tried to 
maintain neutrality in wording during the interview and was conscious of my choice of words, 
for example referring to ‘the study (team)’ rather than the use of ‘I’ in relation to the design 
of the trial.  The interviews were conducted at the patient’s home or a place of their choosing, 
rather than the hospital, to minimise environmental bias.  I also dressed to suit this 
environment, wearing casual clothing rather than my clinical uniform, to help emphasise the 
difference between my roles.      
During this time, I maintained a reflective diary.  I noted points of interest from the 
interviews, emotions displayed by patients and relatives and body language.  I reflected upon 
my strengths and weaknesses as a researcher.  These reflections aided the iteration of the 
topic guide and the development of my interview technique.  The qualitative interviews led 
me to become more emotionally attached to patients.  Rather than simply maintaining a 
clinical relationship, I visited their homes and met their family, which provided context to 
their lives that I would otherwise not have known.   
When patients and relatives spoke negatively of the trial, I was able to remain impartial.  
From a personal view point, whilst I was the trial dietitian and KEATING was being undertaken 
as part of my PhD thesis, recruitment and retention were poor.  Hence, I was keen to speak 
with patients who consented, patients who declined and their relatives to understand the 
challenges they faced and how they made their decision with a view to improving the support 
they received and inevitably improve KD trials going forward.  The patients were an 
inspiration to me, their family and their peers.    
To offer credibility and reliability to the results, the interpretation of themes was developed 
and tested through periodic discussion with two experienced qualitative researchers 
independent of the trial, as I led the process of iterating between the developing analysis and 
the new data.   
I was very appreciative of interviewees’ time and views.  Without their participation in the 
interviews, this research would not be possible and no improvements would be made to the 




5.4  RESULTS 
 
5.4.1  Sample characteristics / contextual factors 
 
Fifteen patients and their relatives were invited to be interviewed.  Of these, 10 patients 
(66%) and five of their relatives, all of whom were white British, took part in interviews 
between January and April 2018.   Of the patients, five were male and five female; of the 
relatives three were male and two female (see table 5.3).  All participants were interviewed 
separately except one patient and one relative who were interviewed jointly.  Individual 
interviews lasted for an average (median) of 44 minutes (36 - 62 minutes) and the dyad 
interview lasted 65 minutes.  Average (median) time from initial contact about KEATING to 
the qualitative interview was 11.4 weeks (6.9 – 22 weeks), with those participants 
retrospectively recruited (T27 to T51) experiencing the longer delays (see table 5.3).     
Those who were retained within KEATING were the youngest patients, those who declined 
were the older patients and those who withdrew were aged between those who retained 
and those who declined. The IMD (272) was also reviewed for each patient (eleven resided 
in England and four in Wales), as illustrated in table 5.3.  Those who retained in the study and 
those who declined were generally from areas ranked of higher IMD, therefore less deprived 
areas of England and Wales, whilst those who withdrew were generally from areas ranked of 




Abbreviations: IMD = Index of Multiple Deprivation; MCT KD= medium chain triglyceride ketogenic diet; MKD= modified ketogenic diet.  
Key: Continued participation = continued with the intervention beyond three months; Early withdrawal = withdrew from the trial following consent and randomisation, but prior to commencing 
a KD; Delayed withdrawal = withdrew from the trial after commencing KD but before the primary end point of three months; Declined = declined to participate in KEATING.  Time to interview = 
time from initial contact about KEATING to qualitative interview. *Index of Multiple Deprivation (England): decile of 1 = 10% most deprived areas of England, decile of 10 = 10% least deprived 
areas of England; Ɨ Index of Multiple Deprivation (Wales): 10% = 10% most deprived areas of Wales, >50% = >50% least deprived areas of Wales.   




















T27 Female 60-69 1* MKD 
 
Early withdrawal 22 No - - - 
T30 Female 70-79 >50%Ɨ - 
 
Declined 22 Yes T30/R Male Husband 
T35 Female 50-59 4* - 
 
Declined 17.1 No - - - 
T39 Female 60-69 30-50%Ɨ MKD 
 
Delayed withdrawal 10.2 Yes T39/R Male Husband 
T44 Male 40-49 2* MKD 
 
Continued participation 14.4 No - - - 
T45 Male 40-49 7* MCT KD 
 
Continued participation 12.6 Yes T45/R Female Wife 
T47 Female 60-69 2* MKD 
 
Delayed withdrawal 9.7 Yes T47/R Male Husband 
T51 Male 50-59 10* MCT KD 
 
Continued participation 6.9 Yes T51/R Female Wife 
T52 Male 60-69 2* MCT KD 
 
Early withdrawal 8.1 No - - - 
T55 Male 60-69 8* - 
 
Declined 9.3 No - - - 
133 
 
5.4.2  Patients’ accounts of their decision-making regarding participating in KEATING 
 
Linked to the study aims, patients’ accounts of their decision-making are presented according 
to the outcome of their decision about KEATING: i) continued participation; ii) early 
withdrawal; iii) delayed withdrawal; and iv) declined participation.  The relationships 
between these decisions are illustrated in figure 5.1.  Throughout the results, verbatim 
quotes are presented in speech marks, with ellipses indicating missing text and square 
brackets indicating replacement or explanatory text.  To preserve anonymity, all patients 
were identified by the patient’s KEATING trial number (e.g. T01) and relatives by an 
associated number (e.g. T01/R).  
Figure 5:1 Qualitative pictorial of decision-making patterns 
 
Key: Emotional consenters = patients who consented to participate in KEATING, intuitively; Considered decliners 
= patients who declined to participate in KEATING who were considered and deliberative in their decision-making.  
Matched decision = the decision of the patient is supported by their relative; Non-matched decision = decision of 
the patient is opposing to that of the relative; Positive validations = positive experiences or encounters which 
positively influence the patients’ decision to continue participating in the trial; Negative validations = negative 
experiences or encounters which negatively influence the patients’ decision to continue participating in the trial; 
Continued participation = continued with the intervention beyond three months; Early withdrawal = withdrew 
from the trial following consent and randomisation, but prior to commencing a KD; Delayed withdrawal = 
withdrew from the trial after commencing KD but before the primary end point of three months; Declined = 






5.4.3  Continued participation  
 
The initial decision of the three patients who continued to participate in KEATING (beyond 
the twelve week primary end point) was recalled as being instantaneous: “I jumped in, you 
know, took the opportunity with both hands … it was a no brainer” (T44).  One explained their 
reaction to hearing about the trial as “give me a straw and I’ll grasp anything” (T51).  They 
emphasised that participating in the trial provided the opportunity for them to “fight for their 
life” (T44), otherwise “if I don’t do this I’m sure as eggs is eggs I’m not going to be here” (T51).  
The patients wanted to commence the diet immediately and reported the feasibility nature 
of the trial to be largely irrelevant: “… [the research team are] doing your study for the 
feasibility of people doing it, rather than what I'm doing it for, which is to turnaround and 
maximise the health benefits” (T45).  Their decision about trial participation was reportedly 
different to how they would normally make a decision; as illustrated by T51, patients did not 
appear to consider the risks of participating, only the benefits: “there were no risks…I know 
the National Health Service are ultra-cautious, they have to be don’t they… benefits well 
there’s a small chance I might live” (T51).  These patients explained how taking part in the 
trial and following a KD offered them control over their condition: “I have no real options 
when it comes to the medical side of it you know, you’ve got to take their best advice.  The 
idea of doing the diet, so that you had some control, was appealing you know” (T44).  
After making their initial decisions, the three patients in this group reported seeking approval 
from their family: “it was a case of speaking to my family and getting their support to make 
sure that they were on board with what I was going to do, my family gave me the thumbs 
[up]” (T44).  Relatives of those patients who continued to participate in the trial supported 
the patients’ decision: “[we would do] anything that works, to be honest, we’d give anything 
a go” (T45/R).   
Randomisation to MKD or MCT KD was recalled to be clearly understood by most patients 
who continued to participate and reportedly held no bearing over their decision to 
participate, with one patient commenting “we have no real idea which is the best” (T51).  
Those randomised to MCT KD and thus consuming nutritional products as part of the diet, 
explained that these products helped them because “I don't know if I’d have had the 
confidence or the ability to do the diet perhaps without the supplement to start with, because 
doing your weights and measures for the entire diet I think must be quite difficult” (T45). 
Patients in this group also spoke to making an ongoing decision to participate on a regular 
basis.  They also spoke of the importance of positive opinions of ‘informed’ relatives and 
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online blogs in this process.  As T51 recalled, “we’ve got a friend who’s an oncologist 
nurse…and she put us in touch with a blogger, erm, so a guy that survived this, he’s 12 months 
down the track”.  All three patients also made reference to the influence of ‘positive stories’ 
from long term KD GBM patient survivors: “there's lot of good results of people having 
positive responses to it [ketogenic diet]… the one story was the guy who had a, erm had the 
same tumour, he’s on this [ketogenic diet], his [tumour] reduced, what's not to want to go for 
that?” (T45).  They also recalled seeking approval from clinicians, because: “if we get this 
wrong, that costs me my life, you don't make decisions on things that you're not fully up to 
speed with.  [Consultant’s name] was the guy in my eyes [to talk to about the trial]” (T44).  
These three patients who chose to remain in the trial also recounted having self-researched 
KEATING, the diet, other clinical trials and holistic treatments after consenting to participate.      
As time passed, the reasons attributed to participation initially became the reasons patients 
recalled for continued participation, along with new factors such as “obviously benefits are 
research for the greater good” (T45) and “losing weight and staying fit and active is definitely 
the way forward” (T44).  Patients reported feeling “more mentally astute and more confident 
at dealing with this [diagnosis] going forward” (T51) and spoke of being motivated to 
continue because “my first scan was so positive” (T51).  Patients explained their motivation 
for following the diet each day through “long term goals” (T44), with ketones providing “a 
quick confidence check and every now and again” (T45) and offering ‘fulfilment’, alongside 
experiencing a “fantastic quality of life with cancer” (T44).  These three patients reported 
these factors to be more important than what food they ate: “I don't care if I have to eat 
cheese nuts and celery every lunch time, it doesn’t bother me” (T44).  Patients reported 
enjoying the ‘dietary regime’, explaining that “I don't need a sneaky chocolate bar and that’s 
for the variety, so I'm actually enjoying the comfort of regimental approach” (T44).  As a 
family, relatives emphasised the diet to be “a new normal for us” (T45/R).  The patients 
attributed their ability to ‘cope’ to the support provided by their relatives, as T45 explained: 
“I get to a point where I’m being a bit tired, so [relatives’ name] will regularly come in and 
say do you want ketone bun and having [wife] there she will go along [and cook]”.  These 
patients who retained in the trial expressed remaining satisfied with their initial decision.   
5.4.4  Early withdrawal 
 
Two patients consented to KEATING but withdrew early after being randomised and receiving 
dietary education, but before commencing the diet.  Consistent with those who continued to 
participate in KEATING, the two who withdrew early described their initial decision to 
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participate as being “more of a gut decision” (T52) or based on “gut instinct” (T27), because 
“[I] don’t want to die so I’ll try anything at the moment” (T52). As T27 explained, “initially, [I] 
was like anything to help and I thought the diet could help, you know because I was full of ‘oh 
let’s do this’ and… it was a gut instinct I think… because if it was going to do me good and I 
was hoping I could do it, maybe sort of slow it [cancer] down” (T27).  
These two patients also described feeling satisfied and “felt very confident” (T27) with their 
initial decision.  It was at a later stage, following dietary education and after discussing their 
decision with a relative, that they decided to withdraw, explaining that, on reflection, they 
had begun “stressing myself out” (T27) over the decision to continue participating in the trial 
and had started to feel as though “it was just too much, I was just trying to take too much 
on” (T52).   
Both patients explained they felt that they would be reliant on the relative to assist them 
with the diet and monitoring during a ‘busy’ time, and this added to their ‘worry’ about 
participating in the trial, as T27 explained: “I wasn’t doing cooking… so it was all [husband], 
erm and putting that pressure on him as well, when he was already worrying about me and 
trying to look after me.  I didn’t want to put that pressure on him.” (T27).  Similarly, T52 
reflected that “just preparing [meals] and trying to sort out where I was at [was a concern] 
because [relative’s name] got her own family and things going on so it was just down to me” 
(T52).  They also spoke of their tendency to ‘comfort eat’, explaining “I’d would just curl up 
on the couch Sunday and think well I’ll just have a cup of tea and a biscuit… open a packet of 
biscuits and they would be gone within twenty minutes” (T52).  Both spoke about feeling 
concerned about how to adhere to the diet, because “it’s a fact that you’ve got to scratch 
your head and work out what you want to eat and what you’re going to fancy eating because 
some of it doesn’t taste that nice…” (T52).  They described ‘struggling’ with “thinking about 
well, what can I eat instead” (T27), which added to their worry because “[I] was thinking too 
much about it and worrying what I was going to replace the carbs with” (T27).   
Upon making the decision to withdraw, both patients described again feeling confident and 
relived: “it was like, erm, a big relief that I’d made that decision” (T27).  Both patients also 
went on to explain that their relatives did not wish them to participate in the trial and agreed 
with their decisions to withdraw: “[husband’s] opinion was just concentrate on getting 
yourself better, you don’t need that as well to think about, that might be too much… so yes 
he wasn’t very happy about me wanting to do it” (T27).  However, they reflected that their 
relatives had no influence on their ultimate decision to withdraw from the trial: “he didn’t 
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have an influence because I’m very strong” (T27).  Interestingly, following early withdrawal, 
both patients also recalled making dietary changes which they felt to be in line with the 
principles of KEATING, but which seemed reasonable and attainable to their lifestyle: “a 
sweet tooth is my main problem but now I’ve cut them [biscuits] all out” (T52) and “it’s all the 
carbs, I eat a lot of bread, I’m trying to cut down at the moment” (T27).   
5.4.5  Delayed withdrawal 
 
Two patients withdrew after consenting to KEATING and following the diet for approximately 
six weeks.  They also recalled their initial decision about trial participation to be 
instantaneous and different to how they usually make decisions: “I thought about it but not 
as long as I would normally, I sort of made a decision on that day that I was going to have a 
go at it” (T47).  In keeping with those who retained and those who withdrew before starting 
the diet, participants described choosing to participate in the trial because it “would be 
beneficial for me” (T47).  They were able to state the aim of the trial and recalled “no promises 
were made at all… just research and they explained about the pilot scheme” (T39).  However, 
both recounted believing that “there's a chance that changing the way we are eating would 
have an impact [on cancer]” (T39), and described considering the benefits of the trial, but 
not the risks: “well, I understood the benefits of it because of the cancerous cells… and the 
risks? I’m not really sure about the risks.” (T47).   
These two patients also explained that they had adequate time afterwards to consider their 
decision but this did not alter their initial decision.  They spoke of discussing their decision to 
participate with their relative.  All felt that they had been influenced by their relatives’ 
opinion, stating “I wouldn’t have done it [participated] on my own” (T39) and that “we had a 
discussion together as to whether or not we felt it was the right thing for me to do… [relative] 
just supported me with it, he felt that I should be giving it a go as well” (T47).  Like the 
patients, relatives also described their decisions as instantaneous: “I’d take anything with 
open arms because anything that would help cure [the tumour], you know… I’d jump at.” 
(T47/R), with relatives attributing a kind of selfishness to their motives: “I wanted her to have 
a go… I suppose it’s a bit selfish really but you know you, there’s a selfish element in it because 
you want her to be here sort of thing” (T39/R).  The two relatives recalled their understanding 
of the trial’s aim to be “to assist the chemotherapy and radiation treatment she was getting… 
and assist the chemotherapy to cure, well, to cure it… that’s why we sort of we’re keen to get 
on the diet” (T47/R) and to “help as regards, erm, wellbeing, you know, for the person” 
(T39/R).  The relatives explained that they were prepared to support the patient with the 
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requirements of the trial - “all the preparation and err the shopping and cooking that was all 
down to me” (T47/R) - and to provide moral support: “I had to be there to encourage, to back 
up when things were a bit flat” (T39/R).  Patients reported appreciating that they would 
require support from their relative to undertake the trial, as T47 explained: “I think it did help 
having a support behind me because obviously I had to rely on him for getting all the correct 
foods in and cooking it for me” (T47).  
The patients’ understanding of randomisation was mixed.  One reported an understanding 
of the process, rationale and intervention arms, explaining that “no personal bias or anything 
at all was coming into it, [it] was just totally, totally at random like scientific…done [on] 
computer” (T39).  The other solely recalled an understanding of the two arms, recalling that 
“I know one of them was I might have to drink, the other food” (T47).  Both patients and 
relatives in this group reported a preference towards one intervention or the other and MCT 
nutritional products (Betaquik, Vitaflo [International] Ltd) were viewed both positively 
(showing favour towards MCT KD ) and negatively (showing favour towards MKD), as 
illustrated in the following quotes: 
“[I] just didn’t fancy the drinks with the fat… just the thought of drinking fats, you know, 
through liquid and the one that I was on was just solid food and food that I liked… I don’t 
think I’d’ve lasted as long as I did” (T47). 
“Well it was have either the full fat drink or go on the food.  [Patient] preference all along I 
think was the food… so that could put people off when they think that… [Patient] was 
dreading the thought of going on a fat one, I think” (T47/R). 
 
Both patients recounted how they or their relatives undertook their own research using 
online search engines after consenting to participate: “I did go on Google and did a little bit 
of research” (T47); “then of course our daughter [researched the study] on Google… next thing 
we had a cookery book arrived and I think another one arrived, erm so she was sort of…trying 
to help” (T39).  These patients also spoke of the influence of online blogs on their decision to 
participate, explaining: “well there’s this guy… I knew that he’d been doing the ketone diet as 
well and he felt like it worked for him.  So I read his blog it encouraged me that it actually 
worked for him, so it encouraged me to take part in it [the study]” (T47). 
The patients spoke about the importance of their clinical teams supporting the study: “it was 
nice to know that you had the backing of the doctors and nurses as well… in the medical 
profession… good to know they back you” (T39), and the perceived ‘safety’ of a trial as it was 
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being undertaken by healthcare professionals “I was going to try something but like when he 
explained about this [the trial] I though that’s even better because you’ve got professionals 
behind you… I thought well you know somebody who knows what they're talking about so I 
felt safer if you like” (T39). 
As time progressed within the trial, initial dietary preferences could change with experience: 
“we perhaps [would have] gone maybe a bit for the supplement side [MCT KD] had we known 
that’s it more difficult to actually do the diet” (T39/R). Indeed, these patients described 
feeling ‘worried’ about what they could eat and the effect of this on their mental wellbeing: 
“I was worrying, I was waking up, I was literally waking up… and that’s all I could think about: 
‘Oh I've got to get my fats intake today’. And that’s all I was thinking about and erm it was 
pulling me down” (T39).  Relatives reported sharing this worry and concern for the patients’ 
wellbeing: “in the end the diet made her feel a bit down…that didn’t help the condition… it 
wasn’t a burden but… it was very stressful for [patient] and, you know, it knocks on to yourself 
doesn’t it, because you want to help or you want to help them as much as you can… if it 
impacts in that sort of [way] it’s a problem then” (T39/R).  Patients and relatives recalled 
taking day-to-day motivation from ketone measurements, but perceiving a lack of results.  
They reported feeling ‘demoralised’ when the readings were low.  The relative of T47 recalls 
their experience: 
 “You don’t see any results, the only results that we were seeing was, as little as they was, 
was [patient’s name] waterworks. Whether or not we were achieving that level [of ketones] 
that you wanted to be at and that was that was the only motivation that we could see that 
was actually working and the blood count whether or not that was working.  So they’re the 
motivation. If you achieve that then you think you’ve done something that week… the low 
ketones it made me feel personally that I wasn’t doing the diet right… it demoralised you” 
(T47/R). 
Both patients reflected that they felt as though they needed to try the diet to understand the 
‘reality’ of participating in the trial: “you had to try the diet to discover how difficult [it was], 
I didn’t realise it would be that difficult” (T39).  Both patients and relatives reported that 
following either KD would be difficult to “live with that forever more” (T47).  Relatives 
reported sharing similar thoughts: “so you don’t know when you’re going into it whether or 
not you’re going to be able to do it, until you try it. And fair play she tried it and she couldn’t 
continue” (T47/R).  Both patients emphasised that they found the diet ‘harsh’ and 
‘monotonous’ and described lacking enjoyment from eating: “I think it was the restriction 
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and harshness of the food really…it’s just totally alien to the way I eat” (T39).  They also 
reported encountering difficulties during festive periods which affected their compliance: 
“Christmas came up I think and with everything there's treatment going on and the diet and 
Christmas and it’s a busy time anyway so I think it maybe that was just unfortunate” (T39).  
Both patients and relatives reflected that the duration of the diet was too long to sustain 
their continuation on the trial: “I’d say the only criticism I’ve got is that it’s possibly too long 
on the diet” (T47/R).   
Both patients recalled discussing their withdrawal from the trial with their relative.  After 
withdrawing from the trial, patients described feeling “free again like I could make my own 
decisions on what I was going to eat... it was a burden having to have just the same type of 
food all the time” (T39), and “so much better and I think [relative’s name] did too because he 
was a bit concerned about me” (T47).  Despite this, neither patient in this group reported 
regretting their initial decision and would undertake the trial again.  Like those who withdrew 
prior to starting the diet, these patients also reported changing what they ate following 
withdrawal from KEATING in ways that inclined towards a KD, such as reducing high 
carbohydrate foods, but were more attainable than a full KD.    
5.4.6  Declined participation  
 
In comparison to those who consented, the three patients who declined KEATING described 
being considered and deliberate in their decisions, consistently describing a lack of perceived 
personal benefit from participation: “the only thing I think about this study is erm what would 
benefit me” (T35); “if you were to say to me I guarantee that, I guarantee that, I guarantee 
you're going to be, better, you know, I might even do it” (T55).  They read the information 
sheet and were able to understand the aims of the trial to be exploring feasibility.  They 
stated being ‘unconvinced’ by the research and that they were unlikely to experience any 
improvements in their quality of life.  Patient T30 summarised this in their quote:  
“I thought well you’ve got to try these things but on the other hand I'm not convinced, yeah 
I'm not really convinced about it at all erm and I've not heard anybody convinced which is 
unfair isn’t it?  I haven’t heard anybody say, “listen this works and it certainly works for 
these people” or whatever, whatever, and I'm thinking, well and also I suppose because I'm 
sceptical about these things a bit… yeah I suppose there isn’t enough evidence really who it 
works with. Well, it probably won’t improve my quality of life. It’s not answering questions 
because it’s too low key to answer the right questions… if you can come back in a couple of 
years down and say it is beneficial, you know, after your studies....” (T30). 
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They described feeling that they would be poor trial candidates due to their dietary 
preferences: “when I read through the thing [patient information sheet]… I just realised I'm 
going to be dreadful. I mean, I've never dieted in my life… me go down to 5 or 10% 
carbohydrates diet? Not going to happen.  Not eating crisps, chips, potatoes? Not going to 
happen” (T55).  Lifestyle and socialising were also factors reportedly considered by those 
who declined: “there's my social life which involves, you know, going round to somebody’s 
house for dinner so you know they are going to put food in front of me and if I start saying 
“oh I don't like this and I don't like that” they're going to wonder who they’ve invited round” 
(T55). 
All three patients commented upon reasons why other patients might participate, such as 
being younger in age and having dependent children: “Certainly if I was 30 or 40 I might have 
a completely different attitude to it. You know, if I had a young family and everything you 
might be saying, well, you know, “anything, I will do anything at all to try and defeat this 
thing” but, you know, I'm just at a different stage in life really now” (T55).  They speculated 
personality to play a role on participation: “I mean all the patients I've seen going for cancer 
treatment are very buoyant so they're I think they're up for anything that helps them” (T30/R).  
They also commented on how other patients may perceive the trial and ‘play the game’ in a 
different way to them: “you can see why people would go down the road of they'd trying 
anything to see does it work… to each his own.  Everybody plays a game differently” (T30).  
Those who declined also explained that quality of life was more important to them than 
quantity and referred to the impact of their age on their decision: “you get to around 70 years 
old and that’s where I am.  So now every day I get up I want a quality day…you know, so 
quality of life is something I'm into right now…and so having a complex regime around diet 
again it doesn’t appeal” (T55).  One viewed the trial as “a waste of your life” (T35), but 
reflected that they may consider participating for “half of the time” (T35).  They considered 
that “younger people will be much more keyed into this study than we are” (T30). 
Two recalled the time commitment and the impact to their family caused by dietary changes 
to be ‘off putting’: “I did want to do it but I was, kind of, ‘will I have time for this?’ and I’m 
tired… I thought ‘can I fit all this in?’ and that was holding me back a little bit… my husband’s 
doing everything in here. I thought ‘oh I don’t want to start changing.  I’ve got to eat this and 
I’ve got to eat that.’” (T35).  All three group of patients also discussed how the media 
influenced their perception of KDs and therefore their decision to take part in KEATING: “I 
did see the television programme a while ago… the guy on the low carbohydrate diet was 
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serious cause for concern after six months….and people like Sky Cycling Team said they'd 
never put anyone on a diet like that its unsafe” (T55). 
All patients discussed how they avoided finding out about their condition and prognosis to 
reduce worry: “All the way through this [disease] I've not gone online I don't want to know 
about it [glioblastoma] …every now and then I see correspondence between consultants and 
GP and stuff and all so I think they're just naturally gloomy a lot of medics so I don't want to 
worry” (T55).  They explained how they wanted to continue with their life: “I don't want 
information, I don't want anything, I just want to go on with my life, that’s how we addressed 
it” (T30). 
The three who declined also recalled having discussed the trial with their relative, with two 
of the relatives agreeing with their decision in relation to quality of life, as illustrated in the 
following quotes: “I did discuss it with my wife… and I think at the end of the day, you know, 
she said her main thing was quality of life yeah” (T55); “well I think it’s something to be 
worthwhile but, erm, I was a bit concerned that it was a very restrictive diet for my wife to 
take at this stage really” (T35/R).  These patients all reported feeling satisfied with their 
decision to decline.  For the remaining patient, their decision to decline was not in agreement 
with their relative’s opinion and this patient described weighing up the ‘pros and cons’ of the 
trial continuously and feeling uncertain over their decision.  T35 described this in their 
account:  
“My sister and my husband and my daughter… would encourage me [to take part in 
KEATING].  She [relative] was saying, you know, “you should read it all and you should go 
through it and it’s supposed to be a really good study” and I said “I will, I will one day when I 
get some energy back”… because I wanted to do it but I didn’t know if I could do it…I kept 
thinking ‘oh because I’ve got that many appointments, have I got time to go to the Walton 
Centre to talk about what I should be doing as a diet?’ But then I think ‘well if I’ve got 
benefits from it yes you should’, you know what I mean?” (T35). 
As with those who withdrew from the study, all patients who declined also considered 
making dietary changes after declining to participate in KEATING: “I just really want to be 
going forward and eating properly and you know not having too many carbs and stuff like” 
(T35).  Some reported making different dietary choices: “I have rebalanced a bit instead of 
meat and that, so many days, I've got fish twice a week now… some recipes for vegetarian 
options” (T35/R).  Some suggested ideas for ‘reasonable’ dietary changes in trials going 
forward: “if it was structured differently if you were to say to me look my advice would be cut 
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down on your carbohydrate and eat these foods and rebalance your diet a bit more… I could 
certainly do that to a certain extent, you know, like I wouldn’t eat two bags of crisps, I would 
only have one” (T55). 
5.5  DISCUSSION 
This qualitative study explored patients’ accounts of their decision-making, comparing those 
who chose to participate in KEATING and those who declined.  It also explored the influences 
of relatives on these decisions and changes in patients’ decision-making over time.  
All patients who consented to participate in KEATING described making their initial decision 
to participate instantaneously and without deliberation. This reflects what others have 
reported about the decision-making of advanced cancer patients in early phase trials 
(241,244) and the decision-making of other cancer populations (273).  These reported 
accounts of the patients who consented to KEATING stand in contrast to the patient decision-
making processes outlined by Gillies et al. (236).  Instead, the decisions of patients who 
consented to KEATING were shaped by fear of GBM and of not having done all they could to 
‘fight’ for their lives.  These fears activated an emotional decision-making heuristic: 
participating in the trial initially provided hope for a cure and optimism for prolonging life 
and reducing fear of death and regret (274).  Altruism was not considered, which is reflective 
of other advanced cancer populations (241,242,244,245). Those who consented initially 
exaggerated the possible health and personal benefits, which optimistically biased their 
interpretation of the aims and objectives of the trial (245) and could result in questionable 
informed consent.  However, the influence of hope and optimism on the decisions of 
advanced cancer patients has also been noted in other studies and may not necessarily 
invalidate their informed consent (244,245,275), with one study which explored end-of-life 
conversations with long term GBM survivors finding a wish to ‘live as long as possible’ and 
prolong life to be important, as in KEATING (276).  Adopting an optimistic stance reflects 
more general life optimism, and can be adaptive for patients as it may help them to cope 
with their prognosis (251,253,277,278).  Challenging this optimism and coping strategy may 
be demoralising for some patients.  Clinicians should continue to use their clinical judgement 
when considering if patients’ consent to participate in a trial is informed or not.  There is 
currently little guidance offered by the Health Research Authority (HRA) Good Clinical 
Practice guidelines (279) regarding this matter.      
In contrast, those patients who declined to participate in KEATING did not make an emotional 
decision. Instead they described being considered and deliberate in their decision-making 
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process.  They weighed up the perceived risks and benefits and perceived quality of life, 
rather than quantity of life, to be of the upmost importance, which is in keeping with other 
brain cancer research (242,280) and with theory described by Gillies et al. (236).  
Interestingly, although those who declined were older in age compared to those who 
consented and altruism did not appear to influence their decision-making.  This conflicts with 
previous studies which report altruism as a key reason for older adults participating in dietary 
clinical trials, however the findings of Fearn et al. (2010) were based on general older adults 
rather than older adults living with cancer (281).   
Following their initial decision, all patients sought to validate their decision by seeking the 
opinion of others.  Patients particularly sought approval from their spouse or partner, 
regardless of whether the patient consented or declined to participate in the trial.  If the 
relative’s decision matched the patient’s decision, then patients reported feeling satisfied 
and confident with their decisions.  This conflicts with pre-consent ‘deliberation’ discussed in 
previous studies, with deliberation occurring after the patients’ initial decision, and highlights 
the role of relatives in patients’ decision-making processes (211,236,282).  Interestingly, what 
patients sought from their relative varied, with some reporting seeking approval only, whilst 
others described wanting to share decision-making and relying on their relative to assist 
them with their decision.  In some cases, the relative offered support for the patient, and in 
one case, conflicting opinions led patients to deliberate and reconsider their initial decision 
(283).  Previous studies have found those patients who prefer to make a shared decision with 
a relative regarding healthcare to be from areas of lower IMD, which is also reflective of the 
KEATING population (247).  However, there is currently a lack of data exploring the influence 
of relatives on the decision of patients with advanced cancer to participate in early phase 
clinical trials.  Godskesen et al., (2013) are the only group to discuss the influence and even 
then relatives themselves were not interviewed (244).  
Patients also sought validation for their decision to participate from an ‘informed relative’ 
with pre-existing healthcare or research knowledge, a phenomena previously noted in other 
studies (245).  Given the influence of relatives on patients’ decision-making, further multi-
perspective qualitative research would be beneficial to explore this concept further 
(284,285).  In addition to seeking the views of their relatives, those who consented began to 
reflect upon their decision in an altruistic manner, considering their family and young 
children (254,285).  This consideration to dependants appeared to be influenced by a desire 
to have ‘tried everything’ (241,245,276), and is in keeping with ‘death anxiety’ noted in 
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previous glioma studies (286) and the perceived positive activism of long term cancer 
survivors (287).  
Most consenting patients also sought the opinion and approval of a clinician.  They trusted 
the clinician’s opinion and viewed the clinician as a supportive member of their decision-
making process, illustrating the role of relational autonomy in validation of their choice 
(235,288).  This element of clinician trust can also be noted in other early phase clinical trials 
(242,244,245).   
After commencing the diet, patients continued to review and validate their own decision, 
whether this was to continue to participate in KEATING or to withdraw.  Those who continued 
to participate in KEATING beyond three months (primary end-point) reported finding 
validation from the media, blogs of long-term KD GBM survivors, clinical imaging and high 
ketone levels. To the authors’ knowledge, this type of ongoing validation has not been 
previously described in the context of trial participation.  In contrast to those who found 
ketone monitoring to be motivating and a source of validation, those who withdrew from 
KEATING reported uncertainty and a lack of validation from ketone monitoring, reporting low 
ketones to be ‘demoralising’, with the decision to withdraw motivated by a need to avoid 
prolonged impacts on their quality of life.  Although a desire to extend quantity of life 
influenced the initial decisions for these patients to participate, quality of life became more 
important as the trial progressed, in keeping with  other brain cancer research (242,280).  
Those who withdrew reported finding the diet difficult to cope with compared to the 
adaptive lifestyle of those who continued to participate.  Those who withdrew also reported 
emotional eating habits compared to the functional eating habits of those who continued in 
the trial.  Those who withdrew from the trial and those who declined were clear that the trial 
period of three months was too long.  Patients reported ‘feeling free again’ once the diet was 
discontinued.  It is important to note, that this may not necessarily equate to dietary 
acceptability outside of a clinical trial.  In a future post-trial environment, information 
regarding the efficacy of the diet may be available, which could alter patients’ willingness to 
engage.   
Despite withdrawing from the trial or declining to participate, all patients reported making 
dietary changes.  There was no evidence base to support this health initiative, which is a point 
of interest, given that a lack of evidence for KDs was one of the reasons for declining 
participation.   
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5.5.1  Strengths and limitations 
 
This study has several strengths. It is the first study to explore patients’ experiences of KDs, 
and their decisions to enter and continue in KD trials for GBM.  It is also one of few qualitative 
studies involving an early phase trial to compare the accounts of patients who consented 
with those who declined.  Patients highlighted the role of relatives in patient decision-making 
and in supporting them with the trial.  Through interviewing patients and relatives as a dyad 
we were able to explore this relationship from both viewpoints.       
There are also several limitations to this study.  Firstly, the sample size was small and we 
cannot be certain that saturation was achieved.  Nevertheless, drawing on the concept of 
‘information power’  (258,259) in qualitative research, this study had a well specified aim, 
and it has provided insights which will be valuable in informing a future phase III trial.   
Further, with regards to sampling, five patients declined to participate in the qualitative study 
(two due to declined health, two declined research participation and one due to the burden 
of a visit), four of which had declined to participate in KEATING.  Given the decline in health 
of two of the patients, our sample may be considered to only represent the views of 
‘healthier’ patients with GBM.   
As the qualitative study was embedded eight months after KEATING opened to recruitment, 
the views of initial KEATING patients remain unknown.  It is possible that the verbal 
recruitment strategy changed over time as the researcher became more familiar with the 
process; therefore the views of those recruited into KEATING first may be different to those 
recruited towards the end of the recruitment period.  Due to this delay in embedding the 
qualitative study logistically its main aim was to inform strategies to optimise and support 
the decision-making of patients invited to participate in future KD trials for patients with 
GBM, rather than inform the KEATING trial itself.     
As some patients were interviewed up to three months after their decision about KEATING, 
they may have found it hard to accurately recall their decision-making process, particularly 
given the nature of their condition and the numerous other decisions they will likely have 
had to make regarding their care and treatment.  Finally, both the qualitative study and 
KEATING were  conducted by the same researcher, which may have influenced patients’ 
willingness to be critical of KEATING or otherwise affected the trustworthiness of the 
qualitative study (270,271).  However, all patients expressed criticisms of KEATING.  In 
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addition, researchers who were independent of KEATING (GC and BY) were closely involved 
in the qualitative study and in scrutinising the interpretations of the data.  
Interviewees were not asked to read through their own accounts after transcription to seek 
the transcript being a true representation of their accounts.  This was secondary to the nature 
of their illness and speed of progression, which would be an ethical concern.   
5.6.1  Implications 
 
The findings of this study have several implications for subsequent KD trial design and 
conduct for patients with GBM.  In order to optimise patients’ decision-making and informed 
consent to trials, researchers planning and working on future trials should consider the 
following suggestions:  
5.6.1.1  Suggestions to optimise the decision-making processes of patients  
 Efforts to optimise informed consent could be aided through the design of bespoke 
decision aids (236,289).  Given our findings that some patients were dependent upon 
their relative to aid their decision, and all patients are reliant upon their relative to 
help implement the diet to an extent, including the relative in initial and ongoing 
conversations about trial participation (with the agreement of the patient), could 
also help to optimise patient decision-making. 
 The views of clinicians who will be actively recruiting patients should also be explored 
as stakeholders to future recruiting trials, as their views currently remain unknown.         
5.6.1.2  Suggestions to optimise study design  
 Some patients reported decreased motivation after six weeks, whilst those who 
declined requested a shorter trial period.  Evidence in animal models demonstrates 
KD to be most effective concomitant to radiotherapy (79).  As such, a six week, 
rather than twelve week, trial period should be considered by future KD trials for 
patients with GBM.   
 Some patients expressed a personal preference for or against the use of MCT 
nutritional products.  Therefore, it may be beneficial to allow the patients to choose 
whether they choose to use such products to support a KD and this option requires 
further exploration in a GBM population.  
 Future trials should embed a longitudinal prospective qualitative study into the trial 
design phase, which focuses on patient and relative understanding and decision-
making in the context of trial participation. This would help to identify and address 
challenges as they arise in future trials.  
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5.6.1.3  Clinical implications  
 Exploring the views of clinicians in the wider organisation and multi-disciplinary team 
where future interventions may be delivered will likely be essential for the 
implementation of KD services in neuro-oncology and for ensuring clinician ‘buy in’.     
5.7 CONCLUSION 
This embedded qualitative study explored the decision-making of patients invited to 
participate in KEATING and their relatives.  Future KD trials for patients with GBM can draw 
on these findings to ensure the decision-making of patients is optimised and adequately 
supported.  The role of relatives in this decision and in supporting patients with the 
implementation of the trial should not be underestimated.  A shorter intervention period of 








SUMMARY, RECOMMENDATIONS AND CONCLUSIONS 
 
6.1  CHAPTER OVERVIEW 
The use of ketogenic diets (KDs) for patients with glioblastoma (GBM) was an important 
question and in keeping with the James Lind Alliance Neuro-Oncology Priority Setting 
Partnership research priorities (1).  This thesis set out to explore i) the evidence for efficacy 
and acceptability of KDs for patients with gliomas; ii) the level of patient interest to support 
a randomised controlled trial (RCT); iii) the deliverability of a KD intervention in an NHS 
setting; iv) the feasibility of a trial protocol (KEATING) and the impact this trial would have 
on patients with GBM; and v) patients’ perspectives of their decision-making when invited to 
participate in KEATING.      
In this chapter, the headline results and conclusions will be discussed and recommendations 




6.2  SUMMARY 
The overall aim of this thesis was to explore the feasibility of using KDs as an adjuvant therapy 
for patients with GBM.  Whilst the preliminary survey and scoping service highlighted the 
level of patient interest to be adequate to support a RCT and that KDs could be delivered to 
patients with glioma within an NHS setting, the practicality of running a KD trial for patients 
with GBM proved challenging.   
 
KEATING initially faced challenges with recruitment, falling below the progression criteria for 
a phase III RCT.  Whilst eventually meeting the recruitment target one month ahead of 
schedule, the rate of recruitment to KEATING (28.6%) was below that of large NIHR-HTA 
funded oncology trials (50 to 89%) (290).  Dietary retention rates were also poor, with 33% 
of patients completing the three month trial period.  This further affected the completeness 
of trial data and subsequent analysis.   
 
A qualitative study was embedded to explore the challenges facing recruitment in further 
detail and proved pivotal in understanding the decision-making of patients invited to 
participate in KEATING.  The initial progression criteria for KEATING were based entirely on 
quantitative outcomes; yet it is also important to consider how the findings from the 
qualitative study may impact upon the decision of feasibility and the design of future trials.   
 
Screening data at the start of KEATING revealed patients were declining due to i) not wanting 
to participate in research; ii) the burden of dietitian visits; and iii) the burden of KD.  Whilst 
these where similar to the barriers noted in the patient survey (chapter 3), an in depth 
understanding was considered vital to improve trial design and the patient experience.    
During the qualitative study those patients who declined appeared considered and deliberate 
in their decision-making process, taking time to consider their options.  They spoke of the 
importance of quality of life; a reason which was not reported in the basic screening log 
explanations in the quantitative results from KEATING.  Quality of life was also not included 
as a possible barrier during the patient survey.  This highlights the effects of researcher bias 
in survey design (156) and the value of qualitative research in addition to trials, surveys and 





The qualitative study also offered insights into why patients decided to take part in KEATING, 
with these patients describing their initial decision as being instantaneous and without 
deliberation.  Patients spoke of wanting to ‘fight’ for their lives and their decisions were 
shaped by a fear of GBM.  Participating offered hope and optimism for prolonging life.  
Patients initially exaggerated the health benefits of participating, which optimistically biased 
their interpretation of the aims and objectives of the trial.  Altruism was considered by those 
who participated, but as a means of validation, later in their decision-making process; 
contradicting the initial survey, in which altruism was the top reason for participating in a KD 
trial.  This willingness to help others features strongly as a reason for being interested in 
trials, but altruism is often conditional to person benefit when actually attending recruitment 
appointments and taking part in a trial (292).   
 
Alongside issues with recruitment, dietary retention within KEATING was also poor (33% at 
three months; n=4), particularly in comparison to the initial scoping service (67% at three 
months; n=4) (169).  The average time to withdrawal during KEATING was 38 days (medium 
chain triglyceride ketogenic diet [MCT KD]) and 39.5 days (modified ketogenic diet [MKD]).   
The GBM population recruited for the scoping service, self-selected to try the diet, with half 
having completed chemoradiotherapy for GBM.  Hence, the scoping service population may 
have been more motivated or engaged with KD, than the general GBM population 
approached for KEATING, resulting in false optimism for trial success.  Reasons for withdrawal 
during KEATING were noted to be due to dietary burden (n=3), nausea (n=1), tumour 
progression (n=1), being recruited to another trial (n=1), non-related serious adverse event 
(SAE; n=1) and a patient reported to have changed their mind, no further information was 
provided (n=1).  The qualitative study offered further insight into these higher than 
anticipated withdrawal rates.  Those who withdrew spoke of finding low ketones 
‘demoralising’, withdrawing due to the negative effect this feeling had on their quality of life.  
Previous studies report quality of life to become increasingly important to patients over the 
brain cancer journey (242,280).  During KEATING, quality of life was not reported as a factor 
for withdrawal, perhaps due to the insensitivity of the predefined case report from, although 
from the QLQ-C30 questionnaire, the global health status of those who withdrew reduced, 
falling below the brain cancer reference value at week six.  These results substantiate the 
findings from the qualitative study, but due to the small sample size limited conclusions can 
be drawn.  For those who continued to participate in the trial, global health status reduced 
within the MCT KD group and improved for the patient following MKD.  Both groups reported 
experiencing a ‘fantastic quality of life’ when interviewed for the qualitative study, describing 
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the diet to offer a sense of ‘control’.  They found motivation for continuing with the diet 
through media outputs, online blogs of long term survivors, clinical imaging and high ketone 
levels and used this as a means of validating their decision.  This corroborates the findings 
from KEATING, in that patients with higher ketones stayed in the trial, whilst those with lower 
ketones withdrew early, at around week six.  Those who were retained in KEATING were also 
generally younger in age and had good prognostic characteristics, which may also have 
influenced their ability to retain within the study and implement the diet.       
 
Those who withdrew also considered the three-month intervention to be undesirable, an 
opinion also reflected by those who declined, further corroborating the findings from 
KEATING.  A shorter, six week intervention, is likely to be more attainable and agreeable to 
the majority of patients.  This could be offered alongside radiotherapy and concomitant 
chemotherapy, which coincides with the proposed optimal time for the diet derived from 
animal model data (79).   
    
The qualitative study also revealed the role of relatives in the patients’ decision-making 
process when invited to participate in KEATING, with patients seeking validation from 
relatives regarding decisions to participate, decline, and withdraw.  In some cases, patients 
shared the decision to participate with their relative, appreciating that they would require 
assistance to implement the diet.  This is an interesting area of research which requires 
further investigation as there is currently a lack of data exploring the role of relatives in the 
decision-making of patients with advanced cancers to participate in early phase pilot trials 
(244).  Relatives were also key in supporting patients to implement the diet.  For those 
patients who continued to participate in KEATING, relatives emphasised KD to be ‘the new 
normal’.  Patients attributed their ability to cope with KD being due to the support provided 
by relatives, but those who withdrew, later reported feeling that they had overburdened 
their relative, which influenced their decision to withdraw.  The role of relatives, both in the 
decision-making of patients and the ongoing support offered, were aspects that were 
underappreciated in the KEATING study.              
 
The preliminary findings from KEATING highlight that there may be a potential role for MCT 
supplements in aiding dietary retention, since more patients in the MCT KD arm completed 
the three month intervention, however patient numbers were limited (n=3 MCT KD; n=1 
MKD).  Volumes of MCT equating to 25% of total energy requirements appear tolerable.  
However, during the qualitative study, patients and their relatives spoke of having a 
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personal preference towards MCT supplements and a preconception of how well the 
supplements may be tolerated.  As a result, future trials may benefit from tailoring 
supplement use to the individuals’ preferences, rather than randomising to MKD or MCT 
KD, but further exploration in this area would be beneficial to understand if patient choice 
over supplement use would increase or alleviate their burden.  
 
This thesis has several limitations.  In relation to the survey, non-random, convenience 
sampling was used at Walton Centre NHS Foundation Trust and patients self-selected to 
complete the online national survey, both of which could create a positive bias in the 
results.  In relation to the scoping service, the small numbers of patients included were self-
selecting, self-referring patients, who commenced MKD at different time-points in their 
treatment pathway, limiting the generalisability of our results in the context of the 
glioblastoma population as a whole.  This also led to an optimistic bias for the trial team, 
when determining recruitment targets and the sample size for KEATING.  
For KEATING, due to the high withdrawal rates at around week six, a post-hoc analysis was 
introduced to extrapolate further information, to help explore issues with dietary retention 
and improve future trial design.  Due to the poor retention rates only limited analysis could 
be undertaken at months three and 12.  The lack of returned food and ketone diaries also 
became problematic and subsequently affected the 12 month analysis.  All accounts of 
dietary intake were also self-reported, and so at risk of reporter bias (227).  The food 
acceptability questionnaire, whilst validated for use in vegan diets, was not validated for 
use in KDs.  
 
Finally, the qualitative study used a small sample size determined by the number of 
patients approached for KEATING and the nature of their deteriorating health.  We cannot 
be certain that saturation was reached.  Nevertheless, drawing on the concept of 
‘information power’ (258,259) in qualitative research, this study had a well specified aim, 
and it has provided insights that will be invaluable in informing future phase III trials.  As the 
qualitative study was embedded eight months after KEATING opened to recruitment, the 
views of initial KEATING patients remain unknown.  It is possible that the verbal recruitment 
strategy changed over time as the researcher became more familiar with the process; 
therefore the views of those recruited into KEATING at the start, may be different to those 
recruited towards the end of the recruitment period.  Both the qualitative study and 
KEATING were  conducted by the same researcher, which may have influenced patients’ 
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willingness to be critical of KEATING or otherwise affected the trustworthiness of the 
qualitative study (270,271).  However, all patients expressed criticisms of KEATING.  In 
addition, researchers who were independent of KEATING were closely involved in the 
qualitative study and in scrutinising the interpretations of the data. 
6.3  RECOMMENDATIONS 
To expand and develop the themes explored in this thesis, future studies should consider the 
following recommendations: 
 To assess efficacy in a phase III trial a six–week diet intervention period would be 
advantageous.  Some patients reported decreased motivation after six weeks, whilst 
those who declined requested a shorter trial period.  As animal models show KD to 
enhance the positive effects of radiotherapy, it would be reasonable to offer KD 
during this time within the confines of a trial.  Future trials assessing efficacy should 
also consider a health economic assessment, with NICE requiring new technologies 
to be both clinically and cost effective.      
 The trial took time to embed within the clinical practice, therefore recruitment 
figures were initially slow.  Future trials could consider a staged, incremental 
recruitment rate to compensate for this issue.  An ‘upstream’ approach to trial design 
may improve recruitment practices and clinical team engagement.   
 Efforts to optimise informed consent could be aided through the design of bespoke 
decision aids, a means of helping patients to make informed decisions about 
participating in a ketogenic clinical trial, taking into account personal preferences 
and values (236,289).  Including the relatives in the initial and ongoing conversations 
about trial participation (with the agreement of the patient), could also help to 
optimise patient decision-making.  
 Future trials should embed a longitudinal, prospective, qualitative study, which 
focuses on patient and relative understanding and decision-making in the context of 
trial participation. This would help to identify and address challenges as they arise in 
future trials.  
 Exploring the views of clinicians in the wider organisation and multi-disciplinary 
team, where future ketogenic trials may be delivered, will likely be essential for the 
implementation of KD services in neuro-oncology and for ensuring clinician ‘buy in’.   
 There may be a role for MCT supplements in improving dietary retention, but volume 
of supplements should be considered.  Paediatric levels cannot be tolerated by 
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adults, but volumes equating to 25% of total energy requirements appear 
acceptable.  Some patients expressed a personal preference for or against the use of 
MCT nutritional products.  It may be beneficial to allow the patients to choose 
whether to use such products to support a KD and this option requires further 
exploration in a GBM population.  
 There is interest from the glioma patient community to support clinical trials with KD 
interventions; however randomisation to a control arm of ‘no diet’ could affect 
recruitment.  Further patient and public involvement (PPI) would be critical to ensure 
trial methods are acceptable to patients.  Further PPI would also be beneficial to 
explore if digital media would aid the completion of food and ketone diaries.  PPI 
should involve patients who have tried KDs before and their relatives/ carers, but 
also patients for whom KD would be new, a view point which is essential if dietary 
retention and trial completion rates are to be improved.  Combining PPI with 
qualitative research may help to engage patients who would not usually participate 
in research (291).  
6.4  CONCLUSION 
Recruitment of patients with GBM to a KD trial is possible.  To assess efficacy in a clinical trial, 
a six week intervention period is proposed.  Future KD trials for patients with GBM can draw 
on the findings of this thesis to ensure the decision-making of patients is optimised and 
adequately supported.  The role of relatives in the patients’ decision-making process and in 
supporting patients to implement KDs should not be underestimated.  Further qualitative 
studies embedded within phase III clinical trials are essential to optimise trial design and 
patient experience.  Future phase III trials would benefit from an internal pilot to further test 
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APPENDIX A: EXAMPLE SEARCH STRATEGY – MEDLINE (OVID) 
1. (ketogenic or ketone or ketosis or carbohydrate restrict* or low carbohydrate or 
high fat or Atkin* or glyc*emic or triglyceride* or medium chain triglyceride*).af 
2. (central nervous system or brain or cerebral or spinal or spine).af 
3. (cancer or tumo*r or malignan* or neoplas* or carcinoma*).af 
4. 2 and 3 
5. (glioblastoma* or astrocytoma* or glioma* or ependymoma* or  
oligodendroglioma* or ganglioglioma* or medulloblastoma* or astrocytic* or 
ependymal*).af 
6. 4 or 5 
7. 1 and 6 






APPENDIX B: QUALITY APPRAISAL CHECKLIST FOR CASE SERIES STUIDES 
(129)  
 
Quality Appraisal Checklist for Case Series Studies* 
Assessor initials and date: 
Author(s) and date of publication: 
Study objective 




2. Was the study conducted prospectively? Yes   ☐ 
Unclear  ☐ 
No ☐ 
3. Were the cases collected in more than one centre?  Yes   ☐ 
Unclear  ☐ 
No ☐ 
4. Were patients recruited consecutively?  Yes   ☐ 
Unclear  ☐ 
No ☐ 
Study population  
5.  Were the characteristics of the patients included in the study 
described? 
(Number of patients, age, gender, disease, treatment history) 
Yes   ☐ 
Partial ☐ 
No ☐ 
6.  Were the eligibility criteria (i.e. inclusion and exclusion criteria) for 
entry into the study clearly stated? 
 
Yes   ☐ 
Partial ☐ 
No ☐ 
7.  Did patients enter the study at a similar point in the disease? 
(Stage of disease, prior treatment) 
Yes   ☐ 
Unclear  ☐ 
No ☐ 
Intervention and co-intervention 
8.  Was the intervention of interest clearly described? 
(Diet, duration, administration) 
Yes   ☐ 
Partial ☐ 
No ☐ 
9.  Were additional interventions (co-interventions) clearly described? 
(Oncological treatments, holistic treatments, involvement in other trials, 
include details of type, dose, frequency/duration) 








10.  Were relevant outcome measures established a priori? 
 
Yes   ☐ 
Partial ☐ 
No ☐ 
11. Were outcome assessors blinded to the intervention that patients 
received? 
 
Yes   ☐ 
Unclear  ☐ 
No ☐ 
12.  Were the relevant outcomes measured using appropriate 
objective/subjective methods? 
Overall survival – time to death from specific time point 
Progression free survival – time to progression from specific time point 
Quality of life – questionnaire 
Acceptability – questionnaire 
Tolerance – quantification of gastrointestinal tolerance 
Compliance - ketosis 
Ketone levels – blood or urinary ketone monitoring 
Glucose levels – blood glucose monitoring 
Yes   ☐ 
Partial ☐ 
No ☐ 
13. Were the relevant outcome measures made before and after the 
intervention? 
 
Yes   ☐ 
Unclear  ☐ 
No ☐ 
Statistical analysis 
14. Were the statistical tests used to assess the relevant outcomes 
appropriate? 
(If no tests used reasons why should be stated) 
Yes   ☐ 
Unclear  ☐ 
No ☐ 
Results and conclusions 
15. Was follow-up long enough for important events and outcomes to 
occur?  
(8 weeks short term follow up) 
 
Yes   ☐ 
Unclear ☐ 
No ☐ 
16. Were losses to follow-up reported? 
 
Yes   ☐ 
Unclear  ☐ 
No ☐ 
17. Did the study provided estimates of random variability in the data 
analysis of relevant outcomes? 
(Standard deviations, confidence intervals, range, interquartile range 
reported or can be calculated from raw data) 
Yes   ☐ 
Partial ☐ 
No ☐ 
18. Were the adverse events reported? 
 
Yes   ☐ 
Partial ☐ 
No ☐ 





Competing interests and sources of support 
20. Were both competing interests and sources of support for the study 
reported? 
 
Yes   ☐ 
Partial ☐ 
No ☐ 
*Note: Assessor specific additions as advised by authors of tool highlighted in red.  
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APPENDIX C: CHARACTERISTICS OF INCLUDED STUDIES 
Champ et al., (2014) 
Methods Retrospective case series. 
Population 6 patients aged 34-62 years, of unspecified gender, with a 
histological diagnosis of glioblastoma.  Study undertaken in 
USA.     
Intervention KD containing less than 50g carbohydrate/day.  Duration 3-12 
months.  
Outcomes  Overall survival 
 Progression free survival 
 Adverse events 
 Retention rates 
 Tolerance  
 Ketone levels 
 Glucose levels 
Notes Previous treatment options varied from biopsy (n=1), to 
subtotal resection (n=2), to gross total resection (GTR) (n=2), 
to GTR with Glidel wafers (n=1).  Medical intervention during 
diet varied from radiotherapy and temozolomide (n=4), 
temozolomide (n=1) and temozolomide and cediranib (n=1). 
Mean serum glucose levels of 53 controls (grade III and IV 
gliomas) were noted but not directly compared to the KD 
patients to assess statistical significance; therefore the 
assessors deemed the study to be a case series.   
Risk of bias 
Study objectives 
(quality of reporting) 
Clear aim. 
Study design  
(study execution) 




Patient characteristics described with clear eligibility criteria.  
Patients entered the study at similar points in the disease.  
Intervention and co-intervention 
(quality of reporting) 
The dietary intervention and the co-medical interventions 
were clearly described.  
Outcome measures 
(study execution) 
Relevant outcome measures were partially stated priori, but 
all outcome measures were assessed using the appropriate 
methods.  It is unclear if outcome assessors were blinded to 
the intervention.  Unclear if all outcome measures were 
assessed pre and post intervention.  
Statistical analysis 
(study execution) 
Unclear statistical testing. 
Results and conclusions 
(study execution and quality of 
reporting bias) 
Adequate duration of follow up, including reported losses.  
Random variability of data was partially reported.  Adverse 
events were fully reported and conclusions were supported 
by study results.   
Competing interests and sources 
of support 
(quality of reporting) 





Nebeling et al., (1995) 
Methods Prospective case series.  
Population 2 female patients. One aged 3 years with grade IV anaplastric 
astrocytoma of the spinal cord and one aged 8.5 years with 
grade III cerebellar astrocytoma.  Study undertaken in USA.  
Intervention Medium chain triglyceride KD (60% MCT, 10% carbohydrate, 
20% protein), provided to 120% recommended daily 
allowance.  Gastrostomy fed (n=1).  Duration 2-14 months 
(protocol 2 months).  
Outcomes  Overall survival 
 Progression free survival 
 Adverse events 
 Retention rates 
 Dietary compliance  
Notes Previous treatment options varied from radiotherapy 
(3600cGys) and chemotherapy (n=1) to multiple surgeries, 
shunt, radiotherapy (5400 cGys) and chemotherapy (n=1).  
Medical intervention during diet consisted of chemotherapy 
(n=1) or no treatment (n=1).  
Dietary tolerance and quality of life were commented upon, 
however lacked objective/subjective methods of 
measurement.  
Risk of bias 
Study objectives 
(quality of reporting) 
Clear aim.  
Study design  
(study execution) 
Prospective, single centre, case series.  Unclear if recruitment 
was consecutive.   
Study population 
(study execution) 
Patient characteristics described, no eligibility criteria 
identified, with patients entering the study at different points 
of disease. 
Intervention and co-intervention 
(quality of reporting) 
The dietary intervention and the co-medical interventions 
were clearly described. 
Outcome measures 
(study execution) 
Relevant outcome measures were stated priori and partially 
measured using the appropriate objective/subjective 
measures.  It is unclear if outcome assessors were blinded to 
the intervention.  Unclear if all outcome measures were 
assessed pre and post intervention. 
Statistical analysis 
(study execution) 
No statistical tests undertaken. 
Results and conclusions 
(study execution and quality of 
reporting bias) 
Adequate duration of follow up, including reported losses.  
Random variability of data was not reported.  Adverse events 
were fully reported and conclusions were supported by study 
results.  
Competing interests and sources 
of support 
(quality of reporting) 






Rieger et al., (2014) 
Methods Prospective case series. 
Population 20 patients (n=13 females), aged 30 to 72 years (median 57 
years), with recurrent glioblastoma.  Study undertaken in 
Germany.  
Intervention KD containing 60g carbohydrate per day, with the addition of 
fermented yoghurt drinks (500ml per day) and two plant oils 
(basic oil and additional oil).  Duration 6-42 months.  
Outcomes  Overall survival 
 Progression free survival 
 Adverse events 
 Retention rates 
 Dietary compliance 
 Dietary tolerance 
 Quality of life 
 Ketone levels 
 Glucose levels  
Notes Previous treatment options varied from radiotherapy (n=20), 
concomitant temozolomide (n=16), temozolomide 5/28 
(n=18), temozolomide 7/14 (n=18), nitrosourea-based 
chemotherapy (n=5), carmustine wafer (n=1) and 
bevacizumab + lomustine (n=1).  Medical intervention during 
diet varied from teniposide (n=1), bevacizumab (n=4), 
bevacizumab and irinotecan (n=3), no treatment (n=13).  
Details of plant oils unidentifiable.  
Risk of bias 
Study objectives 
(quality of reporting) 
Clear aim and outcomes.  
Study design  
(study execution) 
Prospective, single centre pilot study with consecutive 
recruitment.  Protocol utilised. Registration number 
NCT0057146.    
Study population 
(study execution) 
Patient characteristics described with clear eligibility criteria.  
Patients entered the study at similar points in the disease. 
Intervention and co-intervention 
(quality of reporting) 
The dietary intervention and the co-medical interventions 
were clearly described. 
Outcome measures 
(study execution) 
Relevant outcome measures were stated priori and partially 
measured using the appropriate objective/subjective 
measures.  It is unclear if outcome assessors were blinded to 
the intervention.  Unclear if all outcome measures were 
assessed pre and post intervention. 
Statistical analysis 
(study execution) 
Appropriate statistical testing.  
Results and conclusions 
(study execution and quality of 
reporting bias) 
Adequate duration of follow up, including reported losses.  
Random variability of data and adverse events were fully 
reported.  Conclusions were supported by study results.   
Competing interests and sources 
of support 
(quality of reporting) 




Schwartz et al., (2015) 
Methods Prospective case series.   
Population 2 male patients aged 52 and 55 years, with glioblastoma.  
Study undertaken in USA.  
Intervention Energy restricted 3:1 KD (3g fat to 1g of carbohydrate and 
protein combined) consumed orally through a commercially 
available formula (Ketocal®; Nutricia North America).  
Proceeded by 48hour fast. Duration 1-3 months (protocol 3 
months).  
Outcomes  Progression free survival 
 Adverse events 
 Retention rates 
 Dietary compliance 
 Ketone levels 
 Glucose levels  
Notes Previous treatment options were consistent in both patients; 
surgery, radiotherapy and temozolomide.  Medical 
intervention during diet not stated. 
1 patient switched from commercial formula to food of the 
same KD ratio at day 6 due to palatability.  
Risk of bias 
Study objectives 
(quality of reporting) 
Aim not clearly stated.  
Study design  
(study execution) 
Retrospective study, with unclear centre allocations and 
unclear if consecutively recruited. 
Study population 
(study execution) 
Patient characteristics described with clear eligibility criteria.  
Patients entered the study at similar points in the disease. 
Intervention and co-intervention 
(quality of reporting) 
The dietary intervention and the co-medical interventions 
were clearly described. 
Outcome measures 
(study execution) 
Relevant outcome measures were partially stated priori, but 
all outcome measures were assessed using the appropriate 
methods.  It is unclear if outcome assessors were blinded to 
the intervention.  Relevant outcome measures were assessed 
pre and post intervention.   
Statistical analysis 
(study execution) 
Unclear statistical testing. 
Results and conclusions 
(study execution and quality of 
reporting bias) 
Adequate duration of follow up, including reported losses.  
Random variability of data was not reported.  Adverse events 
were fully reported and conclusions were supported by study 
results. 
Competing interests and sources 
of support 
(quality of reporting) 






Strowd et al., (2015) 
Methods Retrospective case series. 
Population 8 patients (n=6 males), aged 28 to 54 years, with glioma (n=3 
low grade oligodendroglioma, n=1 low grde astrocytoma, n=1 
anaplastic astrocytoma, n=3 glioblastoma) and resultant 
seizure disorders.  Study undertaken in USA.  
Intervention Modified Atkins diet (MAD) 15g carbohydrate per day (n=1) 
to 20g carbohydrate per day (n=7).  Duration 2-24 months.  
Outcomes  Overall survival 
 Adverse events 
 Retention rates 
Notes Previous treatment options varied from surgery (n=2), 
surgery, radiotherapy and temozolomide (n=4), surgery and 
temozolomide (n=1) and surgery, radiotherapy, 
temozolomide, bevacizumab, ICT- 107 and veliparib (n=1).  
Medical intervention during diet varied from temozolomide 
(n=1), bevacizumab and LBH589 (n=1), temozolomide and 
bevacizumab (n=1) and no treatment (n=5).  
Risk of bias 
Study objectives 
(quality of reporting) 
Clear aim.   
Study design  
(study execution) 
Retrospective single centre study, unclear if consecutively 
recruited.   
Study population 
(study execution) 
Patient characteristics described, with partially identified 
eligibility criteria.  Patients entered the study at different 
points of disease. 
Intervention and co-intervention 
(quality of reporting) 
The dietary intervention and the co-medical interventions 
were clearly described. 
Outcome measures 
(study execution) 
Relevant outcome measures were not stated priori and 
unable to assess if outcome measures were assessed using 
the appropriate methods.  It is unclear if outcome assessors 
were blinded to the intervention.  Unclear if all outcome 
measures were assessed pre and post intervention. 
Statistical analysis 
(study execution) 
Appropriate statistical testing.  
Results and conclusions 
(study execution and quality of 
reporting bias) 
Adequate duration of follow up, including reported losses.  
Random variability of data and adverse events were fully 
reported.  Conclusions were supported by study results.   
Competing interests and sources 
of support 
(quality of reporting) 





Zuccoli et al., (2010) 
Methods Retrospective case series. 
Population 1 female patient, aged 65 years with glioblastoma.  Study 
undertaken in Italy.  
Intervention Energy restricted 1:1 KD (600kcals/day, 10g carbohydrate, 
32g protein, 10g MCT oil, 20g 4:1 commercially available 
formula [Ketocal®; SHS International] and total fat content of 
42g).  Proceeded by 72 hour fast. Duration 1.8 months (56 
days). 
Outcomes  Progression free survival 
 Adverse events 
 Ketone levels 
 Glucose levels 
Notes ERKD proceeded and concluded with a low calorie diet 
(600kcals/day).   
Previous treatment option included incomplete debulking 
(MGMT positive).  Medical intervention during diet included 
radiotherapy and temozolomide.  
Risk of bias 
Study objectives 
(quality of reporting) 
Aim not clearly stated. 
Study design  
(study execution) 
Retrospective single centre study, recruiting 1 patient. 
Study population 
(study execution) 
Patient characteristics described, with no eligibility criteria.   
Intervention and co-intervention 
(quality of reporting) 
The dietary intervention and the co-medical interventions 
were clearly described. 
Outcome measures 
(study execution) 
Relevant outcome measures were not stated priori and 
partially measured using the appropriate objective/subjective 
measures.  It is unclear if outcome assessors were blinded to 
the intervention.    Unclear if all outcome measures were 
assessed pre and post intervention. 
Statistical analysis 
(study execution) 
No statistical testing undertaken.  
Results and conclusions 
(study execution and quality of 
reporting bias) 
Adequate duration of follow up, including reported losses.  
Random variability of data was not reported.  Adverse events 
were fully reported and conclusions were supported by study 
results. 
Competing interests and sources 
of support 
(quality of reporting) 
No conflict of interest. 
 
 
APPENDIX D: CHARACTERISTICS OF ONGOING TRIALS 
Ghodsi, (2012) 
Trial name or title Therapeutic effect of KD on survival and quality of patients with 
glioblastoma multiforme 
Study identifier  IRCT201204099417N1 
Methods Single centre, single group, open label trial. 
Population Aimed to recruit 20 participants with glioblastoma.  Included 
participants will be aged > 49 years, Karnovsky Performance Score >69, 
surgical intervention and histological confirmation of glioblastoma, 
undergone chemotherapy and radiotherapy.  Potential participants will 
be excluded if other diagnoses are suspected, cannot tolerate KD, KD is 
contraindicated, participant does not agree to regime protocol.  Study 
undertaken in Iran.  
Interventions Energy restricted MCT KD (50% MCT, energy restricted to 
25kcal/kg/day). 
Outcomes Primary outcomes:  
 Survival (defined as time until death). 
Secondary outcomes: 
 Quality of life (assessed by ‘FIM form’). 
Starting date May 2010. 
Contact information ghodsism@tums.ac.ir 
Notes Unable to locate definition of FIM form as quality of life measure.  
Expected completion unknown. 
 
 
Guimaraes Santos & Perieia da Fonseca, (2016)  
Trial name or title Ketogenic diet combined with intranasal administration of perillyl 
alcohol: strategy therapy to refractory Glioblastoma Multiforme to 
standard treatment 
Study identifier  RBR-8x8fd9 
Methods Single centre, parallel group, open label trial. 
Population Aimed to recruit 30 participants with recurrent glioblastoma inhaling 
perillyl alcohol.  Included participants will have recurrent glioblastoma, 
aged 20 to 65 years, received standard therapy (chemotherapy ± 
radiotherapy), inhaling perillyl alcohol.  Potential participants will be 
excluded if experience neurological complications, terminal phase or 
discontinue diet.  Study undertaken in Brazil.     
Interventions KD v control, both groups inhaling perillyl alcohol.  
Outcomes Primary outcomes: 
 Comparison of tumour growth by anterior cerebral magnetic 
resonance imaging at baseline and after 3 months of combined 
therapy with inhalation of perillil alcohol and ketogenic diet. 
Secondary outcomes: 
 Anthropometric changes before and after dietary intervention. 
Starting date October 2015. 
Contact information julianaguima86@gmail.com 






Trial name or title Pilot study evaluating progression free survival in patients using KD while 
receiving chemoradiation for glioblastoma multiforme 
Study identifier  ACTRN12614001056684. 
Methods Single centre, single group, open label phase II pilot study. 
Population Aimed to recruit 20 participants with glioblastoma suitable for standard 
chemoradiotherapy.  Included participants will have histologically 
confirmed glioblastoma, suitable for standard chemoradiotherapy, 
mentally competent to understand the requirements of the diet and 
believe that they are able of achieving them, able to give written 
informed consent.  No age limitations applied.  Potential participants will 
be excluded if diagnosed with diabetes mellitus and are at risk of 
hypoglycaemic episodes, currently pregnant or breastfeeding.  Study 
undertaken in New Zealand.    
Interventions KD (<30g carbohydrate/day). 
Outcomes Primary outcomes: 
 Progression free survival. 
Secondary outcomes: 
 Achievement of ketosis on urinary ketone testing. 
 Compliance with chemoradiotherapy (assessed through 
treatment charts). 
 Compliance with KD (assessed by dietitian from 3 day food 
diaries and 24 hour food intake recall). 
 Food satisfaction (assessed through visual analogue scale). 
 Patient generated subjective global assessment (of malnutrition, 
nutritional intake and appetite). 
 Proportion of patients with adverse events related to KD.   
Starting date October 2014.  
Contact information michael.jameson@waikatodhb.health.nz 






Trial name or title Ketogenic diet treatment adjuvant to radiation and chemotherapy in 
glioblastoma multiforme: a pilot study (GBMXRT) 
Study identifier  NCT02302235. 
Methods Single centre, parallel group, randomised control, open label, phase II 
pilot study.  
Population Aimed to recruit 6 participants with newly diagnosed glioblastoma.  
Included participants will be aged 18-65 years, able and willing to sign a 
consent form, histologically confirmed glioblastoma, documented 
surgical resection or debulking, measurable contrast enhancing 
progressive or recurrent glioblastoma, by MRI imaging ≤2 weeks before 
screening or prior to surgery if done ≤2 months before, Karnovsky 
Performance Score of 70 or more.  Potential participants will be 
excluded if experienced acute intracranial intratumoural haemorrhage, 
prior treatment with small-molecule kinase inhibitor, non-cytotoxic 
hormonal agent, KD ≤6 months of enrolment, planned continued use of 
glucocorticoids, any systemic illness or unstable medical condition that 
may pose additional risk (e.g. cardiac, endocrine disturbances, renal or 
liver disease), history of non-glioma malignancy other than surgically 
excised non-melanoma skin cancer or in situ carcinoma of the cervix, 
history of uncontrolled hyperlipidaemia, active drug or alcohol 
dependence, human immunodeficiency virus, hepatitis C, failure to 
recover from grade 2 toxicities, pregnancy, breastfeeding, use of an 
investigational drug within 1 month of enrolment, inability or 
unwillingness to give written informed consent.  Study undertaken in 
the USA.   
Interventions Energy restricted 4:1 KD (1600kcals/day), commenced at initiation of 
radiotherapy treatment compared to standard diet at initiation of 
radiotherapy treatment, randomised at a ratio of 1:1.  
Outcomes Primary outcomes: 
 Survival time.  
 Time to radiological (MRI) tumour progression (defined 
by  radiographic assessment in neuro-oncology criteria based 
on contrast-enhanced cranial MRI scans evaluating 
measureable disease, measured as the sum of products of 
perpendicular diameters (bi-dimensional measurements) of all 
measurable enhancing lesions and non-measurable disease). 
 Incidence of treatment emergent adverse events (defined as 
Incidence of treatment-emergent adverse events changes in 
laboratory evaluations, changes in physical examination 
findings will be compared between the KD and control 
treatment groups). 
Secondary outcomes: 
 Tolerability of KD (defined as unwillingness by the subject to 
continue with the diet because of possible diet related side 
effects).  
Starting date February 2014.  
Contact information kleinp@epilepsydc.com 





Trial name or title Ketogenic diet as adjuvant treatment in refractory/ end stage 
glioblastoma multiforme: a pilot study (KGDinGBM) 
Study identifier  NCT01865162. 
Methods Single centre, single group, open label, phase I pilot study. 
Population Aimed to recruit 6 participants with treatment refractory glioblastoma.  
Included participants will be aged 18-65 years, able and willing to sign a 
consent form, histologically confirmed glioblastoma, documented 
recurrence or progression after surgical, radiotherapy and 
chemotherapy interventions, measurable contrast enhancing 
progressive or recurrent glioblastoma, by MRI imaging ≤2 weeks before 
screening, (a) ≥ 3months after completion of radiation; (b) 6 weeks from 
a nitrosourea chemotherapy; (c) ≥ weeks from a non-nitrosourea 
chemotherapy (all [a-c] in order to allow recovery from the potential of 
severe toxicity related to these treatments), Karnovsky Performance 
Score of 70 or more.  Potential participants will be excluded if 
experienced acute intracranial intratumoural haemorrhage, prior 
treatment with small-molecule kinase inhibitor, non-cytotoxic hormonal 
agent, KD ≤6 months of enrolment, planned continued use of 
glucocorticoids, any systemic illness or unstable medical condition that 
may pose additional risk (e.g. cardiac, endocrine disturbances, renal or 
liver disease), history of non-glioma malignancy other than surgically 
excised non-melanoma skin cancer or in situ carcinoma of the cervix, 
history of uncontrolled hyperlipidaemia, active drug or alcohol 
dependence, human immunodeficiency virus, hepatitis C, failure to 
recover from grade 2 toxicities, pregnancy, breastfeeding, use of an 
investigational drug within 1 month of enrolment, inability or 
unwillingness to give written informed consent.  Study undertaken in 
the USA.   
Interventions Energy restricted 4:1 KD (1600kcals/day), followed until exit criteria are 
met or for 6 months (exit criteria consists of death or use of 
glucocorticoids).   
Outcomes Primary outcomes: 
 To evaluate the safety of KD (defined as early treatment 
discontinuation, treatment compliance, 7-point Licker hunger 
scale, fasting lipid levels, fasting serum glucose and insulin 
levels). 
Secondary outcomes: 
 To obtain pilot data on efficacy of KD (defined as survival time, 
time to cerebral oedema requiring steroid rescue treatment).  
 To evaluate tolerability of KD (defined as incidence of 
treatment-emergent adverse events during treatment).  
Starting date January 2013.  
Contact information kleinp@epilepsydc.com 





Rieger & Steinbach, (2012) 
Trial name or title Calorie-restricted, ketogenic diet and transient fasting during 
reirradiation for patients with recurrent glioblastoma (ERGO2)  
Study identifier  NCT01754350. 
Methods Single centre, parallel group, randomised control, open label, trial.  
Population Aimed to recruit 50 participants requiring reirradiation for recurrent 
glioblastoma.  Included participants will be aged 18 years and over, 
recurrence of histologically confirmed glioblastoma, at least 6 months 
after first surgery, at least 6 months after first radiotherapy, 
interdisciplinary recommendation for reirradiation, Karnovsky 
Performance Score ≥ 60, creatinine ≤2mg/dl, urea ≤100mg/dl, 
ALAT/ALST ≤7 times the upper limit.  Potential participants will be 
excluded if bowel obstruction/ ileus, insulin dependent diabetes, 
decompensated heart failure, myocardial infarction within last 6 
months, symptomatic arterial fibrillation, severe acute infection, 
malnutrition, cachexia, other medical conditions that might increase the 
risk of dietary intervention, pregnancy, uncontrolled thyroid function, 
pancreatic insufficiency, dementia or clinically relevant alterations of the 
mental state which could impair the ability to implement the diet or 
given informed consent.  Study undertaken in Germany.      
Interventions Energy restricted KD with transient fasting (day 1-3 and day 7-9, 
restriction of carbohydrates to < 60 g and of energy to 21-23 kcal/kg per 
day, day 4-6 fasting) compared to standard nutrition (nutrition as 
recommended by the German Society for Nutrition, energy to 30 kcal/kg 
per day).   
Outcomes Primary outcomes: 
 Progression free survival (defined as progression free survival 
rates 6 months after reirradiation). 
Secondary outcomes: 
 Feasibility (measured as median number on diet per patient 
and average energy and carbohydrate intake per day during day 
1-9).   
 Safety and tolerability (defined as number of patients with 
adverse events). 
 Progression free survival (defined as progression free survival 
rates 1 and 3 months after reirradiation). 
 Overall survival after reirradiation. 
 Frequency of seizures (during days 1-12). 
 Ketosis (urine and blood ketones and metabolic parameters 
[glucose, insulin, IGF-1] during days 1-12). 
 Quality of life (measured by EORTC quality of life questionnaire 
at days 1-12). 
 Depression (measured by SCL-90 at days 1-12). 
 Attention (measured by d2-testing at days 1-12). 
 Response (response assessment 1 month after reirradiation). 
Starting date May 2013. 
Contact information johannes.rieger@med.uni-frankfurt.de    





Trial name or title Ketogenic diet with radiation and chemotherapy for newly diagnosed 
glioblastoma.  
Study identifier  NCT02046187. 
Methods Single centre, single group, open label, phase I/II prospective trial.  
Population Aimed to recruit 14 participants with newly diagnosed glioblastoma.  
Included participants will be aged 18-80 years, histological confirmation 
of glioblastoma, Zubrod Performance Score of <2, able to undergo MRI 
imaging with gadolinium, access to a computer and internet.  Potential 
participants will be excluded if unable to undergo MRI with gadolinium, 
genetic disorders of fat metabolism, receiving sodium valproate, 
diabetes, enrolled into other glioblastoma trial.  Study undertaken in 
USA.   
Interventions 4:1 KD commenced prior to initiation of radiotherapy and 
chemotherapy, followed by modified Atkins diet during monthly 
chemotherapy.  
Outcomes Primary outcomes: 
 Number of participants with adverse events (defined as 
adverse events from initiation of diet until end of radiation). 
Secondary outcomes: 
 Overall survival. 
 Time to progression. 
 Quality of life. 
Starting date October 2013. 
Contact information Not provided.  




Trial name or title Pilot study of a metabolic nutritional therapy for the management of 
primary brain tumours (KETONES) 
Study identifier  NCT01535911. 
Methods Single centre, single group, open label, pilot study. 
Population Aimed to recruit 12 participants with newly diagnosed glioblastoma.  
Included participants will be 18 to 90 years, histologically proven 
glioblastoma, measurable disease after standard therapies, Eastern 
Cancer Oncology Group performance status of ≤2, life expectancy >3 
months.  Potential participants will be excluded if diagnosed with 
diabetes mellitus requiring medication, concomitant use of 
glucocorticoids, cholecystectomy within 1 year prior to study, inability to 
adhere to or tolerate dietary protocol, active malignancy other than 
primary brain tumour, participation in investigational study 2 weeks 
prior to study entry, pregnancy, inability to give informed consent.  
Study undertaken in USA.     
Interventions Energy restricted KD (20-25kcals/kg/day). 
Outcomes Primary outcomes: 
 Changes in brain tumour size (assessed by comparing MRI 
images obtained at beginning of study with those after 
completion of radiotherapy and after an additional 6 weeks of 
diet). 
Starting date April 2012 
Contact information ken.schwartz@hc.msu.edu  





Trial name or title Ketogenic diet adjunctive to salvage chemotherapy for recurrent 
glioblastoma: a pilot study (KGDinrGBM)  
Study identifier  NCT02939378. 
Methods Single centre, parallel group non-randomised control, open label, phase 
II pilot study.  
Population Aimed to recruit 60 participants with recurrent glioblastoma.  Included 
participants will be aged 18-60 years, Karnovsky Performance Score of 
60 or more, histologically confirmed glioblastoma grade IV, ability and 
willingness to sign consent form, documented recurrence or progression 
after surgical resection/ debulking, radiation and temozolomide 
chemotherapy, normal function of liver and kidney.  Potential 
participants will be excluded if any systemic illness or unstable medical 
condition that may pose additional risk (e.g. cardiac, endocrine 
disturbances, renal or liver disease), history of uncontrolled 
hyperlipidaemia or hyperglycaemia, human immunodeficiency virus, 
hepatitis C, pregnancy, breastfeeding, inability or unwillingness to give 
written informed consent.  Study undertaken in China.     
Interventions KD compared to standard diet.  
Outcomes Primary outcomes: 
 Number of participants with treatment emergent adverse 
effects (defined as number of participants with treatment 
emergent adverse effects while on KD). 
Secondary outcomes: 
 Chemo sensitivity of tumour (defined as MRI measured changes 
in tumour size).  
 Overall survival (defined as time to reported death). 
 Ketosis (defined as urinary and blood ketone measurements). 
 Quality of life (defined by Karnovsky Performance Score).  
Starting date October 2016.  
Contact information linsong2005@126.com 
Notes Unclear methods for recruitment to and comparison of arms.  Type of 






Trial name or title Glioma modified Atkins based diet in patients with glioblastoma (GLAD) 
Study identifier  NCT02286167. 
Methods Multi centre, single group, open label feasibility study. 
Population Aimed to recruit 25 participants with glioblastoma.  Included 
participants will be aged 18 years or over, histological confirmation of 
glioblastoma, completed >80% concurrent radiation therapy and 
adjuvant temozolomide without CTCAE grade 3 or 4 toxicities, be greater 
than 7 months from time of completing concurrent chemoradiotherapy, 
Karnovsky Performance Score ≥60, appropriate mental capacities with 
sufficient social support to be able to complete study activities and able 
to provide written consent.  Potential participants will be excluded if 
have a history of metabolic disorders, server acute infection, BMI >35 or 
<20 kg/m2, active bowel obstruction or ileus, active or remote 
pancreatitis, clinically significant hear failure, recent myocardial 
infarction, symptomatic atrial fibrillation, significant renal disease, 
significant hepatic dysfunction, insulin dependent diabetes mellitus, 
conditions that may increase the risk of the diet or significantly reduce 
compliance, concurrent experimental therapies, milk allergy, prior 
treatment with MAD within 9 months prior to study enrolment, inability 
to complete 3 day baseline screening diet record.  Study undertaken in 
USA.     
Interventions MAD with intermittent fasting.  
Outcomes Primary outcome: 
 Feasibility of intermittent MAD in patients with glioblastoma 
(defined as the number of patients able to maintain the diet 
and achieve nutritional goals). 
Secondary outcomes: 
 Biological activity (measured by pre and post study cerebral 
glutamate and glutamine concentrations by MRS). 
 Tolerability (defined by percentage of patients who have an 
adverse reaction of any grade attributed to the diet). 
 Dietary activity (compliance assed by serial changes in serum 
glucose, ketones, weight, body fat composition, change in 
seizure frequency without anti-epileptic drug adjustment).  
Starting date November 2014. 
Contact information rstrowd@wakehealth.edu 







Trial name or title The effect of ketogenic diet on malignant tumours – recurrence and 
progress 
Study identifier  NCT01092247. 
Methods Single centre, parallel group, open label trial. 
Population Aimed to recruit 40 participants with recurrent or progressive high grade 
glioma.  Included participants will be aged 18 years or over, recurrent or 
progressive high grade glioma after failure of at least one standard 
oncological treatment, gliomatosis cerebri including patients declining 
radiation treatment.  Potential participants will be excluded if have 
malignant tumours and are receiving treatment at time of recruitment, 
early termination (patients who discontinue the KD and return to 
standard diet).  Study undertaken in Israel.    
Interventions KD compared to standard diet.  
Outcomes Primary outcome: 
 To study the effect of KD on tumour growth progression and 
longevity in patients with malignant glioblastoma (defined as 
tumour size in repeated MRI studies).  
Secondary outcomes: 
 Performance scale (defined by Karnovsky Performance Score). 
 Quality of life (defined by EQ5D scale). 
Starting date March 2010. 
Contact information vaisman@tasmc.health.gov.il 
Notes Type of KD not defined. Expected completion May 2011 (last updated 






APPENDIX E: WCFT SURVEY EXPLORING KD FOR PATIENTS WITH 
GLIOMAS 
           
        
  
Dietary Treatment for Brain Gliomas 
Gliomas 
Since the early 1920’s a great deal of research has looked at how altering the type of energy 
that the body uses can affect the severity and progression of certain diseases. The ‘Ketogenic 
Diet’ (KD) encourages the body to produce and use ketones as its primary energy instead of 
glucose and has been successful in the treatment of childhood epilepsy. More recently, KD 
has been considered for use in patients with gliomas as these tumours use glucose, not 
ketones, as their main energy source. By limiting the tumour’s main energy source, it may be 
possible to prevent tumour growth and even promote shrinkage. Further, this switch from 
glucose to ketones may make the tumours more responsive to radiotherapy and 
chemotherapy. A small number of case reports have suggested beneficial effects of the KD 
on tumour progression; however well-controlled clinical trials are needed.  
The Ketogenic Diet  
Commitment to the KD involves many lifestyle alterations which can be challenging. For these 
reasons, a number of variations of the KD exist which have been shown to have positive 
results. This survey will focus on a less restrictive form of the diet known as the Modified 
Atkins Diet (MAD). 
The MAD is based on the weight loss diet first described by Dr Robert C. Atkins in 1972. It 
restricts carbohydrates to around 10-20 grams per day (an example of this being 10 
strawberries, 20 raspberries, 2 beetroot and 2 carrots over the course of a day) and 
encourages a high intake of fat which will provide around 65% of total dietary energy. 
Compared to the stricter forms of the KD, the MAD doesn’t limit or strictly measure proteins 
or calories but does require close monitoring under the supervision of a registered dietitian.  
Monitoring is important as some people who follow the MAD may experience some side 
effects due to restricting carbohydrates and increasing their intake of fats. These side effects 
may include: 
 Altered or raised cholesterol or blood lipids 
 Constipation 
 Acid reflux 
 Kidney stones 
 Decreased bone density 
The likelihood of experiencing these side effects varies from person to person, where some 
people may not experience any, whilst others may experience one or more at once. Those 
following the diet must be monitored by a dietitian so that any side effects can be recognised 




Currently, the KD is not routinely available for patients with gliomas in the NHS as: 
a) We do not know whether the diet is acceptable to adults 
b) We do not know whether patients would want to follow it in the longer term 
c) We do not know whether patients would want access to the treatment 
d) Most hospitals do not have dietitians who are funded to support the treatment 
We would like you to complete this survey to help us decide whether patients with gliomas 
attending the Walton Centre clinics would like access to the KD. Following this, we will then 
be in a position to assess whether it would be feasible to run a clinical study in the future.  
For each of the questions below, please enter a tick in the appropriate box:  
Section 1 
1. Please select your age category: Tick 
 a) 16-29 years  
 b) 30-49 years  
 c) 50-69 years  
 d) 70+ years  
2. Please select your gender: 
 a) Male  
 b) Female  
 c) Don’t wish to disclose  




1. Do you do your main weekly food shop at these stores: Yes No 
 a. Tesco?   
 b. Sainsbury’s?   
 c. Asda?   
 d. Aldi?   
 e. Morrisons?   
 f. Other? please write here:                                                                    
2. Do you follow a vegan diet?   
3. Do you have any difficulty preparing or cooking meals?   
4.  Do you use ready meals (e.g. microwave meals)?   
5. If ‘yes’ how frequently do you use ready meals? Tick 
 a) Daily  
 b) Weekly  
 c) Fortnightly   
 d) Monthly   
 
Section 3 
 Yes No Unsure 
1. Should patients with gliomas have access to the ketogenic 
diet? 
   
2. Would you like access to the ketogenic diet?     
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3. Would you be willing to try the diet for a few months to find 
out if it works for you? 
   
4. Thinking about your treatment to date, when would you have 
considered starting this diet?  
Tick 
 Before surgery? (i.e. within a week of seeing your neurosurgeon)  
 After surgery? (i.e. within 2 weeks to 3 months of discharge from 
hospital) 
 
 After surgery but before radiotherapy?   
 After radiotherapy whilst receiving chemotherapy?  
 Yes No Unsure 
5. Would you be interested in taking part in a clinical study to 
try and work out whether the diet can be delivered and is 
tolerable?  
   
6. If ‘yes’, would you still be interested in taking part in a study 
if half the people were given the diet and the other half had 
standard treatment as usual? 
   
7. What would be your motivators to participating in the study? (tick 
all the apply) 
Tick 
 a) To help other adults with glioma  
 b) To access the diet myself  
 c) To get expert advice about the diet   
 d) To improve quality of life  
 e) Other (please state):  
8. What would be your barriers to participating in the study? (tick all 
that apply) 
 
 a) Extra burden of visiting a dietitian  
 b) Not enough time to devote to the study  
 c) Extra expense of travelling  
 d) Extra expense of the diet  
 e) Don’t want to be involved in the study  
 f) Other (please state):  
 







If you would like to be considered to take part in a clinical study in the future please send 




APPENDIX F: NATIONAL SURVEY EXPLORING KD FOR PATIENTS WITH 
GLIOMAS 
       
  
Dietary Treatment for Brain Gliomas 
Gliomas 
Since the early 1920’s a great deal of research has looked at how altering the type of energy 
that the body uses can affect the severity and progression of certain diseases. The ‘Ketogenic 
Diet’ (KD) encourages the body to produce and use ketones as its primary energy instead of 
glucose and has been successful in the treatment of childhood epilepsy. More recently, KD 
has been considered for use in patients with gliomas as these tumours use glucose, not 
ketones, as their main energy source. By limiting the tumour’s main energy source, it may be 
possible to make the tumours more responsive to radiotherapy and chemotherapy, slowing 
tumour growth. A small number of case reports have suggested beneficial effects of the KD 
on tumour progression; however well-controlled clinical trials are needed.  
The Ketogenic Diet  
Commitment to the KD involves many lifestyle alterations which can be challenging. For these 
reasons, a number of variations of the KD exist which have been shown to have positive 
results. This survey will focus on a less restrictive form of the diet known as the Modified 
Atkins Diet (MAD). 
The MAD is based on the weight loss diet first described by Dr Robert C. Atkins in 1972. It 
restricts carbohydrates to around 10-20 grams per day (an example of this being 10 
strawberries, 20 raspberries, 2 beetroot and 2 carrots over the course of a day) and 
encourages a high intake of fat which will provide around 65% of total dietary energy (from 
including foods like double cream, oil, butter and mayonnaise in meals). Compared to the 
stricter forms of the KD, the MAD doesn’t limit or strictly measure protein (such as red meat, 
chicken and fish) or calories but does require close monitoring under the supervision of a 
registered dietitian. For example, the dietitian may monitor your weight, bloods and ketone 
levels then make changes to the diet if required. 
Monitoring is important as some people who follow the MAD may experience some side 
effects due to restricting carbohydrates and increasing their intake of fats. These side effects 
may include: 
 Altered or raised cholesterol or blood lipids 
 Constipation 
 Acid indigestion 
 Kidney stones 
 Decreased bone density 
The likelihood of experiencing these side effects varies from person to person, where some 
people may not experience any, whilst others may experience one or more at once. Those 
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following the diet must be monitored by a dietitian so that any side effects can be recognised 
and treated as soon as possible.  Due to these side effects the KD is not suitable for everyone.   
Currently, the KD is not routinely available for patients with gliomas in the NHS as: 
e) We do not know whether the diet is acceptable to adults 
f) We do not know whether patients would want access to the diet 
g) Most hospitals do not have dietitians who are funded to support the diet 
h) Lack of robust clinical research in the area 
Survey 
We would like you to complete this survey to help us decide whether patients with gliomas 
would like access to the diet. Following this, we will then be in a position to assess whether 
it would be feasible to run a clinical study in the future.  
For each of the questions below, please enter a tick in the appropriate box:  
Section 1 
1. What type of glioma do you have? Tick 
 d) Glioblastoma (grade IV)  
 e) Anaplastic astrocytoma or oligodendroglioma (grade III)  
 f) Low grade glioma (grade II astrocytoma or 
oligodendroglioma) 
 
 g) Other (please state)  
2. Have you received treatment (e.g. surgery, radiotherapy or 
chemotherapy) for a glioma? 
 a) Yes  
 b) No  
3. Please select your age category: 
 a) 16-29 years  
 b) 30-49 years  
 c) 50-69 years  
 d) 70+ years  
4. Please select your gender: 
 a) Male  
 b) Female  
 c) Don’t wish to disclose  
 
Section 2 
 Yes No Unsure 
1. Since your diagnosis have you made any changes to your 
diet? 
   









3. Did you know about the ketogenic diet prior to completing 
this survey? 
   
4. If ‘yes’ where did you hear about the ketogenic diet? Tick 
 a) Charity website  
 b) Clinical trials website  
 c) Online forum/blogs  
 d) Medical team  
 e) Patient support group  
 f) Other (please state):  
 Yes No Unsu
re 
5. Should patients with gliomas have access to the ketogenic 
diet via the NHS? 
   
6. Would you personally like access to the ketogenic diet?     
7. Would you be willing to try the diet for 2-3 months to find 
out if it works for you? 
   
8. Thinking about your treatment to date, when would you 
have considered starting this diet?  
Yes No N/A 
 a) Before surgery? (i.e. within a week of seeing your 
neurosurgeon) 
   
 b) After surgery? (i.e. within 2 weeks to 3 months of 
discharge from hospital) 
   
 c) After surgery but before radiotherapy?     
 d) After radiotherapy whilst receiving chemotherapy?    
 e) After treatment and during monitoring phase?     
 Yes No Unsu
re 
9. Would you be interested in taking part in a clinical study to 
try and work out whether the diet is effective and tolerable?  
   
10. If ‘yes’, would you still be interested in taking part in a study 
if half the people were given the diet and the other half had 
standard treatment as usual? 
   
11. What would be your motivators to participating in the study? (tick all 
the apply) 
Tick 
 f) To help other adults with glioma  
 g) To access the diet myself  
 h) To get expert advice about the diet   
 i) To improve quality of life  
 j) Other (please state):  
12. What would be your barriers to participating in the study? (tick all that 
apply) 
 
 g) Extra burden of visiting a dietitian  
 h) Not enough time to devote to the study  
 i) Extra expense of travelling  
 j) Extra expense of the diet  
 k) Don’t want to be involved in the study  
 l) Fear of side effects  
 m) Carer or family burden  














APPENDIX G: EXIT SURVEY FOR THE KETOGENIC DIET SCOPING 
SERVICE FOR PATIENTS WITH GLIOMAS 
 
Ketogenic Diet and Brain Glioma: Exit Survey 
We are interested in hearing about your experience of the ketogenic diet at The Walton 
Centre. Following this we will then be in a position to assess whether it would be feasible to 
run a clinical study in the future and whether the diet could be offered to other adults with 
brain gliomas. 
For each of the questions below, please enter a tick in the appropriate box/boxes:  
Section 1 
1. Please select your age category: Tick 
 e) 18-29 years  
 f) 30-49 years  
 g) 50-69 years  
 h) 70+ years  
2. Please select your gender: 
 h) Male  
 i) Female  
 j) Don’t wish to disclose  
 
Section 2 
1. How long have you followed a ketogenic diet for? Tick 
 a)    Less than 1 week  
 b)    1 week to 3 weeks  
       c)    4 weeks to 7 weeks  
 d)    8 weeks to 11 weeks  
 e)    12 weeks  
 f)    More than 12 weeks (please state number of weeks ………….)  
2. Why did you stop following the diet? 
       a)   Intolerable i.e. did not like to foods, taste, diet  
 b)   Side effects i.e. vomiting, diarrhoea, constipation  
 c)   Completed the 3 month trial  
 d)   Length of time on diet was too long  
 e)   Extra hospital visits  
 f)    Food costs  
 g)   Found the diet too complicated to follow  
 h)  Felt too unwell to continue  
 i)  Other, please state:  
3. Did your weekly shop:  
 a)   Increase in price?  
 b)  Decrease in price?  




1. Would you recommend a ketogenic diet to other glioma patients? Tick 
 a)   Yes   
 b)  No   
2. If other patients with gliomas were to follow a ketogenic diet when would 
you suggest starting the diet? 
 
 a)  Before surgery (i.e. within a week of seeing your neurosurgeon)  
 b)  After surgery (i.e. within 2 weeks to 3 months of discharge from 
hospital) 
 
 c)  After surgery but before radiotherapy  
 d)  After radiotherapy whilst receiving chemotherapy  
3. Would you recommend the ketogenic service at The Walton Centre to others?  
 a) Yes  
 b) No   
 c) Unsure   

























1. Would you be interested in taking part in a clinical study to try and work out 
whether the diet can be delivered and is tolerable? 
 a)  Yes  
       b)  No   
       c)  Unsure   
2. If ‘yes’, would you still be interested in taking part in a study if half the people 
were given the diet and the other half received standard treatment? 
 a)  Yes  
       b)  No   
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       c)  Unsure   
3. Would you be interested in taking part in a study which required you to try 
the ketogenic diet for longer than 12 weeks? 
 
 a)  Yes  
       b)  No   
       c)  Unsure   
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1. PROTOCOL SUMMARY  
1.1 Population 
This pilot study will be open to all Walton Centre NHS Foundation Trust (WCFT) patients 
with a newly diagnosed glioblastoma (GB), who have undergone surgical resection or 
biopsy and will go onto receive adjuvant oncological treatments.   
1.2 Inclusion/exclusion criteria  
The following criteria must be met by all proposed patients:  
Inclusion criteria:  
 Age ≥16 years  
 Patient at WCFT  
 Performance status ≤2 (Sǿrensen et al., 1993) 
 Confirmed histological diagnosis of GB within last four months via surgical resection 
or biopsy (WHO grade IV, Louis et al., 2016) 
 Will go onto receive or is currently receiving or completed adjuvant oncological 
treatments (radiotherapy, chemotherapy or combination radiochemotherapy) 
Exclusion criteria: 
 Having any prior use of a ketogenic diet (KD)  
 Kidney dysfunction (CKD III/IV, renal stones, cancer, low phosphate/potassium/salt 
diets) 
 Liver dysfunction (alcoholic liver disease, non-alcoholic liver disease, cancer, 
hepatitis, haemochromatosis, primary biliary cirrhosis) 
 Gall bladder dysfunction (gall stones, cholecystectomy in past 12 months, cancer) 
 Metabolic disorder (carnitine deficiencies, β oxidation defects [medium chain acyl-
CoA dehydrogenase deficiency, long chain acyl-CoA dehydrogenase deficiency, 
short chain acyl-CoA dehydrogenase deficiency, long chain 3-hydroxyacyl CoA 
deficiency, medium chain 3-hydroxyacyl CoA deficiency], pyruvate carboxylase 
deficiency, porphyria) 
 Eating disorder (anorexia nervosa, bulimia nervosa, binge eating disorder) 
 Diabetes (requiring medication)  
 Body mass index (BMI) ≤18.5kg/m2  
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 Weight loss medications (Orlistat, Belviq, Contrave, Saxenda, Phentermine 
and Qsymia)    
 Currently pregnant or breastfeeding  
 Performance status ≥3 (Sǿrensen et al., 1993) 
 Medical conditions that may increase risks associated with KD 
1.3 Trial duration 
The trial will recruit 12 patients over a 24 month period.  Follow up will be for 12 months 
from the date the diet is commenced.    
1.4 Description of intervention 
A prospective, non-blinded, randomised, pilot study will be undertaken in patients with GB.  
Patients will be randomised to the modified ketogenic diet (MKD) or the medium chain 
triglyceride ketogenic diet (MCT) for a 12 week period (primary completion).  If patients 
wish to remain on diet, they will be offered dietetic support as part of the trial for a total of 
12 months (secondary completion).  After this time, those who continue with the diet will 
have access to dietetic support and monitoring at 3 monthly intervals if they remain on 
diet.  
1.5 Aim 
To investigate protocol feasibility and patient impact by comparing two KDs in an NHS 
setting, with a view to inform the design of future phase III clinical trials. 
1.6 Objectives 
Primary objective: 




Protocol feasibility objectives  
 To estimate recruitment rate  
 To collect data about the enrolment of patients (consent, randomisation, baseline 
screening) pre oncological treatments 
 To collect data about the enrolment of patients (consent, randomisation, baseline, 
screening) during oncological treatments 
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 To collect data about the enrolment of patients (consent, randomisation, baseline, 
screening) post oncological treatments (within four months of surgical 
intervention)  
 To estimate long term retention  
 To collect data about the dietary adjustments required to achieve ketosis 
 To collect data about dietary compliance 
 To collect data about MCT supplement compliance  
 To collect data about ketosis levels   
 To collect data about dietetic time required for each intervention  
 To assess the protocol refinements required 
 To collect data to inform sample size calculations of future trials 
 Assess completeness of data for all trial outcomes 
 
Patient impact objectives  
 To collect data about quality of life 
 To collect data about food acceptability  
 To collect data about gastrointestinal side effects 
 To collect data about changes in biochemical markers 





















































Patients with GB undergo surgery (resection or biopsy) 
 
Histology confirms GB 
 
Patient referred by consultant into trial 
 
 Patient telephoned to book appointment 
 
 Clinic appointment 1 
Consent obtained and registered 
Baseline assessment (A B C D) 
 
 








Telephone review 1 (week 1) 
 
 Telephone review 2 (week 3) 
 
 Clinic appointment 3 (week 6)  
A B C D 
 
 
Telephone review 3 (week 9) 
 
 
Clinic appointment 7 (12 months)  
A B C D   
 
 
Clinic appointment 6 (9 months)  
A B C D  
 
 
Clinic appointment 5 (6 months)  
A B C D  
 
 
Clinic appointment 4 (week 12)  














*Patients are able to telephone between appointments should further dietary support be 
required.  
2. BACKGROUND 
Glioblastoma (GB) is the commonest form of malignant brain tumour in adults, affecting 2-3 
people per 100,000 per year (Radhakrishnan et al., 1995).  Current treatment options include 
maximal safe resection, radiotherapy and temozolomide chemotherapy (Stupp et al., 2005).  
Despite these treatments, overall survival at two years is approximately 27%, with a median 
survival of 12-14 months (Krex et al., 2007).  Over the last 10 years, several trials of newer 
chemotherapy agents (e.g. RTOG 0825 - Bevacizumab trial [Gilbert et al., 2014]) and targeted 
therapies (e.g. CENTRIC – Celengitide trial [Stupp et al., 2014]) has not improved the survival 
for patients with these tumours.  Therefore, alternative treatment options are being explored 
and there is increasing interest in the possibility of using the ketogenic diet (KD) as an 
adjuvant treatment for patients with GB.  
A KD is high in fat and low in carbohydrate, resulting in the production of ketones as a primary 
energy source, whilst minimising glycolysis through glucose restriction.  Thus, as GBs are 
metabolically active tumours, they become deprived of their energy source.  In animal 
models, implementing a KD as an adjuvant treatment has been shown to enhance survival 
(Woolf & Scheck, 2015), enhance radiotherapy sensitivity (Abdelwahab et al., 2012), improve 
chemotherapy signalling (Allen et al., 2013) and reduced peritumoural oedema (Jiang & 
Wang, 2013).   
Recent studies investigating the use of the KD in humans have focused on the feasibility, 
safety and efficacy.  However, at present, published evidence is based on case studies 
(Nebeling et al., 1995, Kalamian et al., 2008, Schwartz et al., 2015, Zuccoli et al., 2010) and 
one pilot trial (Rieger et al., 2014).    
KDs can be unpalatable and their acceptability to patients with a short survival time has seen 
limited investigation so far (Rieger et al., 2014).  There are various forms of the KD, with the 
two least restrictive being the modified ketogenic diet (MKD) and the medium chain 
triglyceride (MCT) KD.  Both diets are currently used for treating paediatric epilepsy within 
Key 
A Anthropometry (weight, height, waist circumference, fat mass, body mass index 
[BMI], hand grip strength [HGS], mid arm muscle circumference [MAMC]) 
B Biochemistry (renal, bone, liver function test (LFT), fasting lipid, fasting glucose) 
C Collect food and ketone diaries 
D Quality of life and food acceptability questionnaires 
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the National Health Service (NHS) and have proven efficacy in this settling (Neal et al., 2009 
& Kossoff et al., 2006).  
The MKD induces ketosis through encouraging a high fat and low carbohydrate intake, 
without limiting protein, fluid or energy intakes.  There is no need for a fasting start or 
hospitalisation to commence the diet (Bergqvist et al., 2005).  MKD is likely to be the more 
flexible and palatable of the KDs, therefore may be more suitable for adults undergoing 
oncological treatments.   
MCT KD was first described by Huttenlocher et al. (1971) as a modification to the classic KD.  
It allows for the inclusion of larger portions of carbohydrate, thus, improving dietary 
tolerance and acceptability.  A recent study by Martuscello et al. (2015) investigating the use 
of MCT KD in GB animal models found slower tumour progression, increased survival, 
increased body weight and positive changes to serum lipids in comparison to a standard KD 
and controls.   
2.1 Rationale  
 
Little is known about the palatability and acceptability of the KD in oncology patients with a 
limited survival time and suitable outcome measures have yet to be investigated.   
We have recently completed feasibility work at The Walton Centre NHS Foundation Trust 
(WCFT) to investigate tolerance and acceptability of the MKD and the willingness of glioma 
patients to participate in clinical trials.  The feasibility work comprised of: 
1. A patient questionnaire (n=172) 
2. A 3 month assessment of diet (n=6).  
 
Sixty two percent of the questioned population (n=107) would like access to MKD.  Sixty six 
percent (n=114) would be willing to trial the MKD for a 3 month period.  Sixty percent of the 
population (n=104) would be willing to participate in a clinical trial, however if the trial 
involved randomisation between the diet and control (standard treatment + no diet) patient 
willingness to participate reduced to only 52% (n=54).   
Six male GB patients received the MKD. Five patients tolerated the diet, found it acceptable, 
and subjectively reported improvements in quality of life.  With regards to attrition, 1 patient 
dropped out after 4 weeks on diet due to local hospital admission and 1 patient after 6 weeks 
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due to dietary tolerance. Of the four patients who completed the 12 week trial all remain on 
diet, demonstrating the ability for the proposed trial to recruit and retain participants. 
2.1.1 Patient and Public Involvement (PPI) 
Patients from the feasibility project were invited to attend a PPI group.  We sought their 
active involvement in identifying research priorities and outcome measures for KD in GB.  
Their opinion was also sought for improvements required to patient information leaflets, 
recruitment processes, clinic appointments and reducing patient costs to enhance trial 
participation.  The ideas and opinions from the PPI group have been developed and 
incorporated into the protocol and supporting patient information sheets.  The plain 
language summary for the proposed trial was approved by the PPI group.  
2.2 Aim 
To investigate protocol feasibility and patient impact by comparing two KDs in an NHS setting, 
with a view to informing future phase III clinical trials. 
2.3 Objectives 
Primary objective: 




Protocol feasibility objectives  
 To estimate recruitment rate  
 To collect data about the enrolment of patients (consent, randomisation, baseline 
screening) pre oncological treatments 
 To collect data about the enrolment of patients (consent, randomisation, baseline, 
screening) during oncological treatments 
 To collect data about the enrolment of patients (consent, randomisation, baseline, 
screening) post oncological treatments (within four months of surgical intervention)  
 To estimate long term retention  
 To collect data about the dietary adjustments required to achieve ketosis 
 To collect data about dietary compliance 
 To collect data about MCT supplement compliance  
 To collect data about ketosis levels   
 To collect data about dietetic time required for each intervention  
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 To assess the protocol refinements required 
 To collect data to inform sample size calculations of future trials 
 Assess completeness of data for all trial outcomes 
 
Patient impact objectives  
 To collect data about quality of life 
 To collect data about food acceptability  
 To collect data about gastrointestinal side effects 
 To collect data about changes in biochemical markers 
 To collect data about anthropometric changes  
3.0 EXPERIMENTAL DESIGN AND METHODS 
3.1 Trial design 
A prospective, non-blinded, randomised, pilot study will be undertaken in patients diagnosed 
with GB.  Patients will be randomised to receive the modified ketogenic diet (MKD) or 
medium chain triglyceride KD (MCT). 
3.1.1 Primary end point 
To assess retention and drop-out rates, defined as:  
 
i. The number of patients who start randomised treatment as a proportion of the number 
randomised, with reasons for non-compliance.  
ii. The number of patients who complete 12 weeks of diet as a proportion of the number 
randomised, with reasons for non-compliance.  
iii. The time to dietary discontinuation (week 12 or duration to discontinuation if prior to 
this). 
iv. Description of barriers and facilitators to data collection and participant retention.  
 
3.1.2 Secondary end points 
 Estimation of recruitment rates 
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Actual recruitment rates (over 24 months) will be compared to proposed recruitment figures 
(12 patients over 12 months) with purpose of demonstrating trial feasibility for future, 
potential phase III clinical trials.    
 Enrolment of patients  
Ability to comply with protocol enrolment time lines will be assessed by the number of 
patients initiated on diet prior to, whilst receiving, and post oncological treatment.  This will 
inform the feasible time lines in future clinical trials.  
 Long term retention  
The time to dietary discontinuation after week 12. 
 Dietary adjustments required to achieve ketosis 
Dietary adjustments advised by the dietitian will be recorded in the case report form (CRF), 
to inform the macronutrient composition of the MKD and MCT diets required to achieve 
ketosis in this population to inform future protocols.    
 Dietary compliance 
Dietary compliance will be self-reported by the patient at clinic appointments.  The dietitian 
will also analyse self-reported 3 day weighed food diaries (completed at weeks 6, 12 and 
every 3 months thereafter) using DietPlan 7© (nutritional analysis computer programme).  
The results will be compared to dietary fat and carbohydrate requirements (calculated at 
previous clinic appointment) and percentage compliance rates will be calculated.  
 MCT compliance  
MCT supplement compliance will be self-reported through 3 day weighed food diaries 
collected at week 6, week 12 and every 3 months thereafter.  The results will be compared 
to the MCT dose advised (at previous clinic appointment) and a percentage compliance rate 
will be calculated. 
 Ketosis levels 
Ketosis will be monitored by patients self-reporting urinary ketones levels twice per day for 
the first 6 weeks then then once per week thereafter.  Adequate urinary ketosis is defined as 
≥4mmol/L.  Blood ketones and blood glucose levels will be monitored weekly.  Adequate 
blood glucose levels are defined as 3-5mmol/L.  There are no robust guidelines for adequate 
levels of blood ketosis in adults with GB, however from preliminary work by Meidenbauer et 
al. (2015), levels of 2-4mmol/L to be beneficial, therefore patients will be asked to record 
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levels to aid future research.  All figures will be recorded in the ketone diary provided.  The 
dietitian will assess these at each point of contact.    
 Dietetic time required for the interventions 
Dietetic time spent on both clinical and non-clinical activities related to the trial will be 
recorded to aid future protocol design.   
 Protocol refinements required 
Deviations from the protocol will be documented on the deviation log.  This will be used to 
refine future protocols and inform future clinical trials.  
 Sample size estimates for future trials 
Data synthesised from this pilot will inform sample size calculations for future phase III 
clinical trials, based on the primary outcome measure of retention.  
 
 Quality of life 
Quality of life will be evaluated though the EORTC QLQ C30 and QLQ BN 20 questionnaires 
prior to commencing the diet, at week 6, week 12 and every three months thereafter or at 
point of dietary discontinuation if prior to this. 
 Food acceptability 
Food acceptability will be assessed through the Food Acceptability Questionnaire (Barnard 
et al., 2009) completed prior to commencing the diet, at week 6, week 12 and every three 
months thereafter or at point of dietary discontinuation if prior to this.   
 Gastrointestinal side effects 
Gastrointestinal side effects will be quantified from the EORCT QLQ C30 questionnaire and 
through informal clinic assessments documented on CRF.  The Common Terminology Criteria 
for Adverse Events ([CTCAE], version 4.0) will be used to grade gastrointestinal side effects 
documented on the CRF.   
 Changes to biochemical markers 
Biochemical markers (fasting lipid, fasting glucose, liver, renal and bone profiles) will be 
undertaken at baseline and repeated three monthly until discontinuation of diet.   
 Anthropometric changes  
Anthropometry (height, weight, body mass index (BMI), waist circumference, mid upper arm 
circumference (MUAC), mid arm muscle circumference (MAMC), tricep skin fold (TSF)[Body 
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Care, UK], hand grip strength (HGS) [Takei, Japan] and fat mass [Omron, Japan]) will be 
measured at baseline, week 6, week 12 and every three months thereafter.  All 
measurements will be undertaken as per measurement methodology cited in Parenteral and 
Enteral Nutrition Group (PENG), pocket guide to clinical nutrition (Todorovic & Micklewright, 
2011).  See appendix 1 for details.   
 Completeness of data for all trial outcomes 
Completeness of documented data will be assessed to inform feasibility of future clinical 
trials.  
Assistance permitted: 
A carer/ relative may aid the patient in the completion diaries or questionnaires if required, 
with the patient’s permission. 
3.1.3 Defining pilot success 
Pilot success will be graded using a traffic light system.  The pilot will be deemed a success 
and progression to phase III trial will be considered appropriate if the following criteria are 
met:  
Green (go): 
 Recruitment rate of ≥75% of target (n=9) achieved within the 12 month recruitment 
period. 
 ≥75% of patients commenced KD prior to chemoradiotherapy. 
 Retention rate of ≥75% at 3 months. 
 Diet acceptable to ≥75% of patients at 3 months.  
 ≥75% of the proposed data collection completed for each end point.  
 
Amber (review): 
 Recruitment rate of ≥50% of target (n=6) achieved within the 12 month recruitment 
period. 
 ≥50% of patients commenced KD prior to chemoradiotherapy. 
 Retention rate of ≥50% at 3 months.  
 Diet acceptable to ≥50% of patients at 3 months.  





 Recruitment rate <50% of target (n=5) achieved within the 12 month recruitment 
period. 
 <50% of patients commenced KD prior to chemoradiotherapy. 
 Retention rate of <50% at 3 months. 
 Diet acceptable to <50% of patients at 3 months. 
 <75% of the proposed data collection completed for each end point. 
 
Retention rate, dietary acceptance and data collection will be assessed for each diet 
independently.  Recruitment rate and dietary commencement will be assessed using data 
combined from both arms.  
Any components of the pilot considered not feasible or unacceptable to patients will be 
evaluated prior to progression onto phase III clinical trial is considered.  The Shanyinde et al. 
(2011) method will be used to categorise and assess the extent of the issue and the Bugge et 
al (2013) method will be used to evidence the decision making process.    
3.2 Trial population 
3.2.1 Population 
The trial will be open to all WCFT patients with a newly diagnosed GB, who have undergone 
surgical resection and will go onto receive adjuvant chemoradiotherapy.   
3.2.2 Inclusion/exclusion criteria  
All patients considered for the trial must meet the following criteria: 
Inclusion criteria  
 Age ≥16 years  
 Patient at WCFT  
 Performance status ≤2 (Sǿrensen et al., 1993) 
 Confirmed histological diagnosis of GB within last four months following surgical 
resection or biopsy (WHO grade IV, Louis et al., 2016) 
 Will go onto receive, or is currently receiving, or completed adjuvant oncological 






 Having any prior use of a KD  
 Kidney dysfunction (CKD III/IV, renal stones, cancer, low phosphate/potassium/salt 
diets) 
 Liver dysfunction (alcoholic liver disease, non-alcoholic liver disease, cancer, 
hepatitis, haeochromatosis, primary biliary cirrhosis) 
 Gall bladder dysfunction (gall stones, cholecystectomy in past 12 months, cancer) 
 Metabolic disorder (carnitine deficiencies, β oxidation defects [medium chain acyl-
CoA dehydrogenase deficiency, long chain acyl-CoA dehydrogenase deficiency, short 
chain acyl-CoA dehydrogenase deficiency, long chain 3-hydroxyacyl CoA deficiency, 
medium chain 3-hydroxyacyl CoA deficiency], pyruvate carboxylase deficiency, 
porphyria) 
 Eating disorder (anorexia nervosa, bulimia nervosa, binge eating disorder) 
 Diabetes (requiring medication)  
 Body mass index (BMI) ≤18.5kg/m2  
 Weight loss medications (Orlistat, Belviq, Contrave, Saxenda, Phentermine 
and Qsymia)    
 Currently pregnant or breastfeeding  
 Performance status ≥3 (Sǿrensen et al., 1993) 
 Medical conditions that may increase risks associated with KD 
 
3.2.3 Identification of patients 
Patients will be identified at WCFT neuro-oncology multi-disciplinary team (MDT) meeting; 
with documentation within MDT case sheet deemed an appropriate referral.   
Patients will also be identified by neurosurgical consultants at WCFT clinics and referred in 
writing.  Neuro-oncology nurses may also identify patients; however written referrals will be 
required from the consultant.   
They will be approached for recruitment post resection or biopsy, once a histological 
diagnosis of GB is confirmed and a written referral is received from the consultant or MDT.  
The neurosurgical team has the option of providing patients with a patient information sheet 
in clinic.  Patients will be contacted by the investigator by telephone to initially discuss the 
study and offered a screening appointment prior to commencing oncological treatments.   
They will receive a patient information sheet by post if not previously provided by the 
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neurosurgical team. Patients will receive a follow up phone call following initial oncological 
treatment as they also have the option of commencing diet within four months of initial 
surgical intervention.  
3.3 Enrollment 
3.3.1 Screening 
Patients will be screened for eligibility at WCFT neuro-oncology MDT meeting or clinic.   
A screening log will be maintained for all patients referred to the trial and reasons for 
ineligibility will be noted.  
Enrolment will take place for 24 months from the date of opening.  
3.3.2 Consent 
Informed consent will be sought from all patients prior to enrollment.  Through consenting 
to participate in the trial, patients will be consenting to dietary treatment, follow up and data 
collection.   
3.3.3 Embedded Qualitative Information Study  
A qualitative study will be embedded into KEATING, which will be referred to as the 
‘Information Study’ in the patient information documents.  The aim is to identify recruitment 
challenges and aid understanding of the patients’ recruitment experience, by interviewing a 
sub-sample of patients and their relatives/ carers.  Bespoke strategies will then be designed 
to optimise recruitment to future trials related to ketogenic diets and gliomas.  This approach 
of embedded qualitative interviews has demonstrated success at optimising recruitment in 
previous trials (Mills et al. (2003), Donovan et al. (2002), Avery et al. (2014)), and will ensure 
patients are supported in making an informed decision about KEATING.  Full details on the 
embedded qualitative information study can be found in Appendix 3. 
3.3.4 Randomisation 
Following consent and acquisition of baseline data, patients will be randomised into MKD or 
MCT groups after clinic appointment 1.  The patients will be informed of diet group by 
telephone.  A permuted block randomisation method will be adopted, using 
'sealedenvelope'™ randomisation system.  This will be set up and administered by the 
statistician, who is not involved with the recruiting of patients.    
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3.3.5 Baseline  
Baseline data will be collected on the Case Report Form (CRF) at the initial consultation once 
eligibility is confirmed and consent obtained.  Baseline data will include:  
 Past medical history 
 Symptoms at presentation 
 Tumour location 
 Surgical procedure 
 Histopathology and molecular pathology subtypes for glioblastoma (MGMT, IDH-1, 
ATRX, 1p/19q status) 
 Current medication (prescribed and purchased) 
 Current nutritional supplementation (vitamins, minerals, herbal and nutritional 
products) 
 Food allergies or intolerances 
 Level of physical activity (as defined by DH, 1991)   
 Food or fluid texture modification 
 Use of enteral feeding tube  
 Anthropometry (height, weight, BMIƗ, MUAC, TSF, MAMC, HGD, waist circumference 
and fat mass) 
 Biochemistry* (fasting lipid, fasting glucose, liver, renal and bone profiles) 
 Habitual 3 day weighed food diary 
 Habitual gastrointestinal complaints   
 Quality of life measures (EORTC QLQ C30 and QLQ BN 20 questionnaires) 
 Habitual food acceptability (Food Acceptability Questionnaire) 
Ɨ BMI ≤18.5kg/m2 at baseline assessment will result in exclusion from trial, as per exclusion 
criteria.  
*Deranged biochemistry results may result in exclusion from the trial should the exclusion 
criteria be triggered.  This will be at the discretion of the CI.  Biochemistry results may take 
up to 24 hours to process, therefore if deranged resulting in trial exclusion, patients will be 
informed by telephone and appropriate follow up arranged if deemed to be required by the 
CI.   
Histopathology and molecular pathology subtypes for glioblastoma (MGMT, IDH-1, ATRX, 
1p/19q status) classification will be conducted as per the current standard of care. 
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MRI will be conducted as per the current standard of care for patients with GB (Jenkinson, 
2011), resulting in scans at the following intervals: 
 Pre surgery 
 Post-surgery (within 72 hours) 
 Pre radiotherapy 
 1 month post radiotherapy 
 Mid chemotherapy (after 3 cycles) 
 Post chemotherapy (after 6 cycles) 
 Every 6 months from 12-24 months 
MRI scans will include T1 ± gadolinium, T2 and fluid-attenuated inversion recovery (FLAIR) 
sequences.  Extent of resection on post-operative MRI will be determined and recurrence 
will be measured according to the Response Assessment in Neuro-Oncology (RANO) criteria 
(Wen at al. 2010) and data collected on a supplementary CRF for monitoring of disease status. 
Changes to medications and treatment will be recorded; these are permitted to be altered 
in-line with the treating oncologist/neurosurgeons recommendations.  Details of 
concomitant radiotherapy and chemotherapy and adjuvant chemotherapy will be noted in 
the CRF.  
3.3.6 Patient transfers 
If the geographical distance moved is beyond what the patient is now willing to travel, then 
review should be conducted by telephone and post, with the patient’s GP facilitating 
biochemistry collection.  If this is not feasible the patient will be withdrawn from the trial.    
3.3.7 Withdrawal from trial treatment 
If there is a change in the patient’s condition that in the clinician’s opinion justifies dietary 
discontinuation or if the patient withdraws consent, the patient will be withdrawn from 
dietary treatment. In this case, data up until the point of withdrawal will be used in analysis.  
Unless the patient specifically withdraws consent further data will be gathered for 
progression free survival and overall survival analysis.   
3.3.8 Withdrawal from trial completely 
Patients will be made aware at the point of consent that they can withdraw at any time.  No 
reason will be required.  Should a patient withdraw, data will be included in the analysis until 
the point of withdrawal, unless the patient states otherwise.  If they wish for their data to be 
excluded entirely, a CRF for destruction of data will be completed.   
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3.4 Trial treatments 
3.4.1 Introduction 
A prospective, non-blinded, randomised, pilot study will be undertaken in patients diagnosed 
with GB.  Patients will be randomised to receive the modified ketogenic diet (MKD) or 
medium chain triglyceride KD (MCT). 
3.4.2 Equipment and planning 
Patients will be provided with the following when commencing the diet:  
 FreeStyle Optimum Neo Blood Glucose and Ketone Monitoring System® (Abbott 
Diabetes Care, UK) 
 Blood glucose strips (Abbott Diabetes Care, UK) 
 Blood ketone strips (Abbott Diabetes Care, UK) 
 Ketostix® (Bayer, Leverkusen, Germany) 
 Urinary sample pot (NHS Supply, UK)   
 Ketogenic diet prescription information sheet (diet specific) 
 Food diary 
 Food and MCT diary (if applicable) 
 Urinary ketone diary 
 Blood ketone and blood glucose diary 
 Ketogenic recipes -modified for individual requirements and diet (Matthew’s Friends, 
UK)  
 Betaquik recipes – modified for individual requirements for those following MCT diet 
(Vitaflo International Ltd) 
 7 day individualised ketogenic diet plan 
 
Patients will be instructed to check their urinary ketones twice per day for the first 6 weeks 
(upon wakening and 2 hours post evening meal), then twice per week thereafter (2 hours 
post evening meal, same days each week).  Blood glucose and ketones will be tested weekly 
(2 hours post evening meal, same day each week).  These figures will be recorded in the 
ketone diary provided.  The dietitian will assess these at each point of contact.   
The MCT supplement Betaquik ® (Vitaflo International Ltd, Liverpool, UK) is a ready to use 
liquid emulsion drink of MCT and will be supplied by Vitaflo International Ltd. Betaquik is 
nutritional supplement; therefore the quantity will be calculated by the investigator and 
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documented in the CRF.   The manufacturing number and use by date of the supplements 
will also be documented in the CRF for traceability.  
3.4.3 Definitions of targets 
Adequate ketosis is defined as urinary ketones ≥4mmol/L (moderate ketosis is 4mmol/L, high 
ketosis 8-16mmol/L).  Adequate blood glucose levels are defined as 3-5mmol/L. 
3.4.4 Dietary calculations and reporting  
MKD: 
 Fat to provide 80% total energy requirements 
 Carbohydrate to provide 5% of total energy requirements 
 Protein allowed freely  
MCT: 
 Fat to provide 75% total energy requirements (30% total energy requirements from 
MCT fat) 
 Carbohydrate to provide 10% of total energy requirements 
 Protein allowed freely  
Patients (and relatives when appropriate) will receive dietetic counseling and be provided 
with dietary literature to calculate intakes of these food groups.  All patients will commence 
the diet at home, without a fasting start.    
Energy requirements will be appropriate for patient’s age, weight, activity and metabolic 
stress, monitored through weight checks.  To estimate energy requirements a 3 day weighed 
food diary will be analysed using DietPlan 7© (Forestfield Software LTD, Horsham, UK) and 
compared to the PENG (Todorovic & Micklewright, 2011 [American Society of Parenteral and 
Enteral Nutrition, 2002, Barak et al., 2002, Department of Health, 1991, Henry, 2005, 
Hyltander et al., 1991, Knox et al., 1983]) energy requirements, from which a mean energy 
requirement should be estimated.  The requirements can be tailed for weight loss, gain or 
maintenance dependent upon the patient’s needs and wishes.   
Dietary requirements will be recalculated each time a new weight is obtained.  
Seven day diet plans will be calculated by the dietitian based upon total energy requirements.  
Nutritional content will be analysed using DietPlan 7© (Forestfield Software LTD, Horsham, 
UK) to ensure appropriate proportions of carbohydrate, fat and protein.   
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Patients will be required to complete a three day weighed food diary at baseline, 6 weeks 
and 12 weeks and every three months thereafter until discontinuation of diet.   
Patients following the MCT diet will also be required to record intake of MCT within the food 
diary.   
3.4.5 Timing 
Patients have the option of commencing the diet within four months of surgical intervention 
(resection or biopsy).  Patients may therefore commence diet prior to, during or post 
oncological intervention.  All surgical and oncological interventions will be undertaken as per 
current standard of care.    
3.4.6 Associated medications and treatments 
Medications permitted: all medications with the exception of those specified below. 
Medications not permitted: weight loss medications (including Orlistat, Belviq, Contrave, 
Saxenda, Phentermine and Qsymia) and any agents used in diabetic therapy (including 
Biguanides, Sulfonylureas, Meglitinide derivatives, Alpha-glucosidase inhibitors, 
Thiazolidinediones (TZDs), Glucagonlike peptide–1 (GLP-1) agonists, Dipeptidyl peptidase IV 
(DPP-4) Inhibitors, Selective sodium-glucose transporter-2 (SGLT-2) inhibitors, Insulins, 
Amylinomimetics, Bile acid sequestrants and Dopamine agonists).  
Data will be collected on use of corticosteroids, antiemetics, laxatives and antiepileptic drugs.  
Data will also be collected for nutritional supplements consumed by the patient.  All drugs 
prescribed for the patient will be recorded on the CRF.  
3.4.7 Co-enrollment guidelines 
Patients who have participated in and/or are enrolled on another trial may be eligible for the 
trial and should be discussed with the CI.   
Patients enrolled on the trial may be eligible for other non-diet trials and involvement should 
be discussed with the CI.   
Enrollments onto other trials involving diet or dietary supplements are not permitted.   
3.5 Assessments and procedures 
Baseline and follow up data will be collected on the CRF by the person named on the 
delegation log (the investigator).  
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The research site (WCFT) will maintain an investigator site file containing all essential trial 
documentation to allow for evaluation of trial conduct and data quality.    
Table 1 illustrates assessments related to the trial.  
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Eligibility screen  X          
Randomisation  X          
Medical history 
review 
 X          
Medications 
review 
 X          
Anthropometry  X    X  X X X X 
Biochemistry   X      X X X X 
Food diary  X    X  X X X X 
Ketone diary      X  X X X X 
Quality of life 
(QoL) 
questionnaire 
EORCT QLQ C30 








 X    X  X X X X 
Dietary review  X X X X X X X X X X 
Ketone review    X X X X X X X X 
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3.5.1 Procedures for assessing efficacy 
Efficacy will not be determined from this trial due to limitations in sample size.  However, 
MRI will be used to interpret tumour progression and progression free survival for those 
patients enrolled on the trial.  MRI will be conducted as per the current standard of care for 
patients with GB and will include the following sequencing; T1 ± gadolinium, T2 and FLAIR 
(see enrolment).   
Progression free survival will be defined as the time from date of randomisation to date of 
recurrence on MRI.  Recurrence will be as defined by a Neuroradiologist using the RANO 
criteria (Wen et al., 2010).  All scans will be undertaken as per current standard of care.  No 
additional imaging will be required.  Progression free survival data will then be assessed by 
Kaplan-Meier survival analysis.  
Overall survival will be defined as the time from date of randomisation to date of death from 
any cause.  
This information will be recorded in a supplementary CRF for monitoring of disease status, 
as will be completed by the Neuroradiologist.  
3.5.2 Procedures for assessing safety 
Adverse events associated with the diet will be recorded in the CRF (see safety reporting).   
3.5.3 Loss to follow up 
Reasons for loss to follow up will be recorded on CRF.  
3.5.4 Trial closure 
There is a 24 month recruitment period, followed by a 12 month trial period (maximum), 
therefore the trial will close 12 months after the enrollment of the final patient, to allow 
sufficient time for data analysis.  The trial would close early should serious adverse events 
occur as a direct result of the trial intervention, which would be advised by the Sponsor.   
3.6 Statistical considerations 
3.6.1 Sample size 
Feasibility data demonstrates a likely retention rate of 70% participants at 12 weeks. With a 
sample size of 12 we will be able to estimate retention rates of 70% to within a 95% 
confidence interval of ±25.93% (Hooper, no date).  Billingham et al. (2013) demonstrate a 
median sample size of 30 (range 8-114 participants) for UK pilot studies, whilst Hertzog 
(2008) reports on the statistical adequacy for sample sizes of 10-40, thus further justifying a 
sample size of 12 for the current trial.   
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Recruitment time is a limiting factor to sample size.  Given the recruitment window and our 
previous feasibility work demonstrating a patient recruitment figure of 1 per month, a sample 
size of 12 as specified above, should be achievable. 
Cost of resources is also a limiting factor to sample size, given the implications of ketone 
monitoring on resources (see section 7.1).   
Data synthesised from this pilot will inform sample size estimates for future, phase III clinical 
trials.  
3.6.2 Analysis plan 
A detailed analysis plan will be developed prior to the final analysis.  In brief, descriptive 
statistics will be used to summarise retention, recruitment rates, enrolment adherence, 
dietary adjustments, dietetic time, dietary compliance, MCT supplement compliance, ketosis, 
anthropometry changes, biochemistry changes, quality of life, food acceptability and 
gastrointestinal side effects.  The Kaplan-Meier survival curve will be estimated for overall 
survival and progression free survival and displayed graphically with 95% confidence 
intervals.   
3.7 Safety reporting 
3.7.1 Terms and definitions 
Adverse event (AE): is any unexpected situation that takes place during the course of the 
trial.  An AE may be related to the dietary intervention or an unrelated cause. 
Serious adverse event (SAE): an event which results in death, is life threatening, requires 
hospital admission or prolongs hospital stay, results in significant or persistent disability or 
incapacity or results in a birth defect. 
Life threatening: potentially fatal illness or injury at time of occurrence. 
Related: resulted from the administration of the dietary intervention. 
Unexpected: type of AE or SAE not listed on the protocol and is not a likely occurrence.  
3.7.2 Adverse event inclusions and exclusions 
Inclusion: 
 Injury or accident 
 Abnormalities in biochemistry that require further investigation or treatment 
 Exacerbation of a pre-existing illness 
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 Development of an illness during the trial 
 Worsening of baseline symptoms  
 
Exclusion: 
 Previously planned hospital admission 
 Past medical conditions that do not worsen with intervention 
 Medical or surgical procedures undertaken due to the adverse event 
 Elective cosmetic surgery 
 Gastrointestinal side effects unless resulting in hospital admission 
 Altered lipid profiles unless resulting in the commencement of lipid lowering 
medication or further investigations  
 
The Common Terminology Criteria for Adverse Events ([CTCAE], version 4.0) will be used to 
grade AEs.   
All deaths occurring from recruitment to end of follow up will be reported to the Heath 
Research Authority (HRA) Research Ethics Committee (REC).   
3.7.3 Pregnancy 
The effects of KD on pregnancy are unknown; therefore pregnancy is an exclusion criterion 
for the trial.  Should a patient become pregnant the dietary intervention will be discontinued, 
the patient will receive the appropriate dietary counseling for pregnancy and appropriate 
obstetric care will be arranged.    
3.7.4 Severity of adverse events 
The National Institute for Health Research (NIHR) ‘decision tree for adverse event reporting’ 
will be used to grade AE and SAE severity (see appendix 2).   
An AE or SAE will be reported by the investigator; however the CI will be responsible for 
determining causality. The CI will use clinical judgment to determine causality, the result of 
which will be documented on the SAE form.  
3.7.5 Expectedness 
A summary of expected adverse events related to KD and compiled from relevant literature 
(Martin et al., 2016) are as follows:  
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 Gastrointestinal intolerance (such as diarrhoea, constipation, nausea, reflux, 
abdominal discomfort)  
 Altered or raised cholesterol  
 Kidney stones  
 Decreased bone density 
  
 Other risks reported in low numbers include:  
 Anorexia 
 Lethargy  
 Lower respiratory tract infections  
 Hyperammonaemic encephalopathy  
 
Other risks reported in low numbers, with KDs of a higher dietary fat content, include:  
 Infectious disease (pneumonia and sepsis)  
 Acute pancreatitis 
 Gallstones 
 Fatty liver 
 Nephrocalcinosis 
 Status epilepticus, acidosis 
 Dehydration  
 Tachycardia  
 Hunger  
 
A summary of expected adverse events related to tumour are as follows: 
 Headache 
 Numbness to limbs 
 Seizures 
 Cognitive decline 
 Mood and personality changes 





 Disordered speech, vision or hearing 
 
A summary of expected adverse events related to radiotherapy are as follows: 
Short term events (≤3 months post radiotherapy) 
 Scalp erythema 
 Wound breakdown 
 Alopecia 
 Headache 
 Nausea  
 Fatigue  
 Seizures 
Long term events (>3 months post radiotherapy) 
 Cognitive decline 
 Pituitary dysfunction 
 Leucoencephalopathy 
 






 Skin rash 
 Dizziness 
 Blurred vision 
 Insomnia 
 Taste changes 
More severe side effects of chemotherapy (Temozolomide) include: 
 Decreased bone marrow function 
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3.7.6 Follow up after adverse events 
All AE or SAE will be followed up until a satisfactory outcome is obtained or the patient is 
deemed to be stable by the CI.  
3.7.7 Responsibilities – investigator 
The investigator is responsible for informing REC of related and unexpected SAE.  These will 
be sent within 15 days of the CI becoming aware of the event. The HRA SAE report form will 
be used (http://www.hra.nhs.uk/resources/during-and-after-your-study/nhs-research-
ethics-committee-rec-ctimp-safety-report-form/) and emailed to (HRA.Queries@nhs.net).  
The CI may take appropriate urgent safety measures without prior contacting the REC.  
However, the REC will be contacted by telephone immediately and within 3 days in writing 
should a change to protocol occur.   
3.7.8 Responsibilities - REC 
The REC manager will acknowledge receiving all safety reports within 30 days by signing and 
returning a copy of the cover form.  
3.7.9 Safety reports 
A progress safety report will be submitted to REC annually by the CI or delegate and must be 
signed by the CI.  
The NHS REC annual progress report from can be located from the HRA website: 
http://www.hra.nhs.uk/resources/during-and-after-your-study/nhs-rec-annual-progress-
report-forms/  
3.7.10 Contact details and out of hours cover 
This trial is considered low risk and a low proportion of SAE are expected.  The dietetic 
investigator will be the primary contact.  Out of hours cover will be provided in line with 
routine clinical care.  In the event of additional clinical advice being required, the CI will be 
contacted.  Contact details can be found in section 10.   
3.8 Data management 
The CI is responsible for ensuring appropriate conduct at the site.  
3.8.1 Data recording 
The investigator will document all activities at each trial visit, in the patient’s medical notes. 
This data will be recorded using source documents to standardise assessments and activities. 
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All data collected from the source documents will be pseudo anonymised.  Essential trial 
paper documentation (food diaries, ketone diaries, food acceptability questionnaires, EORTC 
QLQ C30 and BN20 questionnaires) and the CRFs (main and supplementary CRF) will include 
a trial number.  Computer data sets will only contain the trial number. The original paper 
copy of the trial documents will be held in the main CRF.   
 
Nutritional analysis will be conducted using DietPlan 7© (Forestfield Software LTD, Horsham, 
UK).  All data will be anonymised prior to analysis using the programme.  No data will be 
stored on this programme due to data protection.  All nutritional analysis will be printed, 
assigned with the appropriate trial number and the original copy will be stored in the main 
CRF.   
A letter to summarise dietetic care and intervention at each appointment will be addressed 
to the referring consultant as per routine dietetic care, a copy of which will be sent to the GP 
and CI.  In addition for trial purposes one copy will be held in the medical notes and one in 
the main CRF.   
The investigator has primary responsibility for ensuring accurate and timely completion of 
clinic source documents and letters (within 24 hours of assessment).   
3.8.2 Data storage 
Data will be pseudo anonymised and transferred onto a password protected electronic 
spreadsheet (Microsoft Excel©) held on University of Liverpool Active DataStore.  No 
identifiable information such as hospital number, NHS number or name will be held on the 
database or used in the dissemination of results.  Patient data within the database will be 
identified with a unique trial number which will relate back to the CRFs.            
The investigator has primary responsibility for ensuring accurate and timely completion of 
the spreadsheet (within 7 working days of data collection).   
As this is a trial, clinic bookings cannot be made on the WCFT booking system.  Therefore a 
password protected Microsoft Excel© spreadsheet will hold data relating to clinic 
appointments, accessed only through a WCFT computer network.   Appointment letters sent 
to patients will also be held within a password protected file, accessed only through a WCFT 
computer.   Approval for this has been sought from the Assistant Divisional General Manager 
and Research, Development and Innovation Manager of WCFT.     
244 
 
The CRFs and all other paper trial documentation will be held in a lockable filing cabinet for 
the duration of the trial, within the Dietetic Office, at WCFT.  Medical notes in use will be 
tracked to and held in a lockable filing cabinet, within the Dietetic Office, at WCFT and then 
returned to the Health Records Library at WCFT when no longer required, as per the WCFT 
Clinical Records Management Policy.    
3.8.3 Records retention 
Data will be held for 10 years to allow for future retrospective comparisons to larger scale 
studies.  After the trial is complete, the essential trial paper documentation and CRFs will be 
archived by the University of Liverpool Records Management Department and held at 
University Records Centre, 150 Mount Pleasant, Liverpool, L69 3GD.  Electronic data will be 
archived by the investigator, in the University of Liverpool Data Catalogue, as per the 
University of Liverpool, Research Data Management Policy.  Source documents are held 
within the medical notes, therefore are retained in the Health Records Library of WCFT, as 
per the WCFT Clinical Records Management Policy.     
Data will be archived with the permission of the CI, who is the custodian.  
3.4 Indemnity  
The student investigator has indemnity cover provided by the British Dietetic Association.  
The University of Liverpool as sponsor holds insurance for injury caused by participation in a 
clinical trial.  The WCFT is an NHS trust, thus has a duty of care to its patients and a legal liable 
for acts of negligence by their employees, which includes those patients participating in the 
trial.   
5. ETHICAL CONSIDERATIONS 
The World Medical Association (WMA) of Helsinki, ethical principles for medical research 
involving human subjects, and amendments up to and including Fortaleza (2013) will be 
abided by.    
HRA REC approval will be sought for this pilot study, involving NHS patients with GB for MKD 
dietary interventions.  Protocol approval will also be sought from WCFT research, 
development and innovation department.  Approval for patient information sheets will be 
sought from HRA REC and Patient Information Panel at WCFT prior to being provided to 
patients.   
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Ethical approval will be overseen by the CI.  The University of Liverpool will be the pilot study 
sponsor.   
Data will be recorded using Microsoft Excel© and statistical analysis undertaken using 
Statistical Package for Social Sciences (SPSS©).   
5.1 Informed consent 
Patients will receive sufficient information and will be given sufficient time to consider 
participation in the trial.  They will be able to discuss their involvement with family members 
if required.  The investigator will comply with Good Clinical Practice (GCP) consent guidelines 
and WMA ethical principles.   
Patients will be referred to the study by written correspondence from the treating 
consultant.  Patients will be telephoned by the investigator to receive an appointment to 
discuss the trial and potential recruitment.   
A trial information leaflet will be provided and discussed with all potential patients.  The 
information sheet will explain the purpose of the study, voluntary participation, 
methodology, advantages and disadvantages of participation, confidentiality, result 
dissemination, right to withdraw and funding providers.  The leaflet will also provide a point 
of contact should the patient require further information.        
Those willing to participate will be asked to sign a consent form.  A copy of the consent form 
will be given to the patient, one copy will be held in the CFR and the original will be placed in 
the patient’s medical notes, along with a copy of the trial information sheet. 
Ongoing willingness to participate in the trial will be sought each time the patient is seen by 
an investigator and documented in the medical notes.  
No explanation will be sought from those patients who do not wish to participate in the trial.  
However, should an explanation voluntarily be provided, a record of this will be kept to 
inform trial feasibility.    
5.2 Trial discontinuation 
Patients who discontinue the trial early will be provided with a patient information sheet 
containing information on how to discontinue the diet.  They will then be followed up 
according to routine clinical care.  Their GP and treating consultant will be informed in 
writing.  For those patients alive after trial closure who wish to continue with the diet, dietetic 
review and monitoring will continue at 3 monthly intervals until dietary discontinuation.  
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6. RISKS AND BENEFITS OF THE TRIAL 
6.1 Risks 
Known side effects from the KD include gastrointestinal intolerance (such as diarrhoea, 
constipation, nausea, reflux, abdominal discomfort), altered or raised cholesterol, kidney 
stones and decreased bone density.  Other risks reported in low numbers include anorexia, 
lethargy, lower respiratory tract infections and hyperammonaemic encephalopathy.  Other 
risks reported in low numbers, with KDs of a higher dietary fat content, include infectious 
disease (pneumonia and sepsis), acute pancreatitis, gallstones, fatty liver, nephrocalcinosis, 
status epilepticus, acidosis, dehydration, tachycardia and hunger (Martin et al., 2016). 
6.2 Benefits 
There are no known potential benefits for patients participating in the trial.  This is a pilot 
study to establish protocol feasibility and dietary impact to patients.  The sample size will be 
too small to draw conclusions for efficacy.  
7. RESOURCES  
7.1 Resources 
7.1.1 Ketone monitoring 
 Blood ketone monitor  
 Blood glucose strips 
 Blood ketone strips  
 Ketostix® (Bayer, Leverkusen, Germany) 
 Urinary sample pot (NHS Supply, UK)   
7.1.2 Anthropometry monitoring 
 Disposable tape measures (Spentex BCA Ltd, UK) 
 Plastic calipers (Body Care, UK) 
 Hand grip dynamometer, T.K.K. 5401 (Takei Scientific Instruments Ltd, Japan) 
 Body fat monitor, BF306 (Omron Healthcare Co. Ltd, Japan) 
7.1.3 Patient information sheets  
 Study information sheet and consent 
 Ketogenic diet prescription (diet specific) 
 Food diary 
 Food and MCT diary (if appropriate) 
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 Urinary ketone diary 
 Blood ketone and blood glucose diary 
 Ketogenic recipes (Matthew’s Friends, UK) 
 Betaquik recipes (Vitaflo International Ltd, UK) 
 7 day individualised ketogenic diet plan 
 Discontinuing the MCT diet 
 Discontinuing the MKD  
 Quality of life questionnaire EORTC QLQ C30  
 Quality of life questionnaire QLQ BN 20 
 Food Acceptability Questionnaire 
7.1.4 Biochemistry 
 Blood forms 
8. RESEARCH REGISTRATION  
The trial will seek registration from ClinicalTrials.gov and will seek portfolio adoption from 
the National Cancer Research Institute (NCRI) Brain Tumour clinical studies group.   
9. DISSIMINATION   
The trial will be undertaken as part of a PhD programme at the University of Liverpool.  
Completion of a thesis is proposed for July 2019.   
Results of the trial will be published as soon as possible, in an appropriate peer reviewed 
journal and presented at appropriate conferences.  The financial sponsor Vitaflo 
International Ltd will be acknowledged, however they will have no part in conducting or 
analysing the trial.   
A newsletter detailing the findings of the trial will be circulated to those patients who are 
alive at time of completion, if the patient previously consented to receiving such information. 
10. TRIAL INFORMATION  
As this trial is being undertaken as part of a PhD programme at the University of Liverpool, 
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PROTOCOL APPENDIX 1: ANTHROPOMETRY METHODOLOGY 
Height 
 Use a stadiometer. 
 The patient is to stand with their back to the measure. 




 Use Marsden (M-520) freestanding digital weighing scales. 
 Patient to stand on scales, independently (without holding objects that would affect 
reading).  
Body Mass Index (BMI) 
 Weight (kg)/ height (m2). 
Mid arm muscle circumference (MUAC) 
 The patient should be sitting. 
 Use the left arm, bare of clothing. 
 Locate the acromion and olecranon process. 
 Use a disposable paper tape measure to measure the distance between the two 
points. 
 Identify the midpoint and measure the circumference of the arm at this point. 
Tricep skinfold 
 The patients left arm should be in a relaxed position. 
 Locate the midpoint identified in the MUAC measurement. 
 Raise the skin by pinching the skin, to obtain a double layer of skin and the underlying 
adipose tissue. 
 Standing behind the patient’s left arm, apply the caliper (Body Care, UK) at a right 
angle to the fold. 
 Repeat measure 3 times.  
Mid arm muscle circumference (MAMC) 
 MAMC (cm) = MAUC (cm) – (3.14 x TSF [cm]). 
 Note the conversion of TSF from mm to cm. 
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Hand grip dynamometry  
 Takei (Japan) hand grip dynamometer should be used. 
 Non-dominant arm, standing and elbow of the arm extended. 
 Can be taken from a sitting position with elbow at 90o angel, but the difference in 
method should be documented and consistently repeated.  
 Patient to compress dynamometer handle.  
 The mean of 3 measures should be documented. 
 
Fat mass (bio electronic impedance analysis)  
 Measured using the Omron (Japan) body fat mass hand held machine. 
 Input height, weight, age and gender.   
 Patient to grip machine in both hands on the metal discs in a seated position, with 
arms straight out in front at a right angle to the body.   
 Measurement should be undertaken a minimum of two hours after food or fluid, 
where possible.  




 The patient should be standing. 
 The measurement should be taken at the midpoint between iliac crest and the costal 
margin of the lower rib.  
 The patient should be asked to look straight ahead and to breathe out, at which point 
the measure should be taken.  
 The measure should not be undertaken in pregnant patients, or patients with 
colostomies, ileostomies or ascites.  
 
All measures should be interpreted according to the PENG pocket guide to clinical nutrition 





PROTOCOL APPENDIX 2: NIHR DECISION TREE FOR ADVERSE EVENT REPORTING  
 
 
PROTOCOL APPENDIX 3: EMBEDDED QUALITATIVE INFORMATION STUDY  
 
Overview 
A qualitative study will be embedded into KEATING, which will be referred to as the 
‘Information Study’ in the patient information documents.  The aim is to identify recruitment 
challenges and aid understanding of the patients’ recruitment experience, by interviewing a 
sub-sample of patients and their relatives/ carers.  Bespoke strategies will then be designed 
to optimise recruitment to future trials related to ketogenic diets and gliomas.   
Recruiting patients to clinical trials is often a challenge. Patients’ decision making processes 
are complex and can be influenced by various factors.  Findings from qualitative studies 
embedded into clinical trials have identified how small changes in communication and trial 
protocol, along with a better understanding of patients’ priorities at the point of approach, 
can help to facilitate recruitment (Hubbard et al., 2016; Poston et al., 2013; White and Hardy, 
2010). Embedded designs are also beneficial for the development of bespoke 
implementation strategies. This approach of embedded qualitative interviews has 
demonstrated success at optimising recruitment in previous trials (Mills et al., (2003), 
Donovan et al., (2002), Avery et al., (2014)), and will ensure patients are supported in making 
an informed decision about KEATING. 
The Information Study does not aim at identifying ways of somehow pursuing patients to 
participate in the trial, but rather to ensure patients are supported in making an informed 
decision and to improve their recruitment and trial experiences.  
Sampling  
A sub-sample of patients and their relatives/carers will be purposively selected for interview. 
Sampling for interviews will aim for maximum diversity and include those who consent to 
KEATING, those who do not consent for KEATING and those randomised to MKD and MCT 
KD. We understand that the principles of informed consent mean that when patients 
withdraw or decline trials they are not obliged to give a reason for their decision if they do 
not wish to. However, we will invite patients to participate in the Information Study even if 
they decline or withdraw from KEATING as they may wish to convey their perspectives and it 
is important to understand the experience of being approached about a clinical trial whatever 
decision a patient makes. We plan to sample both retrospectively and prospectively. Data 
will be collected until saturation is achieved; this is expected to be a maximum of 20 patient 
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interviews and 20 relative/ carer interviews (Harrop et al., 2016).  Patients can be interviewed 
for their sole experience, whilst relatives will only be invited to participate as a dyad with the 
patient.    
Methods 
Prospective recruitment  
All patients approached prospectively about the study will be approached for interview. After 
discussing the trial with the dietitian by telephone and receiving the KEATING patient 
information sheet, the patient will be routinely re-contacted and offered a screening 
appointment. If the patient declines participation in the main trial at that point, then the 
Information Study will be discussed with them in more detail. However, if a patient attends 
a screening appointment for the main trial, then the Information Study will be discussed with 
them at the end of that appointment.   
If the patient expresses interest in participating in the Information Study, and would like a 
close relative or carer (person closely involved in their care) to consider participation, then 
the Information Study patient information sheet and relative/carer information sheet will be 
posted to the patient. The researcher will also discuss the study with the patient’s 
relative/carer at this time, and seek their verbal consent to participate, if applicable. An 
appointment for interview will be scheduled at a time suitable for the participants, usually 
within four weeks of the last telephone conversation, allowing the participants adequate 
time to consider study involvement.  The interview appointment can be cancelled by the 
participants at any time, without being obliged to give a reason for their decision.  Consent 
will be sought from the patient and relative/carer immediately prior to the interview taking 
place.   
Retrospective recruitment  
Patients will also be recruited retrospectively, provided that they were approached about 
the study within three months of the date of ethical approval.  We recognise patients can 
experience cognitive decline over the course of the disease. Therefore we consider this to be 
an appropriate time frame as these patients will still be receiving oncological treatment, thus 
the research team will be able to liaise with the clinical team to determine suitability (those 
patients experiencing cognitive decline will not be approached).  The clinical team will initially 
discuss involvement in the Information Study with the patient and only if the patient agrees 
will they be formally contacted by a member of the research team.        
258 
 
The researcher will telephone those patients who agree to be contacted to discuss the 
Information Study. If the patient expresses interest in participating in the Information Study, 
and would also like a close relative or carer (person closely involved in their care) to consider 
participation, the researcher will also discuss the study with the patient’s relative/carer at 
this time, and seek their verbal consent to participate (if applicable). The Information Study 
patient information sheet and relative/carer information sheet (if applicable) will be posted 
to the patient. An appointment for interview will be scheduled at a time suitable for the 
participants, usually within four weeks of the last telephone conversation, allowing the 
participants adequate time to consider study involvement. The interview appointment can 
be cancelled by the participants at any time, without being obliged to give a reason for their 
decision. Consent will be sought from the patient and relative/carer immediately prior to the 
interview taking place.         
Interviews 
Interviews will take place in the participants own home, workplace, by telephone or at WCFT 
depending on the participant’s preference. Patient and relative/carer interviews will usually 
be undertaken separately, but can be undertaken jointly at the participant’s request.  
Topic guided, semi-structured qualitative interviews will explore participants experience and 
views of the recruitment process.  Interviews will be conversational and participant centered. 
Questions will be open-ended and explore patients’ and relatives’ views and experiences of 
KEATING, the trial arms and the recruitment process. Interviewees will also be asked for their 
views on what might help to improve the recruitment process. Questions will be adapted as 
appropriate to whether patients consented or declined trial participation.  All interviews will 
be conducted by the researcher (dietitian/PhD student) who has the necessary qualitative 
research skills.  As the research as a dual role (dietitian and qualitative researcher), the 
interviews will be conducted in a gentle, sensitive and non-judging manner, to make the 
experience as comfortable as possible for participants.  The topic guides have been designed 
to reflect this.  Our focus is to explore the participants’ views of KEATING, how it was 
discussed and the information they received.  Any questions in which the participant feels 
obliged to justify their decision will be avoided.    Participants will be free to decline to answer 
any questions or terminate the interview at any point.  All interviews will be audio recorded 
and transferred onto a password protected file held on University of Liverpool Active 




Analysis of interviews  
Audio recordings will be transcribed, checked and anonymised for analysis. Interview data 
will be analysed using a thematic approach (Braun and Clarke, 2006) for evidence of: i) the 
information communication needs of participants and relatives and ii) patients’ and relatives’ 
preferences and goals in relation to consent and recruitment. One member of the research 
team (KM) will lead a process of iterating between the developing analysis and new data, and 
other members of the qualitative study team (which will include at least one clinician) will 
develop and test the analysis by periodic discussion. Analysis will not take participants’ 
accounts only at face value, rather our approach will be interpretive and consider both latent 
and manifest aspects of the data (e.g. what we can learn from the way that participants talk 
as well as the explicit content). The design, conduct and analysis of the qualitative study will 
be informed by procedures to support quality in qualitative research (Murphy et al., 1998, 
Seale 1999) including systematic data coding, triangulation and exceptional case analysis. 
Analysis will be assisted by qualitative analysis software. 
Additional considerations  
Participation in the qualitative study is voluntary, and patients will not be obliged to give a 
reason for non-participation in KEATING or the Information Study. Appointment letters sent 
to patients will be held within a password protected file, accessed only through a WCFT 
computer (see data protection, section 3.8.2).  This will contain the patient’s name, address 
and Walton ID number but not the relatives name and address. For interviews conducted by 
telephone, verbal consent will be obtained. If completed in person, written consent will be 
obtained (applicable to both patient and relative/carer interviews).  Patients will be provided 
with a copy of their consent form, a copy will be held in the site file and the original in the 
medical notes.  Relatives/carers will be provided with a copy of their consent form and the 
original will be held in the site file. The University of Liverpool Lone Working Policy will be 
followed by the research team when conducting interviews outside of the researchers’ place 
of work.  
The findings of the Information Study will be used to identify recruitment challenges and aid 
understanding of the patients’ recruitment experience.  This information will be used to 
design bespoke strategies to optimise recruitment to future trials related to ketogenic diets 
and gliomas.  The findings will contribute to a PhD thesis, publications and presentations.  
All recordings will be destroyed from the hand held device after analysis and stored and 
retained in keeping with data from the main trial, see sections 3.8.2 and 3.8.3.  Transcripts 
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will also be stored and retained in keeping with data from the main trial, see sections 3.8.2 










































The initial inclusion criteria for the review are illustrated using the population, phenomena 
of interest and context (PICo) method in table P.1 (240).  
Table P.1: A PICo table illustrating narrative review inclusion criteria. 
Population People with advanced cancers. 
Interest People’s views around decision making regarding participation in early phase 
clinical trials. 
Context Early phase clinical trials.  
 
No restriction was placed on year of study or publication status.  The search was limited to 
English language publications.   
Search strategy 
A three part search strategy was implemented to identify suitable studies for the review. This 
included electronic database searches, hand searching of included study references and 
other resources including conference posters and abstracts.  
Electronic searches 
The following electronic databases were searched.   
8. Cochrane Library 
9. CINAHL Plus 
10. PsycINFO 
11. ORRCA database  
12. Google Scholar 
The search was undertaken between 22nd and 26th June 2018.  An example search strategy 
can be found in appendix Q.  The search strategy and terms were adapted for use within 
other databases.   
Hand searches 
References from literature included in the review were hand searched to identify other 





Conference abstracts and posters were included in the search to identify recent studies 
undertaken that may not yet be published or are ongoing.   
Searches continued until a purposive sample was obtained, adopting the methods used in 
qualitative research, searching until a sufficient number of studies were retrieved to reach 
saturation (240).  Wider articles were explored for context.        
Screening included studies 
All articles identified by the search were screening title and abstract. Those fitting the 
inclusion criteria were considered suitable for this narrative review (see P.2).  An inclusive 
rather than exclusive approach was taken when obtaining full papers (240).   
Table P.2: Eligibility criteria screening tool  
 Inclusion Exclusion 
Population  People with advanced cancers*  People with other cancers 
Interest  Decision making regarding 
early phase clinical trials 
 Other interests 
Context  Early phase clinical trials  Non early phase clinical 
trials 
Study design  Any qualitative study  All quantitative  
Overall 
decision 
 INCLUDED  EXCLUDED 
Notes  




APPENDIX Q: EXAMPLE SEARCH STRATEGY FOR NARRATIVE 
LITERATURE REVIEW 
 
(Experience* OR perceive* OR perception* OR attitude* OR opinion* OR agree* OR accept* 
OR refuse* OR refusal OR decline* OR judge* OR prefer* OR consent* OR autonomy OR 
equipoise OR barrier* OR facilitate* OR opportunit* OR challenge*) 
AND 
(Qualitative OR “mixed method” OR feasibility) 
AND 
(Recruit* near/6 trial) 
AND 
(Cancer) 
ORRCA database search strategy  
ORRCA database recruitment domains: A5, B1, B3, B10, C3, D2 




APPENDIX R: QUALITATIVE INTERVIEW TOPIC GUIDES 
(Version 3.0, 01/MAR/2018) 
Topic guide for patient interviews for the qualitative study in KEATING 
The aims of the study will be re-discussed with patients – We are interested in hearing about 
patient experiences of being approached to take part in the KEATING study.  We understand 
that studies like KEATING can be a lot to understand and through this information study we 
are trying to learn how we can improve our explanations to patients and if we can make any 
changes to improve patient experience.   
Reassurance will be provided regarding confidentiality and the interviewer will check the 
patient is happy to continue.  
Study information and recruitment process 
1. I’d like to ask you some questions about the KEATING study…who initially told you 
about the study? 
Prompts: Can you tell me about the run up to the study?  Can you remember when you were 
first diagnosed?  Can you remember what was spoken about in terms of treatment options?  
Did they mention the study?  Was this face to face or by phone?  What information did they 
provide?  When did they first discuss the study with you? Where were you up to with your 
treatment?  Was this a good time to talk about studies?  Where you expecting to be 
contacted by the dietitian? What were the main points that stood out from the conversation 
with the study team? What were your initial thoughts about the study? Is there anything 
would you change about how you were approached?  When would you prefer to be 
approached?  Who would you prefer to approach you about the study? Are there any 
improvements that could be made? 
2. What is your understanding of the reason why the study is being done?  
Prompts: What is your understanding of what the study aimed to investigate? What type of 
diet was it looking at and why? Are you able to tell me a bit about what this involves for 
patients? Did you have any prior knowledge of ketogenic diets in glioblastoma? Was anything 
unclear or confusing? What is your understanding of the risks and benefits are with this diet?  




Prompts:  Did you find the wording and layout suitable? Is there anything that you would 
change? Were any parts helpful? Did you have any questions after reading the leaflet?  
Decision making  
4. Before making your decision about taking part did you seek information from 
anywhere else?  
Prompt: Did you discuss your involvement in the study with your family or friends? Did you 
discuss the study with a doctor or nurse? Did either the doctors/ nurse or family/ friends 
provide you with opinions?  How important were their opinions in your decision?  Did you 
look into other sources of information, such as the internet – if so, then which sites/ 
organisations?  Did you feel comfortable voicing your decision/ opinion? Would you have 
been as willing to take part withut your relative?  How do you think that might have been?  
5. (Can you tell me about how you came to your decision to take part/not take part in 
the study?) 
Prompts: When did the decision start to form in your mind?  How do you usually make 
decisions (gut reaction or evidence based/ informed decision)?  How certain were you with 
your decision?  How confident were you with your decision? How confident were you in 
telling others about your decision? Did you have an initial feeling about whether you wanted 
to take part or not?  What are your thoughts on the use of ketogenic diets for people with 
glioblastomas? Did anything particularly worry you about the study? Did anything create a 
barrier to you participating? Did anything seem appealing about the study?  Did you feel it 
was your decision?  Were you given enough time to think things over? How do you feel about 
the information you were given to make the decision (more or less needed)? Do you have 
any particular views on being randomised to one diet or the other? Or the methods used to 
randomise?   
6. Are there any potential changes that could be made to alter your opinion? 
Prompts: Any changes to the study design?  Changes to how you are told about the study 
and what it involves? How did you feel about the length of the study being 12 weeks?  
7. When thinking about the treatment you have received, is there any time when you 
think starting the diet would be most appropriate? 
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Prompts: This could be not at all, before/after surgery, before/ during/ after radiotherapy or 
before/ during or after chemotherapy or after all treatment has finished. Can you tell me a 
bit more about that?  
8. Did you consider any other studies or treatments? 
Prompts:  Other studies that may be open to you locally or nationally?  Have you taken part 
in research previously? Would you take part in potential future studies? Have you looked into 
any other diets or nutritional supplements?  
9. If you had the chance to be involved in the study again would you make the same 
decision?  
Prompts: If changed decision why is that?  
KEATING participants only 
10. What did you think when you were told about your allocated diet?  
Prompts: Did you have a diet preference? Did you have any worries or expectations?  Do you 
have any particular views on being randomised to one diet or the other? Or the methods 
used to randomise.  Would you rather have had a choice?  Did your opinion influence how 
long you stayed on that diet?   
11. What has your experience of the KEATING study been so far? 
Prompts: Has your experience influenced your views on research?  Do you have any tips for 
a similar study in the future? Has any part been particularly burdensome? Have there been 
times when the diet has been more difficult to follow?  (E.g. fatigue).  How did you feel 
around the time of finishing chemo/radiotherapy?  How did this affect the diet?  Has any part 
been particularly enjoyable?   Have there been times when the diet has been easier to follow?  
Are there any motivating factors to staying on the diet?  Are there any changes we could 
make to help people stay on the diet? 
Conclusion  
12. Is there anything else you would like to talk about that we haven’t covered? Do you 
have any questions for me?  Thank you for taking the time to talk to me.  
General prompts: 
Can you tell me more about that?  What is your understanding of that?  
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Topic guide for relative interviews for the qualitative study in KEATING 
The aims of the study will be re-discussed with the relative/carer – We are interested in 
hearing about relatives’/carers’ experiences of the patient being approached to take part in 
the KEATING study.  We understand that studies like KEATING can be a lot to understand and 
through this information study we are trying to learn how we can improve our explanations 
to patients and relatives/ carers and if we can make any changes to improve both of your 
experiences.   
Reassurance will be provided regarding confidentiality and the interviewer will check the 
patient is happy to continue.  
Study information and recruitment process 
1. I’d like to ask you some questions about the KEATING study….who initially told you 
about the study? 
Prompts: Can you tell me about the run up to the study?  Can you remember when they were 
first diagnosed?  Can you remember what was spoken about in terms of treatment options?  
Did they mention the study?  Was this face to face or by phone?  How did you feel about the 
patient being contacted? Did you speak to a member of the study team yourself? If so, what 
did they discuss with you?  What were your initial thoughts?  Is there anything you would 
change about the way you were both approached?  Who would you prefer to be contacted 
by? 
2. What is your understanding of the reason why the study is being done? 
Prompts: What it is your understanding of what the study aims to investigate? What type of 
diet was it looking at and why? Are you able to tell me a bit about what it would involve for 
patients? Did you have any prior knowledge of ketogenic diets in glioblastoma? Was anything 
unclear or confusing? What do you think the risks and benefits are with this diet? How would 
it impact their lifestyle or routine?  
3. What would it involve for you as a relative/ carer?  
Prompt:  Would it impact upon your lifestyle or routine?  
4. The patient received an information sheet about the study, did you read over it?  
Prompts: If so, what are your views on it?  Did you find the wording and layout suitable? Is 
there anything that you would change? Were any parts helpful? Did you have any questions 
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after reading the leaflet?  If you didn’t read it, what are the reasons for this? Would you have 
liked to have read it?   
Decision making 
5. Before the patient decided about taking part in the study, did they discuss the study 
and their involvement with you?  
Prompts: What were your thoughts about the study? What was your initial feeling about 
them taking part or not? When did the decision start to form in your mind?  How do you 
usually make decisions (gut reaction or evidence based/ informed decision)?  Did you seek 
information from elsewhere?  Did you discuss the study with another family member or 
friend?  Did you discuss it with their doctor or nurse? Did you consider other sources of 
information such as the internet? If so, which sites/ organisations? Do you feel your opinion 
influenced their decision to take part or not? Do you think they would have been as willing 
to take part without you?  How might that have been?  
6. (How did you come to reach your opinion about their involvement in the study?)  
Prompts: How certain were you with your decision?  How confident were you with your 
decision? What are your thoughts on the use of ketogenic diets for people with 
glioblastomas? Did anything particularly worry you about the study? Did anything create a 
barrier to the patient participating? Did anything seem appealing about the study?  Were you 
both given enough time to think things over? How do you feel about the information you 
were given to make the decision (more or less needed)? Do you have any views on patients 
being randomised to one diet or the other? Or the methods used to randomise?  Would you 
rather have a choice? 
7. Are there any potential changes that could be made to alter your opinion? 
Prompts: Any changes to the study design?  Changes to how we tell patients about the study 
and what it involves? How we involve their relatives/carers in the process?  
8. Did you consider any other studies or treatments? 
Prompts:  Other studies that may be open to you locally or nationally?  Would you encourage 
the patient to take part in potential future studies? Have you looked into other diets or 
nutritional supplements?  
9. If the patient had the chance to be involved in the study again would your opinion of 
the study change?  
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Prompts: If so, what are the reasons for this change of opinion? Do you think this would 
influence their decision to take part?  If not, what has confirmed your opinion?  
KEATING participants’ relatives/ carers only 
10. What has your experience of the KEATING study been so far? 
Prompts: Has your experience influenced your views on research?  Do you have any tips for 
a similar study in the future? Has any part been particularly burdensome?    Have there been 
times when the diet has been more difficult to follow?  (E.g. fatigue).   How did they feel 
when they finished chemo/radiotherapy?  Did this have any effects on the diet?  How do you 
think they felt?  Has any part been particularly enjoyable?  Have there been times when the 
diet has been easier to follow? Are there any motivating factors to staying on the diet?  Are 
there any changes we could make to help people stay on the diet? 
Conclusion  
11. Is there anything else you would like to talk about that we haven’t covered? Do you 





Topic guide for joint patient-relative interviews for the qualitative study in KEATING 
The aims of the study will be re-discussed with patients and relatives/carers – We are 
interested in hearing about patient and relatives’/carers’ experiences of being approached 
to take part in the KEATING study.  We understand that studies like KEATING can be a lot to 
understand and through this information study we are trying to learn how we can improve 
our explanations to patients and relatives/carers, and if we can make any changes to improve 
both of your experiences.   
Reassurance will be provided regarding confidentiality and the interviewer will check the 
participants are happy to continue.  
Study information and recruitment process 
1. I’d like to ask you some questions about the KEATING study… who initially told you 
about the study? 
Prompts: Can you tell me about the run up to the study?  Can you remember when you were 
first diagnosed?  Can you remember what was spoken about in terms of treatment options?  
Did they mention the study?  Was this face to face or by phone?  Who initially told you about 
the study?  Were you both present? What information did they provide?  When did they first 
discuss the study with you? Where you expecting to be contacted by the dietitian?   Did you 
both speak with the researcher by phone? How did you find the telephone discussion with 
the dietitian? What were the main points that stood out from the conversation with the 
dietitian? How did you both feel about being contacted? What were your initial thoughts 
about the study? Is there anything would you change about how you were approached?  
When would you prefer to be approached?  Who would you prefer to approach you about 
the study? Are there any improvements that could be made? 
2. What is your understanding of the reason why the study is being done and what it 
involves for patients and for relatives?  
Prompts: What did it aim to investigate? What type of diet was it looking at and why? Are 
you able to tell me a bit about what the study would involve for patients? Are you able to tell 
me a bit about what the study would involve for relatives Did you have any prior knowledge 
of ketogenic diets in glioblastoma? Was anything unclear or confusing? What do you think 
the risks and benefits are with this diet?  Would it impact upon your lifestyle or routine?  
3. We posted an information sheet to you about the study.  What are your views on it? 
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Prompts:  Did you both read it over? Did you find the wording and layout suitable? Is there 
anything that you would change? Were any parts helpful? Did you have any questions after 
reading the leaflet?  
Decision making  
4. Before making your decision about taking part did you seek information from 
anywhere else?  
Prompt: Did you discuss taking part in the study together? Did you discuss the study with a 
doctor or nurse? Did either the doctors/ nurse for family/ friends provide you with opinions?  
How important were their opinions in your decision?  Did you look into other sources of 
information, such as the internet – which sites/ organisations?  Do you think they would have 
been as willing to take part without you?  How might that have been? 
5. Can you tell me about how you came to your decision to take part/not take part in 
the study? 
Prompts: When did the decision start to form in your minds?  How do you usually make 
decisions (gut reaction or evidence based/ informed decision)?  How certain were you with 
your decision?  How confident were you with your decision? Did either of you have an initial 
feeling about whether you wanted (said patient) to take part or not?  What are your thoughts 
on the use of ketogenic diets for people with glioblastomas? Did anything particularly 
worrying either of you about the study? Did anything create a barrier to you participating in 
the study or supporting (said patient) to participate in the study? Did anything seem 
appealing about the study to either of you?  Did you feel it was the patient’s decision or a 
decision you made together?  Did you feel confident in voicing your opinion?  Could anything 
be done to make you feel more confident in voicing your opinion? Were you both given 
enough time to think things over? How do you feel about the information you were given to 
make the decision (more or less needed)? Do you have any particular views about patients 
being randomised to one diet or the other? Or the methods used to randomise? 
6.  Are there any potential changes that could be made to alter your opinion? 
Prompts: Any changes to the study design?  Changes to how we tell you about the study and 
what it involves?  
7. When thinking about the treatment you have received, is there any time when you 
think starting the diet would be most appropriate? 
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Prompts: This could be not at all, before/after surgery, before/ during/ after radiotherapy or 
before/ during or after chemotherapy or after all treatment has finished. Why is that?  
8. Did either of you look into any other studies or treatments? 
Prompts:  Other studies that may be open locally or nationally?  Have either of you taken 
part in research previously? Would either of you take part in potential future studies? Have 
you looked into other diets or nutritional supplements? 
9. If (said patient) had the chance to be involved in the study again would you both make 
the same decision?  
Prompts: If changed decision why is that?  
KEATING participants only 
10. What did you think when you were told about your allocated diet?  
Prompts: Did either of you have a diet preference? Did either of you have any worries or 
expectations?  Do you have any particular views on being randomised to one diet or the 
other? Or the methods used to randomise. 
11. What have your experiences of the KEATING study been so far? 
Prompts: Have your experiences influenced your views on research?  Do either of you have 
any tips for a similar study in the future? Have there been times when the diet has been more 
difficult to follow?  (E.g. fatigue).   How did they feel when they finished chemo/radiotherapy?  
Did this have any effects on the diet?  How do you think they felt?  Has any part been 
particularly burdensome? Has any part been particularly enjoyable?  Have there been times 
when the diet has been easier to follow? Are there any motivating factors to staying on the 
diet?  Are there any changes we could make to help people stay on the diet? 
Conclusion  
Is there anything else either of you would like to talk about that we haven’t covered? Do you 
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